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ABSTRACT 
 
 
For over 20 years, cell-penetrating peptides (CPPs) have been used as delivery 
vectors transporting macromolecules (cargos) into live cells for cell biology manipulations 
and therapeutic applications. While the exact mechanism of cell penetration remains 
controversial, it is thought that CPPs are first internalized inside endocytic vesicles and 
have been reported to escape to the cytosolic space of cells. However, while the 
internalization of CPPs inside vesicles has proven to be highly efficient, their endosomal 
escape activity remains suboptimal and poorly understood. This is a severe limitation of 
the CPP-mediated delivery approach because the macromolecules’ escape is essential if 
the cargo is to interact with its cytosolic/nuclear targets. Multiple approaches to enhance 
CPP’s endosomolytic activity have been explored (summarized in Chapter 1). 
Multivalency has been proposed as a possible new approach, in which multiple copies of 
a molecule are attached as one functional unit. It has been hypothesized that the use of 
multivalent CPPs will result in an increase in their local concentration at the membrane; 
and as a consequence enhance their membrane disruption property.  
 In Chapter 2, I report on the generation of a multivalent CPP: dfTAT, a dimeric 
version of the most studied CPP, TAT. Similar to TAT, dfTAT enters cells via 
macropinocytosis. Interestingly, while monomeric TAT is extremely inefficient at 
escaping the endocytic pathway, I demonstrate that dfTAT escapes endosomes with an 
unprecedented level of efficiency. Cytosolic penetration of dfTAT can be achieved in 
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multiple cell lines and primary cells, without impacting the cell’s physiology. Most 
importantly, dfTAT can efficiently deliver a wide variety of macromolecules and cell-
impermeable small molecules efficiently into the cytosolic space of live cells.  
In Chapter 3, I report on the role that chirality and protease-resistance have on the 
endosomal escape behavior of dfTAT. By inverting dfTAT’s chirality from L to D 
stereochemistry, I generated a protease-resistant dfTAT (D-dfTAT). Interestingly, I show 
that while the mechanism of cellular entry remains the same, D-dfTAT’s cellular 
internalization is substantially lower than dfTAT. Nonetheless, once in the endosome, D-
dfTAT escapes with a higher efficiency than its L-counterpart. Finally, while dfTAT 
treatment is relatively innocuous to cells, D-dfTAT unexpectedly exerted a prolonged anti-
proliferative activity.  
The literature underscores the important role that arginine residues play in CPP 
cellular internalization. However, due to the low endosomolytic activity of most CPPs, 
residues vital for endosomal escape have not yet been established. In Chapter 4, I 
determined that the arginine residues are both necessary and sufficient for dfTAT 
endosomolytic activity. Interestingly, a minimum number of 12 arginine residues is 
required for sufficient endosomal escape.  
Overall, this work identifies a novel endosomolytic agent and identifies some of 
the molecular features important for cellular permeation. In turn, my results lay the 
foundation for new and optimized versions of the dfTAT prototype that may find 
applications in a variety of delivery approaches.  
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NOMENCLATURE 
 
Antp   antennapedia homeodomain 
ATCC  American Type Culture Collection 
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COI                      cargo of interest 
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DRBD                  double-stranded RNA-binding domain 
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EGFP   enhanced green fluorescent protein 
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EIPA                   5-(N-Ethyl-N-isopropyl)amiloride 
ESI                       electrospray ionization 
FBS   fetal bovine serum 
FITC   fluorescein isothiocyanate 
Fl  carboxy-fluorescein 
FACS                   fluorescence activated cell sorting 
FRET   Förster resonance energy transfer 
GTPase                guanosine triphosphate hydrolase 
HA2   haemagglutinin protein II 
HBTU  2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium        
hexafluorophosphate 
HDF     human dermal fibroblast 
HEPES                4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV  Human immunodeficiency virus 
HNF                     human newborn fibroblasts 
HPLC   high-performance liquid chromatography 
HRP                      Horse Radish Peroxidase 
HSPG   heparin sulfate proteoglycan 
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IP                          intra-peritoneal injection  
IPTG   isopropyl -D-1-thiogalactopyranoside 
ITC                      isothermal calorimetry 
kDa   kilo Dalton 
L-15   Leibovitz’s 15 
MALDI                matrix-assisted laser desorption/ionization 
MAP   model amphipathic peptide 
mCPP                   multivalent CPP 
MOI                     molecule of interest 
MPTP  mitochondrial permeability transition pore 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MVB   multivesicular bodies 
NLS  nuclear localization signal 
NMR   nuclear magnetic resonance 
ON                       oligonucleotides 
OVA                    ovalbumin 
p53   protein 53 
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PAD   pro-apoptotic domain 
PBS   phosphate buffer saline 
PCI  photochemical internalization 
PCR   polymerase chain reaction 
PG                        proteoglycan 
PNA  peptide nucleic acid 
Ptd   phosphatidyl 
Ptd-Ser                 phosphatidyl serine  
RBC   red blood cell 
RNase A              ribonuclease A 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SPPS   solid-phase peptide synthesis 
TAT   Trans-Activator of Transcription 
TCEP   tris(2-carboxyethyl)phosphine 
TFA   Trifluoroacetic acid 
TMR  5(6)-carboxytetramethylrhodamine 
WT                      wild-type 
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1. INTRODUCTION 
 
1.1 Significance of the delivery of macromolecules into live cells 
Delivering macromolecules such as RNAs and proteins to the inside of live cells 
is likely to have a huge impact on the fields of therapeutic and biomedical research. For 
example, delivery of transcription factors such as Oct4, Sox2, and Klf4 can be used to 
reprogram fibroblasts into pluripotent stem cells1. This delivery, however, is impeded by 
the presence of a selectively permeable plasma membrane that acts as a barrier blocking 
entry of large hydrophilic molecules to the cytosolic space of live cells. Therefore, 
overcoming this natural barrier is a crucial first step. Techniques such as scrape-loading, 
microinjection, and electroporation have all previously been used, but these fall short in 
terms of efficiency of delivery to a large population of cells2-5. This severely limits the 
application of these techniques, especially in areas such as drug delivery. Other 
approaches include the use of bacterial toxins, virus-like particles, cationic lipids for 
delivery of DNA/RNA, nanoparticles, and liposomes for the transport of well-known 
insoluble drugs and proteins6-10. Many of these approaches, however, suffer from high 
cell toxicity and undesirable immunogenic effects, are time-consuming, require a high 
level of expertise, or offer low delivery efficiency11. Therefore these methods, although 
useful, remain unsuitable for many applications. One promising approach that could 
circumvent many of these issues is the use of cell-penetrating peptides (CPPs); this 
method has attracted attention recently due to its non-invasiveness in cell-impermeable 
macromolecular delivery12. 
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1.2  Cell-penetrating peptides as delivery vectors 
1.2.1 History of cell-penetrating peptides  
In 1988, Pabo and Loewenstein independently demonstrated that the trans-
activator of transcription (TAT) protein from the human immunodeficiency virus type 1 
(HIV-1) has the ability to cross the plasma membrane and activate gene expression of a 
reporter gene13, 14. Following this, work was aimed at understanding the mechanism by 
which this 86-amino acid protein, that is hydrophilic in nature, is able to enter cells. 
Several years later, it was reported that TAT enters cells by adsorptive endocytosis, and it 
was this report that underscored its possible use for the delivery of proteins into cells15. At 
this time, Lebleu and colleagues were interested in delineating the exact sequence 
responsible for TAT protein translocation16. Their research identified a cluster of basic 
amino acids extending from positions 48 to 60 that appeared to be unstructured and 
responsible for the protein’s cellular internalization property. The sequence now known 
as the TAT peptide (amino acid sequence: RKKRRQRRR) was the first identified and 
continues to be the most well-studied cell-penetrating peptide (CPP)17.  
 CPPs, sometimes also referred to as protein transduction domains (PTDs), are 
short peptide sequences composed of 5 to 30 amino acids. These peptides can be used to 
deliver biomolecules into live cells by a simple co-incubation protocol, or by covalently 
conjugating the peptide to the molecule of interest (MOI). CPPs can be further classified 
according to different properties, such as their physiochemical characteristics or, more 
commonly, their origin18. Regarding the latter, CPPs have been classified into three 
groups. Similar to the TAT peptide penetratin, VP22 and pVEC belong to peptides derived 
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from proteins19, 20. For example, penetratin is a 16-mer peptide derived from the third helix 
of Drosophila antennapedia homeodomain (Antp)21. The second group consists of 
chimeric peptides that originate from two fused constructs; these include Transportin, 
MPG, and Pep-1. Transportan (TP) was derived from fusion of the neuropeptide galanin 
to the wasp venom peptide mastoparan22. The third group is classified as synthetic 
peptides, which have since been identified based on the structural activity relationship of 
well-known CPPs. This class includes model amphiphatic peptide (MAP) MAP-17, 
GALA, R6W3, and the polyarginine peptide (which is characterized based on 
structure/function studies with the TAT peptide). Other well-known CPPs include CADY, 
Xentry, and PPTG117, 23-27.   
From a physio-chemical standpoint, CPPs are classified as cationic, amphipathic, 
or hydrophobic in nature. Cationic CPPs include the TAT and synthetic polyarginine 
peptides. At a physiological pH, these are positively charged, due to enrichment of the 
basic amino acids arginine and lysine found in their sequence. MAP, GALA, and P28 are 
three examples of amphipathic peptides in which one face has a hydrophobic patch and 
the other is either cationic, anionic, or polar28-30. Residue substitution experiments have 
shown that even though many of these peptides are cationic, their translocation activity is 
a consequence of their amphiphilicity. Hydrophobic CPPs are the least-identified class; 
however, one emerging group is stapled peptides that involve a ring-closing olefin 
metathesis31. Interestingly, studies have shown that the staple itself, independent of the 
nature of the residue, contributes to the cellular internalization due to its higher affinity 
for the plasma membrane18.   
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1.2.2 The importance of “arginine residues” in cellular penetration 
Mutational analysis studies of the TAT peptide by Mitchell et al., Wender et al., 
and Futaki et al. have identified the crucial role that arginine plays in the activity of 
cationic peptides32-34. Wender et al. reported that truncation of the TAT peptide and 
individual mutations of its residues to alanine resulted in a significant decrease in the 
internalization of CPPs. Additionally, this work demonstrated that although TAT contains 
eight positive charges, its activity could be recapitulated by a peptide containing six or 
seven positive residues. Furthermore, peptides containing seven or more arginine residues 
exhibited a higher efficiency of internalization than TAT, as evaluated by flow 
cytometry32. Work done in the Rothbard laboratory showed that polyarginine peptides 
were internalized into T-cells more efficiently than polymers of lysine or ornithine of 
similar peptide lengths33. Altogether, these studies indicated that the cationic nature of the 
arginine residue was not the sole factor necessary for cell internalization.  
Rothbard et al. showed that there was no strict requirement for side chain length 
or backbone chirality (L- vs. D-polyarginine); however, the guanidinium group on the 
arginine residue and other heptamers containing guanidinium did play a key role in 
cellular internalization33. This was clearly demonstrated by experiments where arginine 
was replaced with citrulline, an isostere of arginine that contains oxygen instead of 
nitrogen in the guanidino group. Thus, a urea group found in citrulline replaced the 
guanidinium group of arginine. A heptamer of citrulline showed no cellular internalization 
activity at concentrations up to 100 μM. Interestingly, the pKa of guanidinium is 12, while 
urea has a pKa of about 0.1; the difference results in the dramatic change in charge of the 
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molecule at a physiological pH. This makes the NH group of guanidinium an excellent 
hydrogen bond donor and allows for stable bidentate hydrogen bonds with anions such as 
the phosphates and sulfates found at the cell surface. This interaction will be discussed in 
the sections below.   
It is important to note that all experiments in these two studies were performed 
using flow cytometry analysis. While flow cytometry is a useful tool that allows one to 
analyze the total fluorescence intensity found in cells, it cannot differentiate between cells 
that have a cytosolic fluorescence distribution, punctate distribution (i.e., peptides trapped 
inside endocytic vesicles), or peptides bound to the cell surface35. Futaki et al. used 
fluorescence microscopy to evaluate the internalization property of arginine-rich peptides, 
showing that arginine-rich peptides derived from many sources have the ability to reach 
the cytosolic space of a macrophage cell line: RAW264.2 cells. The authors also reported 
that a minimum number of approximately eight arginine peptides per chain were required 
for efficient cell translocation34. While microscopy is a technique that allows for 
differentiation of peptide localization, this study was performed after cellular fixation, 
which was reported to lead to experimental artifacts (i.e. artificial release of material from 
endosomes due to membrane permeabilization during fixation protocol) 35, 36. This work 
ultimately led to the research conducted with live cell microscopy, which showed that 
polyarginine peptides could display a cytosolic fluorescence distribution37, 38. Such 
research underscores the remarkable difference in internalization properties of lysine and 
arginine residues in the context of live cell microscopy.  
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1.2.3 In cellulo applications for the CPP TAT 
Cell-penetrating peptides provide a promising tool for the delivery of various 
biologics into live cells. In this section, I will provide examples of macromolecules (with 
a focus on proteins, and nucleic acids) being delivered into cells and describe the 
usefulness of this application. The examples were obtained from an extensive list of 
molecules internalized into live cells with the aid of CPP, which includes small molecule 
drugs, antibodies, peptide-based imaging agents, liposomes, and nanoparticles39.  
Protein Delivery 
The transportation of proteins and hydrophilic peptides across a plasma membrane 
can be difficult, due to the barrier-like nature of the membrane. For more than 20 years, 
laboratory research has investigated the possibility of using cell-penetrating peptides to 
deliver a wide variety of peptides, proteins, and enzymes (i.e., cargo) to the insides of 
cells. Researchers have used methods such as covalently tagging the CPP to the cargo of 
interest (COI) or simple employment of a co-incubation protocol (CPP and COI incubated 
together, with no direct conjugation)40. Proteins delivered by CPPs can be classified into 
two groups: reporter peptides/proteins that give a simple readout upon delivery, and 
functional peptides/proteins that result in a change in the detectable cellular response 
pathway. As early as the 1990’s, studies by Fawell et al. showed that TAT could be used 
to deliver reporter proteins such as β-galactosidase, horseradish peroxidase (HRP), a 
domain of Pseudomonas exotoxin A, and ribonuclease A (RNase A), by direct conjugation 
into a variety of cell lines including HeLa and primary human keratinocytes11. The authors 
compared the amount of β-galactosidase activity found in cells by the transfection method 
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or by protein delivery using TAT. Their results showed that the activity was observed on 
the time scale of minutes to hours for TAT; however, using transfection the activity 
occurred on a time scale of hours to overnight. Their conclusion was that the efficiency of 
delivery was far greater using the TAT peptide. However, these experiments lacked the 
controls that would account for variability attributed to the difference in expression level 
of each plasmid and the transfection efficiency. Unfortunately, while these experiments 
laid the foundation for protein delivery, they were performed using cellular fixation; this 
process overestimates the amount of protein that reaches the cytoplasm, due to artifacts of 
sample preparation.  
In another example, Kim et al. described the use of TAT as a therapeutic and 
prophylactic vaccine. T-cells recognize the pathogen-derived peptides exposed on the 
major histocompatibility complexes class (MHC) I and II, upon macrophage infection by 
the pathogen. For this to occur, the protein or peptide exposed to the cell surface must 
reach the cytosolic space of the cells. At that time, protein-based vaccines failed to hijack 
the immune system because the protein was unable to cross the plasma membrane. In 
1997, researchers conjugated TAT to ovalbumin (OVA), and showed the ability of this 
conjugate to stimulate the MHC class I responses in T-cells41.  
In 2004, to understand the mechanisms of CPP translocation, Dowdy and 
colleagues developed an assay that employs Cre recombinase. Cre recombinase is an 
enzyme that mediates the recombination of a region of a gene flanked by two loxP sites42. 
In this assay, a TAT- Cre fusion mediates the excision of the stop codon from a loxP-Stop-
loxP upstream of the DNA sequence coding for EGFP. Therefore, for cells to express 
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EGFP, TAT-Cre must enter the cells and translocate to the nucleus to excise the stop 
codon. This assay is extremely valuable, since it allows for the characterization of the 
mechanism of CPP internalization in addition to efficiency in protein delivery, without the 
need for cellular fixation protocols. Using flow cytometry analysis, these researchers 
successfully delivered TAT-Cre to the cytosol of the cells. Interestingly, the majority of 
the TAT-Cre was shown to be entrapped in macropinosomes (endocytic vesicles formed 
as a result of macropinocytosis). This work highlights that while TAT can mediate cellular 
entry of a biologically active enzyme inside cells, the efficiency remains suboptimal due 
to the generally low endosomal escape efficiencies of TAT and cationic CPPs.   
Transcription factors that can induce pluripotency have been delivered inside cells 
using CPPs. This has been used as an alternate approach to transfection of the cells with 
plasmid containing the genes that codes for these transcription factors. Kim et al. fused 
Oct4, Sox2, Klf4, and c-Myc (which had previously been shown to induce pluripotency 
by viral expression of transcription factors) to polyarginine and expressed the constructs 
in HEK293 cells. The cell extract from these cells were incubated with newborn human 
fibroblast (HNF)43, 44. Initial attempts at cell extract incubation were not successful, so the 
researchers reasoned that protein delivery needed to be repeated to observe the effect. In 
fact, treatment of HNF cells for multiple cycles (1 cycle = 16 hr protein treatment and six 
days of incubation with an essential media) resulted in formation of colonies with iPSC 
(induced pluripotent stem cells)-like morphology, and showed the expression of markers 
of pluripotency43. This indicated that CPPs could in the future be used for therapeutic 
applications such as organ transplants. 
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In 2014, work by Ramakrishna et al. reported the first use of the nonaarginine CPP 
9R to deliver Cas9 and guide RNA into human cells45. The clustered, regularly 
interspaced, short palindromic repeat (CRISPR)-associated (Cas) system is an RNA-
guided DNA cleavage process found in bacteria; it is important to their adaptive 
immunity46, 47. Research by the Doudna lab and others recognized the utility of this process 
in targeting and altering the genomes of various organisms. The guide RNA, which 
consists of CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA), are necessary 
to direct the endonuclease or Cas9 protein to a specific gene on the DNA that is 
complementary to the guide RNA (gRNA), thereby making double-stranded breaks 
(DSBs) at the specific genome locus. Typically, the Cas9 and guide RNA are expressed 
in cells following plasmid transfection or microinjection. However, plasmid-based 
delivery systems are notorious for problems such as uncontrolled integration of plasmid 
DNA into the host genome, and immunogenicity problems48, 49.The authors showed the 
delivery of the modified Cas9 and gRNA into cells via a reporter assay, using an RFP-
GFP reporter plasmid containing the guide RNA recognition site between the two genes. 
In this plasmid, the GFP was initially out of frame and the transfected cells only expressed 
RFP. Successful delivery of the Cas9/gRNA conjugated to TAT resulted in the non-
homologous end joining of the DSB and a frameshift that resulted in GFP expression. 
Using flow cytometry, the researchers showed a 6.2% increase in the population of cells 
expressing GFP, and hence the positive delivery of Cas9/gRNA. They also reported 
reduced off-target effects, as compared to the plasmid-delivery approach. This can be 
attributed to the rapid degradation of the protein and RNA after delivery. Similar work 
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using CPPs has been performed to deliver other nucleases such as zinc fingers, and 
transcription activator-like effector nucleases50, 51. Interestingly, while these results are 
promising, they also indicate that more effective CPPs may need to be developed to 
achieve efficient delivery to a larger cell population.  
One common characteristic of the proteins described above is the requirement that 
only a small amount be delivered to the cytosol for biological activity to be detectable. 
Many of these proteins are enzymes that upon successful cytosolic delivery can reach their 
target and exert their effect. These enzymes can, therefore, be either reused or alter a signal 
that can be further amplified, as is the case with TAT-Cre and amplified EGFP 
expressions. Unfortunately, however, these assays overestimate the efficiency of the CPP 
endosomal escape, a condition that will be described below.   
Gene Delivery 
Gene delivery to the nuclei of target cells to dysregulate disease-associated genes 
has proven to be a promising therapeutic tool 52. However, due to its large size, it is often 
quite difficult to deliver highly negatively charged DNA to live cells because it does not 
efficiently permeate through the plasma membrane. Viral vectors have been used to 
overcome this barrier; they show promise in the integration of exogenous DNA into a wide 
variety of host genomes. However, they face major drawbacks, including immunogenicity, 
toxicity, and difficulties with largescale generation53.Therefore, non-viral vectors such as 
CPPs are an ideal alternative approach.  
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RNAi, for example, is a valuable tool for manipulating cells and discovering new 
therapeutically relevant targets. SiRNA does not readily enter cells and approaches 
developed to delivery siRNA often results in low efficiency and high cellular toxicity54. 
Using cationic CPPs to deliver siRNA by direct conjugation leads to charge neutralization 
and, consequentially, inactivation of CPPs and limited siRNA delivery52. In 2009, Dowdy 
and colleagues reported the delivery of a TAT fusion with a double-stranded (ds) RNA-
binding domain (DRBD) capable of binding siRNA with a high level of affinity54. In this 
work, the researchers showed efficient siRNA delivery and RNAi response in multiple 
cell lines (including several that are difficult to transfect) with no cellular toxicity. 
Additionally, they delivered various siRNA’s, and claimed that their methodology could 
be implemented for a wide range of siRNA. 
The use of oligonucleotides (ONs) is now of interest to the therapeutic industry. In 
brief, ONs are used to form RNA:DNA duplexes that can be sterically blocked or 
recognized by RNase H (termed “antisense”); essentially, they cleave the RNA and disrupt 
gene expression55. This class of therapeutic agent is designed to inhibit important genes 
involved in nuclear splicing and endogenous microRNA56, 57. ONs can be used to sterically 
block protein translation and are more advantageous, due to their greater specificity and 
lower number of off-target effects. These ONs can be synthetically generated, since they 
do not need to be recognized by RNase H. The generation of synthetic ONs opens the door 
to manipulation and optimization that may enhance their use in therapeutic applications.  
One example of a synthetic ON analogue are peptide nucleic acids (PNAs), which 
were recently shown to be promising in gene inhibition. PNAs have a backbone composed 
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of N-(2-aminoethyl)-glycine units linked by amide or peptide bonds, instead of the 
deoxyribose or ribose sugar backbones found in DNA or RNA, respectively. The bases 
are linked to the backbones by a methylene and carbonyl groups. PNAs show very strong, 
sequence-specific RNA binding that can be attributed to less electrostatic repulsion, since 
PNAs do not contain a negatively charged phosphate backbone. Despite being uncharged, 
PNAs are still incapable of cellular entry. Therefore, CPPs have been used as a means of 
enhancing their delivery properties. Langel and colleagues were the first to demonstrate 
that the use of PNA-CPP conjugates blocked the expression of the galanin receptor mRNA 
in human Bowes cells by a 21-mer PNA coupled to Penetratin and Transportan58. Many 
other studies followed their lead, using a variety of CPPs including TAT, polyarginine, 
and Penetratin-PNA constructs; however, the results indicated that these constructs were 
inefficient at retaining their biological activity at low concentrations. According to 
fluorescence-activated cell sorting (FACS) and microscopy analysis, the conjugates were 
taken up by cells and remained trapped in the endocytic pathway. The efficacy of PNA 
delivery by CPP is enhanced by the addition of endosomolytic agents such as chloroquine 
and calcium ions59, 60. Therefore, as in many cases, endosomolytic entrapment of CPPs 
remains a limiting factor in delivery, and methods to enhance CPP activity will help 
advance this application.  
 
1.2.4 In vivo applications for CPP TAT 
The therapeutic in vivo use of proteins has previously been limited to extracellular 
targets and receptors. This is mainly because the proteins used must cross many barriers 
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(including the mucosal membrane and bloodstream) before reaching their target cells. CPP 
conjugation to such therapy can circumvent some of these issues. CPPs can be used to 
increase cellular absorption and protein bioavailability to organs known to be 
impenetrable. One early study that laid the foundation for the in vivo applications of CPPs 
was from the Dowdy lab. Their work reported on the in vivo delivery of β-galactosidase 
to various tissues in mice – including the brain – by intraperitoneal injection of TAT-β-
galactosidase fusion protein61. Following this example, CPPs have been used to deliver 
proteins and peptides as a means of targeting diseases such as cancer, diabetes, and 
ischemia. These studies have also shown CPPs’ success traversing epithelia and the blood-
brain barrier.  
The TAT peptide, for example, has been shown to be effective in cancer treatment 
by delivering various tumor suppressor proteins that are either altered or dysfunctional. 
The p53 tumor suppressor protein is known to induce growth arrest and apoptosis in 
response to cellular stress. More than 50% of all cancers show a mutation in the p53 gene; 
therefore, one approach to combating cancer is via restoration of p53 activity in affected 
cells. However, delivery of the p53 protein to human cells has proven to be challenging. 
While gene therapy could be a way of expressing exogenous p53 in cancer cells, this 
method is associated with a low level of efficiency and undesirable immune responses62. 
Strategies have been employed to restore endogenous p53 in cancer cells, because all cells 
have either wild-type or mutant p53. A peptide derived from the C-terminus of p53 
(p53C’) was shown to activate and restore function to the DNA binding of p53 by an 
unknown mechanism63. Many researchers have used CPPs to enhance the cellular uptake 
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of these p53 peptide constructs. For example, a proteolytically stable TATp53C’ conjugate 
administered by intra-peritoneal injection (IP) to a peritoneal carcinomatosis mouse model 
was shown to induce apoptosis in cancerous cells. These researchers also identified 
specificity and dependency in the peptide to induce arrest in cells that specifically express 
p53. Cancerous and noncancerous cells deficient in p53 showed no response to peptide 
treatment64. Similarly, the p53C’ mdm-2-binding domain of p53 and peptides derived 
from the p16 tumor suppressor have also been conjugated to other CPPs, and have shown 
efficacy in vivo65-67. 
Casein kinase 2 (CK2) is a protein dysregulated in many human cancers that allows 
for the survival of cancerous cells. A cyclic peptide, p15 was shown to inhibit the 
phosphorylation activity of CK2 in vitro68. In this work, the TAT peptide was directly 
conjugated to the cyclic p15 peptide and intratumorally administered to a TC-1 lung 
epithelial tumor implanted in a C57BL6 mouse model. Treatment with this peptide led to 
a decrease in tumor volume compared to a control peptide and phosphate-buffered saline 
administration. These results persisted even after cessation of the peptide treatment, 
indicating that this peptide displays anti-tumor properties.   
Other areas in which CPPs have been used to deliver proteins in vivo include 
treatment of systemic and local inflammation by delivery of a suppressor of cytokine 
signaling69, and cerebral ischemia attributed to proteins from the Bcl-2 family for 
reduction in cerebral infarction70.The latter study and many others showed success in 
using CPP delivery of proteins across the highly restrictive blood-brain barrier (BBB). 
Interestingly, while many CPPs have been used in a variety of in vivo and human clinical 
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trials, there is currently no therapy approved by the Food and Drug Administration (FDA) 
that uses CPPs such as TAT71. Many Phase I and II clinical trials have been implemented 
with varied levels of success; this may in part be due to the challenges and limitations 
discussed below.   
 
1.2.5 CPP-mediated delivery challenges and limitations 
While it is evident that CPPs are useful vectors for delivery in a wide range of 
applications, CPPs have intrinsic limitations that must be addressed. Sensitive assays 
using CPPs show that while they are efficiently endocytosed into cells, their endosomal 
escape efficiency remains sub-optimal. CPPs conjugated with a fluorophore, for example, 
display a punctate peptide distribution when observed using fluorescence microscopy72. 
This distribution is consistent with peptide entrapment in the endocytic compartment. This 
step is necessary because it results in the cargo reaching its biological target (typically 
located in the cytosol or nucleus). While various approaches to enhancing the 
endosomolytic property of CPPs have been implemented and will be discussed in further 
detail below, this remains a bottleneck in the delivery field.  
Another parameter affecting CPP activity is their susceptibility to degradation, due 
to their peptidic nature. This aspect is problematic for both in cellulo and in vivo 
applications. Researchers have employed, for example, unnatural amino acids to 
circumvent this problem. Proteolytic stability will be described below, as many in vivo 
models have implemented this approach as a means of improving CPP activity (as shown 
above with the p53C’ peptide). Furthermore, till date, the lack of sensitive assays that can 
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be used to detect CPPs remains a limitation. For example, to understand the mechanisms 
by which CPPs hijack cells, it is important to track the CPPs upon delivery. This also aids 
in optimizing the delivery approach in failed applications. However, to date the favored 
means of tracking CPPs is by labeling them with a fluorophore, which has been shown to 
affect their membrane permeation activity73. Furthermore, target selectively is a major 
problem for CPPs. Most are not selective to specific cell types, tissues, or organs, which 
is a key drawback for therapeutic applications. However, promising work in this area has 
aimed at increasing CPP selectively by generating activatable (aCPPs) or stimuli-
responsive CPPs, or by adding a localized sequence to direct them to a specific target. 
Roger Tsein first introduced aCPPs in 2004. His work detailed the generation of CPPs that 
remained inactive until exposed to a cancerous cell. The CPPs were engineered to have 
metalloprotease sequence recognition sites that were cleaved upon reaching the cancer 
cells (due to their secretion of metalloproteases). This cleavage resulted in a separation of 
the CPPs from their inactivator (polyglutamate sequences); the CPPs were then activated 
and capable of penetrating the specific cancer cells74. This work has, for example, been 
used for tumor imaging in a mouse model.  
 
1.3 Proposed mechanisms of cellular entry for TAT and its derivatives 
 
While it has been clearly established that CPPs are useful for delivering molecules 
to the interior of cells, the detailed mechanism of how these peptides promote cellular 
internalization remains controversial. For example, most early mechanistic studies using 
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arginine rich CPPs were performed on cells that were fixed. Results from such 
experiments indicated that the D-enantiomer version of the peptide showed similar 
translocation efficiency to the L-isomer CPP. This dismissed the involvement of 
membrane receptors in peptide internalization32, 75. Cellular fixation, however, was later 
found to result in many artifacts and difficulties in evaluating the data35, 36. Currently, these 
artifacts are avoided through the use of live cell microscopy. Additionally, differences in 
the nature of the cargo conjugated to the same CPP have resulted in variability in the 
reported routes of cellular entry. Therefore, a consensus view of the mechanism of cell 
penetration is that two major routes of cellular entry coexist for CPPs. The first is via a 
direct crossing of the plasma membrane, a mechanism that is known to be energy-
independent. The second involves the endocytic pathway. In this scenario, the CPP 
reaches the cytosolic space of a cell via a two-step process: endocytic uptake followed by 
endosomal release. Studies have shown that the CPP internalization process is dependent 
upon multiple factors such as the sequence, concentration, cell type, cell differentiation 
state, and nature and size of the cargo/detection fluorophore73, 76-82. Work by Duchardt et 
al. highlights how three simultaneous mechanisms might occur in three well-known 
CPPs83. 
 
1.3.1 CPP direct membrane translocation  
Evidence of direct membrane translocation was found by using fluorescence 
microcopy on live cells at 4°C (an energy depletion state) 34, 84. In this research, it was 
shown that depleting the energy source did not diminish the uptake of the TAT peptide or 
19 
 
affect its intracellular localization. These results suggest an endocytic-independent route 
for TAT cellular entry and support the notion of a direct membrane mechanism for CPP 
translocation. Consequently, models have been proposed to explain how CPPs might cross 
this bilayer; three such models are the inverted micelle, carpet, and barrel stave or toroidal 
pore models85.  
Derossi et al. was the first to propose the “inverted micelle model.” In this model, 
CPP interaction with the cellular membrane triggers a disruption, forming an inverted 
micelle in the bilayer. As a result, the peptide is located in the inner core of the micelle. 
This can be followed by the inverse mechanism whereby the CPP disturbs the micelle. 
Disruption of the membrane results in the peptide reaching the cytosolic space of the cell. 
NMR studies with the peptide Antp have shown that it can cause micelle formation86. This 
model explains how small hydrophilic molecules can translocate across the membrane; 
however, it fails to explain how large macromolecules can be trapped in the micelle 
membrane and then escape, due to their size limitations. 
In the carpet model or “membrane thinning,” the ability of CPPs to translocate across 
a plasma membrane is attributed to a major destabilization87, 88. This model was used to 
describe the translocation of CPPs at higher levels of concentration. First, the CPP binds 
to the membrane and covers the phospholipids on it in a carpet-like manner. This causes 
a secondary structure change  
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Figure 1-1 Models proposed for CPP direct membrane translocation mechanism. The 
Toroidal pore model: The CPP inserts into the lipid bilayer and induces a membrane 
curvature. The Barrel-stave model: the CPP inserts perpendicularly into the lipid bilayer 
to form a pore in the membrane. The inverted micelle model: The CPP induces the 
formation of inverted hexagonal structures (inverted micelles) in the lipid bilayer .The 
carpet model: the CPPs are adsorbed parallel onto the lipid bilayer, and at a threshold 
concentration this causes a membrane disruption similar to that of a detergent like effect.  
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in the CPPs, and a transient disruption of the bilayer structure. In membrane thinning, 
upon CPP interaction with the outer leaflet of the plasma membrane, rearrangements in 
the membrane cause a local surface tension that allows the CPPs to intercalate within the 
membrane. The carpet model depends heavily on the presence of hydrophobic amino acids 
that are not found in all CPPs. 
In pore formation models such as “barrel stave” or toroidal pores, the peptide 
oligomerizes and inserts itself into the membrane85, 89. In a “barrel stave” model, the 
hydrophobic residues in the CPPs interact with the lipid tails, while the polar residues form 
a ring-structured lumen that is the pore. However, the toroidal model suggests that the 
CPPs interact exclusively with the polar head group of the phospholipid, which results in 
pore formation. While the pores formed are described as transient, they allow for sufficient 
entry of the CPPs into the cytosolic space of the cell. 
Together, these models explain certain aspects of CPPs’ ability to directly 
translocate across membranes. However, one of the major drawbacks is that they fail to 
explain how the uptake of a large hydrophilic cargo can be achieved, especially with no 
associated cellular toxicity. Therefore, it is apparent that while these models describe 
certain aspects of how the CPPs translocate, there is likely an additional mechanism by 
which CPPs and cargo are internalized. 
 
1.3.2 Energy-dependent mechanisms: Endocytosis  
It was necessary to reevaluate the work done on CPPs, as early experiments hinted 
at artifacts in the handling of the samples. Researchers tested whether endocytosis 
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remained a plausible mechanism by which CPPs might be internalized. Endocytosis is a 
naturally occurring phenomenon whereby cells internalize biomolecules, toxins, and many 
required nutrients83, 90-92.  Endocytosis can be divided into two major classes: phagocytosis 
and pinocytosis. Phagocytosis, also referred to as “cell eating,” is a cellular process that 
typically occurs in macrophages; it entails the engulfment of cell debris, bacteria, and 
other large particles93. Pinocytosis, or “cell drinking,” involves the regulated 
internalization of smaller particles; it can be divided into the following sub-groups: 
macropinocytosis, clathrin-mediated, caveolae-mediated, clathrin, and caveolae-
independent endocytosis90, 94. Regardless of the exact endocytic pathway, a CPP must 
interact with the cell’s surface. This is followed by endosomal entrapment and escape 
sufficient to allow the cargo to reach its cytosolic target. The following sections will focus 
on these events. 
 
1.3.3 Cell surface interaction 
As mentioned earlier, the bidentate nature of the side chain of the arginine residue 
found in most CPPs is crucial in its cellular internalization properties. The guandinium 
moiety can form a hydrogen bond with anionic groups such as phosphates, sulfates, and 
the carboxylates found on the components of a cellular membrane95, 96. Such moieties can 
be located on proteoglycans (PGs), or proteins that are glycosylated and situated on the 
cell’s surface. Two examples of PGs include the transmembrane syndecan and membrane 
lipid-linked glypicans97. Linear glycosaminoglycans (GAGs) are often substituted with 
sulfates and, to a lesser extent, carboxylates98. Heparin Sulfate PG (HSPG) plays an 
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important role in the uptake of many arginine-rich CPPs99-102. In vitro experiments 
performed using dynamic light scattering (DLS) and isothermal titration calorimetry (ITC) 
have shown that CPPs, including TAT and nona-arginine, have a high affinity for binding 
to GAGs. This affinity and multiple sites at which CPPs can bind to GAGs are mainly 
driven by electrostatic forces and, to some extent, hydrogen bonding. DLS measurements 
also show the ability of CPPs to form GAG clusters of approximately 2.1 x 105 heparin 
molecules per cluster.   
In cellulo experiments have shown that the uptake of arginine-rich peptides was 
significantly reduced when heparin was incubated in the medium, or upon pre-treatment 
of cells with trypsin resulting in the removal of cell-surface PGs. Work by Raines and 
Chernomordik indicated that the internalization of TAT and nonaarginine was reduced in 
mutant cell types deficient in heparan sulfate (HS) 99, 103. Interestingly, it was also 
demonstrated that HSPG and proteoglycans played an important role in the induction of 
F-actin organization and macropinocytosis100, 104. EIPA, an inhibitor of macropinocytosis, 
significantly reduced the internalization of arginine-rich CPPs in normal cells; however, 
the inhibitor had no effect on the lamellipodia or cellular uptake of the peptide in a 
proteoglycan-deficient CHO (Chinese-hamster ovary)-A745 cell line. The internalization 
of TAT in an HSPG-deficient cell line was 20% to 30% less than that of the wild type. 
Furthermore, the cellular uptake of R8 CPPs was further decreased in proteoglycan-
deficient cell lines, as compared to those that were only HSPG-deficient. These results 
underscore the involvement of additional receptors (including HSPG) that play a role in 
the cellular uptake of arginine-rich CPPs. For example, Futaki and coworkers used a 
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photo- crosslinking approach to identify the membrane-associated receptors of arginine-
rich CPPs. They identified specifically the HSPG Syndecan-4 as a binding partner for the 
photo-labeled octaarginine (R8) CPP105. Others have also reported that over-expression of 
both syndecan-2 and syndecan-4 results in an increased internalization of R8 and TAT.  
HSPGs are known to be involved in many cellular processes, and have been 
reported to be instrumental in ligand catabolism106, 107. For example, some ligands that 
bind HSPGs are endocytosed, which allows them to enter the degradative cellular 
pathway. More importantly, both syndecans and glypicans are actively endocytosed inside 
cells108, 109. For example, assays show colocalization of TMR-R8 with syndecan-4 in 
endocytic vesicles. This advocates that HSPGs have the ability to play a role in CPP 
endocytosis. Moreover, two possible modes of CPP internalization via endocytosis and 
HSPG interactions has been suggested. In the first, CPPs bind to HSPGs (Figure 1-1), 
which then trigger endocytosis via possible interaction with other receptors ultimately 
resulting in CPP internalization in endocytic vesicles. In the second, HSPG’s act as 
binding sites for CPPs that allow for piggybacking into cells. 
 
1.3.4 Endocytic internalization and trafficking 
Various studies have alluded to the ability of CPPs to hijack many pinocytosis 
pathways involving membrane ruffling100. Researchers have employed a variety of 
experimental approaches, such as: low temperature (4°C) incubation, incubation with 
drugs known to inhibit specific endocytic trafficking, colocalization experiments with 
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endosomal markers, and blocking of the endocytic pathway by overexpression of 
dominant negative (DN) protein markers110. Since endocytosis is an energy-dependent 
process, flow cytometry analysis of cells incubated with TAT have shown a dramatic 
reduction in the amount of CPP taken up by these cells after incubation at 4°C99, 111. 
Similar results were obtained by incubating cells using sodium azide and deoxyglucose, 
which depleted the cellular ATP pool99. Futaki and colleagues showed that these results 
could be generalized to various cationic CPPs, such as FITC-labeled arginine-rich 
peptides112, 113.   
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Figure 1-2 Model of the trafficking of a CPP-cargo conjugate through the endocytic 
pathway. From left to right: A CPP-cargo binds to heparin sulfate proteoglycans (HSPGs) 
on the cell surface and induces endocytosis. Endocytosis leads to uptake and entrapment 
of the CPP-cargo inside an endocytic vesicle. The endosomal membrane contains the lipid 
phosphatidylserine (Ptd-Ser) in its outer leaflet. During endosomal maturation, a vacuolar 
H+-ATPase acidifies the lumen of endocytic organelles. The CPP-cargo reaches early 
endosomes (pH~6.5). Concurrently, hydrolases partially degrade HSPGs and release HS 
fragments. Upon further maturation, the CPP-cargo reaches multivesicular bodies, late 
endosomes (pH~5.5), and lysosomes (pH~4.5). The membrane of the intraluminal vesicles 
of late endosomes is enriched with BMP. HS is further degraded to smaller fragments. The 
CPP-cargo is susceptible to degradation due to the low pH and lysosomal hydrolases. The 
figure is used with permission114.  
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This approach does not allow for differentiation among different types of 
pinocytosis (i.e., macropinocytosis, clathrin-mediated, and caveolae-mediated 
endocytosis). However, researchers have attempted to decipher the exact mechanism. To 
do so, selective inhibitors of these endocytic pathways were used to shut down the pathway 
and evaluate the CPP penetration. It was demonstrated that cells treated with inhibitors of 
macropinocytosis, such as cytochalasin D and amiloride (as well as amiloride analogues), 
showed a dose-dependent decrease in TAT and TAT-cargo conjugate uptake111, 115. 
Experiments using such inhibitors, however, are not ideal, as many have been associated 
with cytotoxicity, which could have an impact on the results77. Additionally, within the 
CPP field the specificity of these inhibitors is an issue for debate. An alternative approach 
involves genetically engineering cells to knock down or knock out the expression of 
important endocytic regulators (eg. clathrin or caveolin) to decipher the exact mechanism 
of cellular entry84.  
Markers that probe for specific endocytic routes have been used to evaluate the 
pathway by which CPPs are internalized. These assays are typically evaluated by 
determining the colocalization efficiency between a fluorescently labeled marker and the 
CPPs. For example, an arginine-rich CPP was shown not to colocalize with transferrin, a 
marker for clathrin-mediated endocytosis, while penetratin showed colozalization with 
this marker83, 112, 113. Additionally, common fluid phase markers used for 
macropinocytosis have been employed, such as fluorescent dextrans molecules and FM4-
64115. Results showed that TAT and TAT-cargo conjugates stimulated macropinocytosis 
by a dose-dependent increase in the uptake of dextran markers111, 115. While 
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macropinocytosis is the most recognized uptake mode for the TAT peptide (and will be 
the focus of the discussion below), it is important to note that research has alluded to the 
involvement of clathrin and caveoloe-mediated endocytosis99, 116, 117. Additionally, work 
by Duschardt and colleagues compared the internalization mechanisms of the above-
mentioned CPPs, and noted that they simultaneously occur via all three endocytic 
pathways83. Together, these results suggest a dependence on the exact endocytic pathway, 
based on the physiochemical nature of CPPs. While all of the described mechanisms are 
plausible, the controversy might be explained by the different experimental conditions 
used in all of the experiments, including: cell lines, incubation times, and peptide 
concentrations. 
Since CPPs have been described as a tool for the delivery of cargo to the insides 
of cells, it is important to note that the mechanism of cellular entry described for CPPs 
could be altered by the nature of the cargo81. While this adds to the complexity of the 
process, experiments have indicated the involvement of endocytosis over the direct 
membrane translocation mechanism suggested for CPP entry alone. The CPPs enter via 
the endocytic pathway, a process that involves multiple vesicles and maturation events. 
Macropinocytosis, for example, is a membrane ruffling that occurs in many cell types and 
typically is stimulated by growth (and other cellular factors)90. This ruffling is triggered 
by rearrangement of the cytoskeleton by actin118, 119. It has been shown that treatment of 
cells with an octa-arginine CPP results in significant rearrangement of the F-actin, similar 
to what is observed by epidermal growth factor (EGF), a substance that is known to induce 
this event112. Additionally, cytochalasin D, an inhibitor known to induce F-actin 
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depolymerization, leads to a significant decrease in peptide uptake. Similar results have 
been observed in vitro, using the TAT peptide120. In macropinocytosis, the distal edges of 
the membrane ruffles close up and engulf their extracellular material. A macropinsome is 
formed upon the constriction and closure of the ruffles and open cup-like structure of the 
cellular membrane. Occasionally, the ruffles will recede back into the cytoplasm without 
macropinosome formation. Macropinosomes vary in size from 0.2 to 10 μm in diameter, 
and their formation is not necessarily dependent upon a ligand-receptor interaction121. By 
comparison, the vesicles formed by clathrin and caveoloe-dependent endocytosis are 
smaller (50 and 100 nm, respectively)122, 123. The difference in vesicle size suggests that 
there may be an upper limit to the size of the cargo that can be delivered.  
Irrespective of the exact endocytic internalization process, the CPP and its cargo 
are initially trapped inside the endocytic vesicles. The endocytic pathway involves a 
maturation process that includes an exchange of membrane components, movement 
toward the perinucleur membrane, vesicular fusion and sorting events, an intraluminal pH 
drop attributable to the presence of a vacuolar-type H+ - ATPase (V-ATPase) that pumps 
protons across the membrane, acquisition of degradative enzymes and other 
proteins/lipids, and organelle morphology changes. In the first step, a cargo or CPP is 
internalized into early endosomes (EE). Early endosomes are known to be highly dynamic 
compartments, due to their homotypic fusion capacity124. EEs receive endocytic cargo 
through all types of endocytic pathways91.These organelles are highly complex and 
typically consists of a cisternal region with a thin tubular structure (~60 nm), and a large 
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vesicle (~300-400 nm) that is multi-vesicular in nature125. This gives the EEs a cis-trans 
polarity and could give specificity to docking and fusion sites on the membrane.  
The membrane structure is difficult to envision, as it involves a different curvature, 
composition and organization than that of the plasma membrane. This is due to the action 
of molecular machines that allow for the segregation of proteins and lipids in these 
membranes. The membranes are highly mosaic, with key components that regulate the 
membrane organization and protein transport found in functionalized domains. For 
example, the movement of these vesicles on actin cytoskeletons is regulated by small Rab 
GTPases. There are more than 60 members of the Rab family that are associated with 
different membranes via a geranylgeranyl group attached to the C-terminus of the 
GTPases126. Rab proteins are considered organelle markers, due to the restriction of their 
distribution on respective membranes. For example, Rab5 is typically found on EE 
membranes and is a major regulator for EE maturation. Intraluminal vesicle (ILV) 
formation occurs in EEs in the large vesicles mentioned above. Detachment of these 
vesicles from EEs results in formation of multi-vesicular bodies (MVB) that are typically 
400 to 500 nm in diameter. The vesicles are known to serve as a transport intermediary 
between early and late endosomes (LE)124.  While little is understood about the exact 
membrane lipid composition, it is recognized that MVBs vary between EEs and LEs. The 
lipids and proteins could be selectively sorted into such vesicles because of newly formed 
invaginations at the bilayer.  
Maturation of MVBs results in the formation of LEs. These organelles can vary in 
size and morphology; however, similar to EEs, they have tubular and multi-vesicular 
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regions. They are characterized by a limiting membrane that contains proteins such as 
Rab7 and LAMP1 (or the lysosomal-associated membrane protein-1)127. Interestingly, late 
endosomes are highly enriched with a negatively charged lipid lysobisphosphatidic acid 
(LBPA is interchanged in this text with bismonoacylglycerophosphate (BMP))128, 129. 
BMP is, in particular, enriched in the ILV membranes of LEs, and is not found in upstream 
endocytic organelles. Interestingly, BMP has been implicated in the escape of some 
viruses into the cytosolic spaces of cells by a back-fusion mechanism130, 131. With respect 
to CPPs, it has been shown that TAT binds to BMP-enriched liposomes with a high level 
of affinity132. Furthermore, TAT can specifically promote the leakage and fusion of BMP-
containing liposomes. The last step in this endocytic pathway is a “point-of-no-return.” 
This involves LE fusion with lysosomes. At this stage, the cargo content of the LE is 
narrowed down to molecules that must be degraded. The lysosome compartment contains 
over 60 different acidic hydrolases that are necessary for macromolecular degradation and 
nutrient recycling133. It is crucial that CPPs escape the endocytic pathway before reaching 
this compartment, where the cargo would be degraded (Figure 1-2).  
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Figure 1-3 CPP-cargo conjugate endosomal escape. From left to right: A CPP-cargo 
binds to HSPGs on the cell surface and enter cells, which leads to entrapment of the CPP-
cargo inside an endocytic vesicle. After the CPP-cargo reaches early endosomes, MVBs 
or late endosomes it can escape from the endocytic pathway (red arrows). This is the 
preferred point of exit for a CPP-cargo conjugate in order to avoid degradation. The CPP-
cargo is susceptible to degradation and, in order to avoid degradation and inactivation, it 
needs to escape the endocytic pathway before it reaches lysosomes. The endosomolytic 
activity of CPPs is low and endosomal escape is inefficient. Consequently, the amount of 
CPP-cargo delivered into the cytosolic space of cells is very low. The figure is used with 
permission114. 
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1.3.5 Endosomal escape: The bottleneck 
For a cargo to achieve its biological function, it must reach its cytoplasmic or 
nuclear target. Therefore, after endocytic uptake of the CPP cargo, the CPP must display 
endosomal escape activity. As mentioned above, this must occur before the peptide 
reaches the lysosome in order to avoid CPP and/or cargo degradation. This step is crucial 
because it determines the amount of cargo released to the cytosolic space of the cells. The 
lumen of the endosome closely resembles the outside of the cell; no biological or 
phenotypic response is elicited in these vesicles. However, the endosomal escape property 
of many CPPs is suboptimal, which severely limits the application of many well-known 
CPPs134. Yet many studies have provided evidence that endosomal escape of CPPs does 
occur. For example, Dowdy and colleagues developed assays that employ the CRE 
recombinase system to distinguish between CPPs bound to the cell’s surface (or are 
endocytosed) and cargo that escape from vesicles115, 117. As explained above, this 
illustrates that the incubation of T-cells with TAT-Cre excises the stop codon flanked by 
the loxP sites and induces the expression of EGFP in these cell lines. Similarly, Dowdy 
and colleagues also showed that a CPP fused to a double-stranded RNA binding domain 
was able to deliver siRNA and mediate an RNAi response in a variety of cell lines54. This 
research indicates that endosomal escape of these CPPs occurs; however, these are both 
non-stringent assays, since only a few molecules of Cre or siRNA need to escape the 
endocytic pathway for the phenotypic response to be observed. Conversely, many 
fluorescent or mass spectrometry-based approaches reveal (to different extents) that most 
of the CPPs remain trapped in the endocytic vesicles135-138. For example, TAT has been 
34 
 
conjugated to a ubiquitinated cargo that is designed to be cleaved upon reaching the 
cytosol due to the presence of the deubiquitanse enzymes139. However, the results show 
that while the conjugate was internalized by cells, the ubiquitin was not cleaved. This lead 
to the conclusion that the protein was unable to reach the cytosolic space at a detectable 
level. Additionaly, TAT has been conjugated to dipheria toxin-A (dtA) fragment, which 
is a known potent inhibitor of protein synthesis. This conjugate; however, showed no 
cytotoxicity. This indicates that while the TAT-dtA interacts with the cell surface, its 
escape from endosome hampers its ability to inhibit protein synthesis140. These examples 
highlight that while endosomal escape occurs, it is a highly inefficient process, which 
makes studying the mechanism of this process difficult.  
Studies exploring how a CPP can directly cross the plasma membrane can also be 
applied to endosomal membranes. This is due to the notion that the peptide will encounter 
a similar membrane asymmetry at either the plasma membrane or inside the endocytic 
vesicle. For example, research has suggested that the crossing involves interaction of the 
CPPs with negatively-charged lipids141, 142. The outer leaflet of the plasma membrane (and 
to some extent, the inner leaflet of the endosomal membrane) is composed of zwitterionic 
phospholipid, while the inner leaflet (outer leaflet of endosomal membrane) contains 
negatively-charged lipids such as phosphatidyl serine (Ptd-Ser) 143-145. It has been 
suggested that the CPP on the outer leaflet and the Ptd-Ser underneath it form a membrane 
capacitor that results in a transmembrane potential146. This potential is large enough to 
form electropores through which the CPP and its cargo can pass. Consistent with 
experiments by Tunnemann et al., this model also predicts that oligorarginines entering 
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cells must be superior to oligolysines, and that the more arginines present, the faster the 
transduction147. As explained above, oligolysines are not able to form the CPP-PS 
capacitor, and more arginines result in a higher transmembrane potential. Indeed, while 
this same mechanism could be used to explain CPP release from the endosomal vesicles, 
one must question why the CPP would not disrupt the first membrane it encounters, the 
plasma membrane. One possible explanation involves the interaction of CPPs with 
HSPGs. Such interaction at the cell surface decreases the overall pool of CPPs at the 
membrane. The model also suggests that pore formation depends on the concentration and 
cargo. As a CPP enters the endocytic pathway, it is still bound to the HSPG, limiting its 
ability to form pores. However, the HSPG is gradually hydrolyzed along the endocytic 
pathway. Once the CPP is no longer interacting with the HSPG, it is free to destabilize the 
endosomal membrane.  
As mentioned above, the ILVs of late endosomes are highly enriched with 
negativelycharged lipid BMP. It has been shown that TAT binds to BMP-enriched 
liposomes with a high level of affinity132. Furthermore, TAT specifically promotes the 
leakage and fusion of BMP-containing liposomes. It has also been shown that both 
fluorescently labeled TAT and polyarginine peptides colocalize with Rab5+ and Rab7+ 
cells (Rab5/7+ cells are transfected with plasmids that code for GFP fusions of WT Rab5 
and Rab7 proteins respectively)136. This suggests that these peptides travel along the 
endocytic pathway. Interestingly, the blocking of this pathway by an overexpression of a 
dominant negative Rab5 indicates that TAT escapes the pathway at a stage downstream 
of the early endocytic vesicles. Recently, using a similar approach our lab identified the 
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late endosome to be the escape point of a dimeric version of the TAT peptide. Using a 
combination of in vitro and in cellulo assays, we found this escape to be mediated by the 
interaction of dfTAT with BMP. Using liposomes as a model system, we demonstrated 
that dfTAT causes the leakage and fusion of BMP-containing membranes. These results 
are similar to the work published by Melikov et al. using monomeric TAT. Finally, we 
propose that dfTAT translocates and delivers cargo into the cytosolic space by a leaky 
fusion event occurring in the late endosomal compartment.  
 
 
1.4 Approaches to enhancing CPPs’ endosomal escape properties 
Multiple approaches have been exploited to enhance CPPs’ endosomal escape 
properties, including lysomotropic agents, pH-dependent membrane-active peptides 
(PMAPs), endosomal escape domains (EEDs), photochemical internalization (PCI), and 
multivalency114, 148, 149. Typically, lysomotropic agents are small molecules taken up into 
lysosomes. One of the most well-known lysosomotropic agents is chloroquine, a base that 
accumulates in endosomes and lysosomes upon protonation. Chloroquine’s function is 
concentration-dependent; however, at high concentrations it results in endosome swelling 
by accumulation of counterions of protons in the endosomal lumen150, 151. It has been 
shown, for example, that increasing the concentration of chloroquine can result in 
enhanced delivery of TAT-Cre and TAT-PNA (two cargos mentioned earlier) conjugates 
into the cytosolic spaces of cells115, 152, 153. However, chloroquine has not seen significant 
success in in vivo applications, due to its high cytotoxity. 
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 PMAP-CPP fusion proteins have been used to increase the endosomal escape of 
various cargos. PMAPs typically undergo a conformational change in the endocytic 
pathway as they become protonated; this is due to a decrease in the pH of the lumen of 
endosomes154. This conformational change results in the insertion of the PMAP into the 
membrane; that, in turn, leads to a preference for the lysis of the endosomal membrane, 
while keeping the plasma membrane intact155. One example is HA2, a peptide derived 
from the hemaglutinin protein of the influenza virus. Wadia et al. first reported the 
usefulness of HA2 for the endosomal escape of TAT-Cre. The TAT-HA2 caused an 
enhancement of TAT-Cre cytosolic delivery, as judged by an increase in EGFP 
expression115. This fusion construct has been demonstrated to be useful in certain 
therapeutic applications. A fusion of HA2 to p53 and the CPP R11 (HA2-p53-R11) 
yielded a more efficient reduction in the proliferation of cancer cells, when compared to 
p53-R11 alone156. While many of these concepts are easy to develop as fusion constructs, 
it is was shown that it was not necessary to fuse the cargo to TAT-HA2; a simple 
coincubation protocol of the cargo and TAT-HA2 can be performed157. This is important 
because the cargo of interest is directly conjugated to the PMAP-CPP, which in some 
instances may affect its activity. Similar to lysosomotropic agents, PMAPs have also been 
associated with toxicity and the retention of a PMAP-CPP-cargo conjugate at the 
endosomal membrane.  
EEDs are hydrophobic peptides that can be fused to CPPs to enhance their 
endosomal escape. These domains were inspired by the notion that hydrophobic residues 
are important in virus-mediated endosomal escape. To show their usefulness, a split-GFP 
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fluorescence auto complementation assay was used that allows for a direct correlation of 
the amount of cargo delivered, without signal amplification149. As was reported in 2005, 
the removal of  β-strand 11(β-11) from the GFP construct resulted in a non-fluorescent 
GFP 158, 159. However, trans-coincubation of β-11 with this non-fluorescent fragment 
reconstitutes the fluorescent GFP protein. Using this assay, researchers showed that upon 
incubation of the EED GFWFG tagged TAT peptide fused to the GFP-β-11 in cells, stably 
transfecting the GFP-β1-10 fragment, resulted in an enhanced GFP signal (when 
compared to the GFP-β-11 conjugated to TAT alone). While some of the EEDs containing 
additional hydrophobic residues were toxic to cells, these researchers noted that the 
construct reported above was optimal for enhanced endosomal escape and low toxicity. 
Although this work appears to be a promising approach, further biophysical studies on 
these EEDs are required to delineate their mechanisms of action.  
In an alternate strategy, photosensitizers have been used as a means of disrupting 
endocytic vesicles. In 2004, it was shown that fluorescein and Alexa-Fluor 633 labeled-
CPPs initially entrapped in endosomes were released into the cytosolic spaces of cells, 
upon light irradiation with a 488 nm or a 633 nm laser160. This was also used for the 
delivery of proteins to the insides of cells. FITC-labeled CPP R11s conjugated to p53 were 
released from endosomes, upon light irradiation at 480 nm; they accumulated in the 
cytosolic and nuclear compartments161. Experiments using TMR-TAT indicated that the 
fluorescent CPPs produced singlet oxygen upon light irradiation162. Interestingly, it has 
been shown that while a nona-lysine peptide labeled with TMR, TMR-K9, accumulates in 
endosomes at a higher level than TMR-TAT, it remains trapped and cannot escape upon 
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light irradiation163. This suggests a synergistic affect between the CPP and the fluorophore, 
which transforms the fluorophore into an effective photolytic agent. In general, CPP-
mediated photochemical internalization (PCI) and PCI have, however, also been 
associated with toxicity. While several reports have suggested that this strategy can occur 
without killing cells, many others have shown it to be independent of fluorescent peptide 
concentration164. For instance, plasma membrane permeabilization and blebbing were 
observed when light was used to release TMR-TAT from endosomes. Alternatively, CPP-
mediated PCI has the potential for in vivo uses such as selective cell targeting (e.g., cancer 
cells), since this approach allows for both temporal and spatial control over the process165. 
Attachment of multiple copies of CPPs to the same structural unit, also known as 
multivalent CPPs, has also been used as a means of enhancing the endosomolytic activity 
of CPPs. As this is an approach I used in my thesis work, I will describe the research in 
this field in the section below.  
 
1.4.1 Multivalency: Enhancing endosomal escape 
Multivalency refers to the attachment of multiple copies of a functional element 
together to form a single multivalent unit. Multivalent interactions are observed in many 
biological systems, including in the viral and bacterial attachment to a host cell’s surface 
components and the human immune response166, 167. Multivalent ligands can interact with 
multivalent or multiple monovalent (one-copy) receptors168. The central advantage of 
multi-valency is an increase in the avidity observed in the multivalent compound when 
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compared to the affinity of a monovalent molecule. This is due to an increase in the local 
concentration of the molecule, which is a consequence of the restriction in spatial 
configuration of each functional element. This phenomenon is referred to as the chelate or 
avidity effect169.  
 
1.4.2 Approaches to and implications of cargo delivery 
Different methods have been exploited to generate multivalent CPPs (mCPPs), 
such as complexation, oligomerization/aggregation, and certain coupling mechanisms. 
These approaches have allowed for the pairing of multivalent peptides with cargos of 
interest169. For example, Torchillin et al. reported on the complexation of over 100 TAT 
peptide copies to a liposome modified with the PEGylated lipid p-nitophenylcarbonyl-
PEG-phosphatifylethanolamine(pNP-PEG-PE)170. These TAT-conjugated liposomes 
have been used in the DNA transfection of mouse fibroblasts and Lewis Lung carcinoma 
cells171, 172. Additionally, it has been shown that various CPPs conjugated to liposomes 
can enhance their internalization properties in a manner dependent upon the number of 
CPPs per liposomal surface173. In another study, superparamagnetic nanoparticles were 
complexed with TAT peptides to achieve a multivalent CPP complex174, 175. These 
complexes demonstrated a dose-dependent increase in translocation efficiency as a 
function of the number of TAT copies, and have been used to track hematopoietic stem 
cells and antigen-specific T-lymphocytes176, 177.   
The cargos being delivered have in some instances been used to generate 
multivalent CPP systems. Such loads typically either oligomerize or are prone to 
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aggregation. For example, several CPPs have been fused to p53, the tumor suppressor, 
due to its ability to form a tetramer178, 179. Specifically, using solid-phase peptide synthesis 
TAT, decaarginine and decalysine have been fused to the N-terminus of the 
tetramerization domain of p53 (p53tet) (Figure 1-3), which corresponds to residues 325 
to 355180, 181. The results showed that the tetravalent peptide displayed a 10- to 100-fold 
enhancement in internalization efficiency, when compared to a monomeric counterpart 
(an L334P mutation in the p53 tet resulted in the generation of mutants unable to form a 
tetramer known as p53 mono). These tetravalent compounds have also been used as a 
more  
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Figure 1-4 mCPP systems and their interactions with membranes. (a) Strategies used 
to generate mCPPs. From left to right: (1) The p53tet-CPP system involves connecting the 
tetramerization domain from the human tumor repressor protein p53 to a CPP. The peptide 
sequence is generated using SPPS. After purification of the peptide sequence, p53tet 
selfassembles into a tetramer producing a tetravalent CPP. (2) Loligomers are a “squid-
like” mCPP system. The CPP is attached on the surface of a polylysine branch scaffold. 
The scaffold and the peptide are generated using SPPS. The number of branches of this 
mCPP system will depend on the number of Lys coupling steps. (3) The branched CPP 
system involves the generation of a peptide scaffold of Lys(ε-NH-Cys)Gly repeats to 
which a CPP-thioester is added using native chemical ligation (NCL). The peptides were 
generated using SPPS although production of recombinant peptide or protein thioesters is 
possible using intein fusions. A fluorophore was added on the N-terminal end of the 
scaffold peptide to serve as both an imaging agent and a small model cargo. (4) 
Dendrimers are mCPPs having a “tree-like” shape and are usually generated using 
divergent or convergent methods. CPPs have been attached to the surface of 
polyamidoamine (PAMAM), polypropylenimine (PPI) or polyethylenimine (PEI) 
dendrimers. The number of CPPs on dendrimers is among the highest observed for 
MCPPs. (b) A possible model for the mode of action of CPPs versus that of MCPPs. In 
this example, a CPP-cargo is present at the membrane of endosomes at a low local 
concentration, leading to poor endosomolytic activity. In contrast, a MCPP-cargo displays 
multiple copies of the CPP. This leads to efficient membrane interactions and a possible 
enhancement in membrane disruption. In some cases however, too many CPP copies 
might cause unproductive membrane interactions such as tight binding to HSPGs. This in 
turn might lead to poor cellular penetration. The figure is used with permission114. 
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efficient means of delivering DNA into cells (as compared to monomeric forms), with the 
tetravalent decaargine (10R-p53tet) peptide being the most efficient at cellular entry. An 
additional example is fusion constructs of Antp or TAT with the Grb10 SH2 domain or 
the BH4 domain of Bcl-XL182, 183. These domains are predicted to form aggregates in a 
solution, due to a stretch of five or more amino acids that have a 50% probability of 
undergoing β-strand driven aggregation. 
Another example of multivalent CPPs was generated through a branching system. 
For example, dendrimers are functionalized scaffolds to which multiple CPPs can be 
conjugated.184-188 Dendrimers are highly branched molecules that have tree-like shapes. A 
specific example of a dendrimer is a “squid-like” construct known as a loligomer189-192. A 
loligomer contains eight CPP copies conjugated on a branched polylysine scaffold. These 
branched peptides have been successful at condensing DNA and increasing the efficiency 
of its internalization through the formation of a DNA-dendrimer conjugate192. Loligomers 
have also been conjugated to antigenic epitopes, and have successfully generated cytotoxic 
T-cell responses191. Other scaffolds have been created to generate mCPPs that display two, 
three, or four CPP copies. For example, a TAT peptide functionalized with a C-terminal 
thioester was conjugated to the cysteine of a (Lys(ε-NH-Cys)Gly)n scaffold by native 
chemical ligation193, 194. Also, CPPs modified by the addition of cysteine residues have 
been dimerized to form simple multivalent CPP systems with enhanced internalization 
properties195, 196. The latter will be the approach I use in this thesis to generate a simplistic 
multivalent CPP system. 
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1.4.3 Limitations and challenges 
While multivalent CPP systems have been shown to enhance internalization 
properties, many challenges to this approach still exist. One of the major difficulties for 
mCPP is construct generation; such reagents are complex and difficult to synthesize 
compared to their monomer counterparts. This often leads to low yields, limitations on the 
size of the molecule generated, and homogeneity in the final product194. Additionally, the 
effectiveness of using branched CPPs for in vivo delivery systems is uncertain, due to their 
potential immunogenicity. Multivalent CPPs share common structural features with 
multiple antigenic peptides (MAPs). MAPs induce immune responses by their display of 
multiple copies of an antigen that can be recognized by T-cells. In a similar fashion, 
mCPPs may induce comparable undesirable immune responses in vivo. Moreover, it is not 
completely understood how multivalent CPPs are internalized or result in enhanced 
endosomal escape, as compared to their monomeric counterparts.  
While some laboratories have reported an enhanced efficiency in dimeric CPPs, 
other research has shown that a scaffold with two TAT copies does not lead to enhanced 
cell penetration. Such results clearly highlight that the exact nature of the construct could 
affect the cell penetration properties. Therefore, structure activity relationship studies are 
necessary to understand how molecular parameters participate in CPP interaction with cell 
surfaces and internalization mechanisms. While some research has reported that mCPPs 
interact with heparan sulfate proteoglycans and are internalized via the endocytic pathway, 
many questions remain as to how these peptides escape from that pathway. Furthermore, 
many strategies have been developed to enhance their endosomal escape properties, as a 
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number remain suboptimal. These include combining the multivalency and with pH-
responsive domain (as mentioned above). Lastly, as described for their monomeric 
counterpart, the effect of conjugated cargo on the internalization and overall mechanism 
of mCPPs remains unknown. Therefore, in-depth structure activity and mechanistic 
studies are important to finding the answers to many unanswered questions. This would 
allow for the optimization and generation of new and improved delivery agents.  
 
1.5 Enhancing the chemical stability of CPPs  
 
Despite their promising application as a drug delivery tool, the use of CPPs and 
branched CPPs has been limited due to their inherent chemical instability. Such peptides 
are prone to degradation by extracellular and intracellular proteases. This degradation can, 
ultimately, diminish CPP activity, since it may result in inactive compounds or a decreased 
concentration of the peptide exposed to the biological matrix. To avoid or slow down the 
kinetics of CPP degradation, stable or non-degradable CPPs have been generated.  
 
1.5.1 Classes of non-degradable CPPs 
Stereochemical modifications  
One of the simplest approaches employed to improve CPP stability is changing the 
stereochemistry of the amino acid incorporated into them. The D-form of amino acids is 
not recognized by cellular proteases, and therefore peptides that are stable can be 
generated in this fashion. D-amino acids can be incorporated into the entire peptide 
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sequence, or at different positions within the sequence. Researchers have found success 
with several CPPs, such as polyarginine, pVEC, and penetratin32, 75, 197. Studies have also 
shown that the stability of a CPP can be modulated by changing the position and number 
of D-amino acids incorporated in its sequence198. As peptide chirality can play a role in 
the interaction of CPPs with the cell surface, altering the stereochemistry could affect the 
internalization efficiency and general mechanism. Additionally, the impact of the chirality 
of CPPs (e.g., R9 and penetratin) on cellular internalization has been reported to vary 
among different cell lines199.  
While the incorporation of D-amino acids could improve the stability of CPPs, it 
was reported that D-penetratin resulted in a decrease in uptake of some cargos, as 
compared to the L-counterpart200. To circumvent this problem, studies with human 
calcitonin (hCT)-derived CPPs have shown that substituting only the residues recognized 
by proteases will improve stability while maintaining the CPPs’ internalization 
property201. In the 1980s, Chorev and Goodman hypothesized that exchanging the peptide 
sequence in all D-amino acids (inverso) and then reversing the order of the amino acid 
sequence (retro) would result in a peptide with side chains that would preserve the 
stereochemistry as the parent L-amino acid peptide202, 203. These peptides referred to as 
retro inverso (RI) peptides, have been implemented as a means of enhancing peptide 
stability in many applications, with a history of mixed success204, 205. Dowdy and 
colleagues used the RI construct of the TAT peptide conjugated to a p53 activating peptide 
(RI-TATp53C’) to activate the p53 protein in cancer cells. They showed that the RI-
TATp53C’ could arrest the cell cycle at a substantially lower concentration than the L-
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isomer peptide p53C’TAT. Additionally, a single treatment with the L-isomer resulted in 
the cells reentering the cell cycle after 24 h, while the RI peptide was able to maintain its 
activity for more than seven days64. Similar results have been observed for other CPPs, 
such as penetratin206.   
Incorporation of non-natural amino acids 
Non-natural amino acids can be incorporated into the peptide chain as a way of 
avoiding recognition by proteases. For example, alternative alpha (α) amino acids with 
unnatural side chains or the amino group attached to a group other than the alpha carbon 
have been used. This approach maintains the peptide backbone topology, while generating 
unrecognized side chains. For example, α-amino isobutyric acid, a non-natural amino acid, 
is known to promote helix formation; this conformational constraint may increase peptide 
stability207. This approach was used to enhance the functionality of the CPP mitoparan208. 
Additionally, α-aminoxy acids have been employed as scaffolds to enhance the stability 
of analogous oligoarginine peptides209. Peptide hybrids were generated by alternating the 
α-aminoxy acids and a natural α-amino acid, resulting in peptides with enhanced stability, 
low cytotoxicity, and efficient cytosolic-penetrating CPPs210.  
Similarly, beta (β) and gamma (γ) amino acids have been incorporated solely or in 
addition to α-amino acids into peptide chains. In β-amino acids, the amino group is 
attached to the β-carbon instead of the α-carbon. These β-amino acids have been used to 
study the effects of the conformational stability and geometry of the guanidium group on 
polyarginine CPPs211. The β-amino acids’ incorporation into CPPs resulted in more stable 
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conformers and CPPs with enhanced penetration efficiency, when compared to non-
modified CPPs212-214. Similar results have been reported using γ-amino acids215. 
Cyclic and stapled peptides 
Cyclic peptides were inspired by molecules observed in nature, such as 
cyclosporin. Cyclosporin is a natural product obtained from fungus that is known to be a 
stable cyclic peptide composed of modified D-amino acids. Encouraged by this peptide, 
N- to C-termini cyclization of many CPPs has been performed in an effort to enhance their 
proteolytic stability. For example, Tunneman et al. incorporated additional lysine and 
glutamic acid at respective TAT termini to allow for cyclization216. Results from this work 
showed that while cyclic and linear TAT entered cells with similar levels of efficiency, 
the kinetics of the entry were different. Cyclization of the peptide resulted in its entering 
cells at a faster rate (by 15 min) than linear TAT. While cyclization enhances the stability 
of CPPs, the authors also proposed that the conformational restriction that allows for 
maximal separation of the guanidinium groups aids in the enhanced internalization of 
cyclic CPPs217. Further examples of cyclic peptides include: macrocyclic CPPs, bicyclic 
CPPs, and cyclic cysteine knots (CCK), all of which have been reported to have enhanced 
stability, increased internalization and release properties, and lower cytotoxicity218-220. 
Bicyclic peptides can be used as a dual-function CPP, with one cycle responsible for 
internalization and the other for targeting purposes. This has been applied to intracellular 
targets such as Pin 1 isomerase and tyrosine phosphatase 1B. CCK’s, or cyclic peptides 
that have six cysteines in their sequences for disulfide bond formation, were inspired by 
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nature. CCK scaffolds have been engineered and modified to be used in therapeutic 
applications221.  
Stapled peptides, as mentioned above, are peptides that have a stable α-helix 
structure. The α-helix can be stabilized via side chains cross-linking on the same side of 
the helix, including disulfide bridges or hydrocarbon stapling (click chemistry involving 
a ring-closing olefin metathesis, etc.). The increase in helicity of the stapled peptides 
depends on the amino acid sequence and exact position of the staple. While this 
conformational restriction aids in the proteolytic stability of the peptide, interest in stapled 
peptides has primarily been due to their intrinsic cell-penetrating properties. Even though 
stapling does not mean that a peptide becomes cell-permeable, most stapled peptides are18. 
This is thought to be due to the conformational restriction of the peptide, as seen with 
cyclic peptides. However, it remains unclear whether the staple itself, the increase in 
helicity or the exact residues play a bigger role in the cellular penetration activity of these 
peptides18. 
 
1.5.2 Limitations and challenges 
Ways to improve peptide stability are regularly being researched222. Enhanced 
stability, however, may come at the cost of a decrease in biodegradability. Many stabilized 
CPPs are made of non-natural amino acids that cannot be reused for new protein synthesis. 
Additionally, it is important for a peptide to be degraded after achieving its biological 
response, since this may reduce cellular toxicity levels. Interestingly, it has been reported 
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that while RI peptides are more stable than their L-counterparts, they are associated with 
severe cytoxicity223. This toxicity is characterized for example by a loss of mitochondrial 
transmembrane potential, decreased metabolic activity, cellular morphology changes, and 
an induction of apoptosis. Additionally, while L- to D- conversion can enhance the 
stability of CPPs, it could also affect CPP cellular internalization223. For example, the RI 
form of M918 is a CPP derived from the tumor suppressor protein p14ARF, which exhibits 
lower internalization levels than its L-counterpart. While this is not the case for all CPPs, 
it raises the issue of whether the generation of new stabilized CPPs requires complete 
reevaluation of their internalization efficiency and mechanisms. Essentially, the effect on 
internalization could ultimately also affect endosomal escape. Assuming fewer CPPs are 
internalized, a lower CPP concentration at the endosomal membrane would result in less 
efficient membrane disruption.  
 
1.6 Goal of this research 
In this study, I used a multivalent approach to improve the endosomal escape 
property of CPPs. Many multivalent methods suffer from complexity in the synthesis, low 
yields, and high toxicity; I aim to overcome all of these complications. My work focuses 
on the generation of a multivalent CPP that combines the important parameters of an ideal 
delivery strategy: simplicity of synthesis and protocol, high delivery efficiency, low 
cellular toxicity, and the ability to deliver proteins to live cells. Due to the low level of 
efficiency previously seen in CPPs, it has been difficult to decipher the exact molecular 
parameters required to generate effective endosomolytic agents. With a highly efficient 
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multivalent system, I hope to answer two key questions: 1) What is the impact of peptide 
chirality and proteolytic degradation on cell penetration (Chapter 3)? and 2) What are the 
important residues in CPP sequence required for endosomal escape (Chapter 4)? Next-
generation peptides based on the multivalent prototype were generated using solid phase 
peptide synthesis (SPPS) to asses these questions. Liposomes were used as an in vitro 
model membrane system, allowing for the assessment of these peptides and comparisons 
to be made in a controlled setting. These assays were complemented with in cellulo assays 
that allow me to distinguish the activity of the various peptide constructs in their cellular 
environment. The results of this work will aid in the development of new and improved 
delivery agents for both therapeutic and cell biology applications.  
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2. DELIVERY OF PROTEINS, PEPTIDES AND CELL-IMPERMEABLE SMALL 
MOLECULES INTO LIVE CELLS BY INCUBATING WITH THE HIGHLY 
ENDOSOMOLYTIC DELIVERY AGENT, dfTAT157, 224 
2.1 Introduction 
 
In this chapter, I aimed to generate a multivalent CPP system that enables the 
delivery of macromolecules inside live cells. Using a simple synthesis approach, I generate 
a dimeric fluorescent derivative of the CPP TAT, dfTAT, and determine its activity inside 
cells. I hypothesize that dfTAT will have an enhanced endosomolytic activity compared 
to the monomer TAT. This is based on the notion that multivalency increases the local 
concentration of CPPs at the membrane. Here, I demonstrate that dfTAT penetrates live 
cells by escaping from endosomes with a particularly high efficiency. By mediating 
endosomal leakage, dfTAT also delivers a variety of proteins to the cytosolic space of 
cells after a simple co-incubation protocol. I show that cytosolic delivery is achieved in 
several cell lines and primary cells, with relatively small amount of material remained 
entrapped inside endosomes. Delivery did not require a binding interaction between 
dfTAT and a protein, multiple copies could be delivered simultaneously, and delivery 
could be repeated.  
 
 
*This chapter is reprinted with permission from “Protein delivery into live cells by incubation with an 
endosomolytic agent” by Erazo-Oliveras, A.+; Najjar, K.+; Dayani, L.; Wang, T.-Y.; Johnson, G.A. and 
Pellois, J.-P. Nature Methods 2014, 11 861-867. doi: 10.1038/nmeth.2998. +authors contributed equally. 
Copyright (2014) by Kristina Najjar 
* This chapter is in part a collaboration from Alfredo Erazo Oliveras Dissertation titled: “Cytosolic 
delivery of proteins, peptides and cell-impermeable small molecules into live cells utilizing virus-inspired 
multivalent cell-penetrating peptide: principles and mechanism”.  
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Surprisingly, dfTAT-mediated delivery did not noticeably affect cell viability, cell 
proliferation or gene expression. dfTAT-based intracellular delivery should be useful for 
cell-based assays, cellular imaging applications and the ex vivo manipulation of cells. 
2.2 Results 
Protein transduction strategies are extremely useful for the investigation and 
manipulation of cellular processes. For example, proteins labeled with fluorophores, stable 
isotopes or reactive tags and delivered into live cells can, for instance, be used for imaging 
applications or in cellulo structure determination by NMR, respectively225-227. Despite the 
unique opportunities provided by protein transduction technologies, current protocols are 
often suboptimal134, 228. Proteins fused to a protein transduction domain (PTD) or CPP 
typically use the endocytic pathway as a route of cellular entry229. However, the majority 
of PTD-protein fusions endocytosed by cells typically remain trapped inside endosomes; 
as a result, the amount of protein that reaches the cytosol of cells is low, and the biological 
outcomes achieved are poor230. A possible solution to this problem is to increase the ability 
of proteins to escape from the endocytic pathway. This is possible with membrane-
destabilizing agents that disrupt endosomes231-233, but to date, the efficiencies of available 
reagents have remained low234, 235. Ideally, a delivery strategy should combine efficient 
endosomal escape, low cell toxicity and convenience. I aimed to develop an innocuous 
endosomolytic agent that efficiently delivers protein cargos into cells.  
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2.2.1 Generation of dfTAT and its monomeric counterparts 
 I used TAT as the template for my design of the dimeric delivery vehicle. The 
fluorescent peptide CK(ε-NH-TMR)-TAT (fTAT) was generated by SPPS using standard 
Fmoc protocols. I introduced a lysine at the N-terminus of TAT bearing a Mtt protecting 
group at the ε-NH2. The lysine side chain protecting group was removed orthogonally with  
2 % trifluoroacetic acid (TFA) and modified with TMR for fluorescence imaging. I added 
a cysteine at the N-terminus to permit dimerization by disulfide bond formation (Figure 
2-1). Disulfide bonds are relatively stable inside endosomes but are cleaved following 
endosomal escape and upon entry into the reducing cytosolic space of cells134, 236, 237. TFA 
cleavage and preparative scale reverse phase HPLC purification afforded fTAT (Figure 
2-2 (A)). Incubation in oxygenated medium and oxidation of the free cysteine thiol of 
fTAT generated the dimer (CK(ε-NH-TMR)TAT)2 (dfTAT; Figure 2-2 (B)). 
Alternatively, the thiol of CK(ε-NH-TMR)TAT was acetamidated to obtain a peptide 
(acfTAT) that cannot dimerize (Figure 2-3) or was reacted with bis(maleimido)ethane to 
obtain a nonreducible dimer (nrdfTAT) (Figure 2-4). dfTAT, acfTAT and nrdfTAT were 
purified by HPLC and their identities were evaluated by MALDI-TOF mass spectrometry 
(Figure 2-3, 2-4 and 2-5). 
 
 
 
 
55 
 
 
 
 
Figure 2-1 Multivalent CPP system using disulfide bonds. Peptides will be generated 
using SPPS, which should allow obtaining higher yields than before. The multivalent CPP, 
dfTAT, will be generated by a simple oxidation step with a peptide containing one Cys 
residue (top) then allowing the product of that reaction to react with itself to form the 
dimer product.  
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Figure 2-2 Chemical structure of fTAT and dfTAT. (a) fTAT contains the TAT 
sequence, a fluorescently- labeled Lys residue and Cys residue (Lys and Cys were 
conjugated to the N-terminus of TAT). (b) The thiol group in fTAT is oxidized to form a 
disulfide bond and generate dfTAT. The exact mass of each peptide is shown. 
b
b
b 
a 
57 
 
 
 
 
Figure 2-3 Characterization of acfTAT. (a) Chemical structure of acfTAT and its exact 
mass. The alkyl amide group on the peptide prevent dimerization in cells (arrow). (b) 
HPLC chromatogram of pure acfTAT and MALDI-TOF spectrum. 
 
 
b
b
b 
a 
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Figure 2-4 Characterization of nrfTAT. (a) Chemical structure of nrfTAT and its exact 
mass. (b) HPLC chromatogram of pure nrfTAT and MALDI-TOF spectrum. The 2153 
m/z peak corresponds to doubly charged nrfTAT. 
 
b
b
b 
a 
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Figure 2-5 Characterization of dfTAT. HPLC analysis of reduction reaction of dfTAT 
after addition of the reducing agent tris(2-carboxyethyl)phosphine (TCEP). Pure dfTAT 
was mixed with a solution of TCEP (50 mM) in water and allowed to react for 15 min. 
The HPLC chromatogram shows a peak with rt = 14.3 min and is identical to the retention 
time of pure fTAT. 
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2.2.2 dfTAT penetrates the cytosol of live cells efficiently 
I incubated fTAT, acfTAT, dfTAT and nrdfTAT for 1 h with HeLa cells, the mouse 
neuroblastoma cell line Neuro-2a and human primary dermal fibroblasts (HDFs). 
Internalization was first assessed by fluorescence microscopy. acfTAT (1–20 μM) 
localized in a punctate distribution consistent with accumulation of the peptide inside 
endosomes72 (Figure 2-6 (A)). The fluorescence signal of dfTAT was also punctate below 
2 μM but became distributed in the cytosolic space and nucleus of an increasing number 
of cells at higher concentrations (Figure 2-6 (B) and 2-7). The overall amount of dfTAT 
inside cells (in the cytosolic space and endosomes) also increased with the concentration 
of dfTAT administered extracellularly (Figure 2-6 (C)). I delivered dfTAT into the 
cytosolic space and nucleus of additional cell lines and primary intestinal porcine 
epithelial cells (Figure 2-8). In all cases, cells were not stained with SYTOX® Blue, 
indicating that their plasma membrane was not compromised and that the cells imaged 
were alive. Similarly to acfTAT, fTAT was localized inside endosomes at up to 10 μM. 
However, at 20 μM, many cells displayed cytosolic fluorescence, indicating that fTAT 
reproduced some of the activity of dfTAT by possibly dimerizing in situ (Figure 2-9). 
Finally, nrdfTAT displayed a cytosolic distribution similar to that obtained with dfTAT 
(Figure 2-10), indicating that the disulfide bond present in dfTAT was not required for 
cytosolic penetration. 
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Figure 2-6 Cytosolic delivery of dfTAT in live cells is efficient. (a) Cellular localization 
of acfTAT and dfTAT assessed by fluorescence microscopy. Cells were incubated for 1 h 
with either acfTAT (20 μM) or dfTAT (5 μM), washed and imaged with a 100× objective. 
Monochrome images represent the emission of TMR at 560 nm. Scale bars, 10 μm. (b) 
Comparison of the cytosolic delivery efficiency of acfTAT, fTAT and dfTAT. Cells were 
incubated with acfTAT, fTAT or dfTAT (1–20 μM) for 1 h. The number of cells with 
detectable cytosolic and nuclear fluorescence distribution in microcopy images was 
counted and divided by the total number of cells present (1,000 cells per experiment). (c) 
dfTAT overall uptake in HeLa cells as a function of the concentration of dfTAT present 
in the incubation medium. Cells were incubated with dfTAT (1–10 μM) for 1 h, and 
relative uptake was assessed quantitatively by measuring the bulk fluorescence of cell 
lysates (300,000 cells per experiment). a.u., arbitrary units. The data in b and c represent 
the mean of triplicate experiments and the corresponding s.d. 
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Figure 2-7 Cytosolic and nuclear fluorescence distribution of dfTAT is concentration 
dependent. HeLa cells were incubated with varying concentration of dfTAT (1, 2, 2.25, 
2.5, 2.75, 3, 4, 5 μM). Cells were washed and imaged. Inverted monochrome images (20X 
objective) show a dramatic increase in the cytosolic delivery of dfTAT between 2-5 μM. 
Although not shown here, the number of cells in each image is approximately the same as 
determined by brightfield imaging. Cells that display a fluorescence punctate distribution 
are not clearly visible under these imaging conditions. Further analysis of these cells using 
100X objective clearly show a fluorescence punctate distribution indicative of peptide 
trapped in endosomes. Scale bars: 50 μm 
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Figure 2-8 Delivery of dfTAT was achieved in multiple cell types. HeLa, COLO 316, 
NIH 3T3, HaCaT, Neuro-2a, MCH58, primary HDF and primary IPEC-1 cells were 
incubated with 5 μM dfTAT for 1 h, washed and imaged The fluorescence signal detected 
was in the cytosolic space and nucleus of cells (top panel 100X objective). After imaging 
cells were incubated in a humidified atmosphere containing 5 % CO2 for 24 h, washed and 
imaged. (top panel: 20X objective, bottom panel: 100X objective) Cell morphology did 
not change after 24 h. Cell viability was assessed by exclusion of the cell-impermeable 
dye SYTOX® Blue after both 1 h and 24 h. The TMR fluorescence at the 24 h time point 
is different to that obtained at the 1 h time point presumably because of the intracellular 
degradation of the peptide. Scale bars: 20X objective, 50 μm; 100X objective, 10 μm. 
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Figure 2-8 Continued. 
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Figure 2-8 Continued. 
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Figure 2-9 fTAT cellular localization after incubation with live cells depends on its 
concentration in the extracellular media. Inverted monochrome (black = fluorescence 
signal, white = no signal) fluorescence images of HeLa cells incubated with 10 or 20 μM 
of fTAT for 1 h. fTAT displays at fluorescence punctate distribution at 10 μM fTAT (left 
panel) while at 20 μM fTAT shows a significant increase in the population of cells 
displaying cytosolic and nuclear fluorescence distribution. Scale bars: 50 μm. 
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Figure 2-10 Delivery of nrdfTAT into live cells. Cells were incubated with nrdfTAT ((i) 
2.5–5 μM and (ii) 5-10 μM*) for 1 h. Fluorescence images (monochrome (white = 
fluorescence signal, black = no signal) 20X image, center panel) show cytosolic delivery 
of nrdfTAT into HeLa cells at both concentrations. SYTOX® Blue (2 μM) was used as 
an indicator of cell death. Scale bars: 50 μm (inverted monochrome 20X image).  
*The concentration of nrdfTAT was estimated by measuring the absorbance of TMR using 
a spectrophotometer, as described with other peptides. However, nrdfTAT has two TMR 
spaced by a 8.0 Å BMOE linker and such close proximity might affect the extinction 
coefficient of TMR. In order to take this effect into account, a concentration range for 
nrdfTAT was calculated based on the extinction coefficient of free TMR (91,500 mol-
1cm-1) and that of dfTAT (45,500 mol-1cm-1) (dfTAT also has two TMR in close 
proximity).  
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2.2.3 dfTAT penetrates the cells in a two-step process 
To test whether endosomal escape is involved in delivery of dfTAT, I assessed the 
effects of molecules that influence endocytosis238-241. Whereas filipin and chlorpromazine 
(inhibitors of caveolae- and clathrin-mediated endocytosis) had little effect, amiloride 
(inhibitor of macropinocytosis) and bafilomycin (vacuolar H+-ATPase inhibitor) inhibited 
the delivery of dfTAT, suggesting that macropinocytosis and endosomal acidification are 
important for cytosolic penetration (Figure 2-11). To assess whether endosomal escape 
could be visualized, dfTAT was incubated with cells for 5 min to permit endocytic uptake; 
cells were washed and then imaged in a pulse-chase experiment. dfTAT was initially local-
ized in a punctate distribution consistent with that of endosomes (100X objective, data not 
shown). Yet, an increasing number of cells displayed a cytosolic distribution at later time 
intervals. When imaged with a 20X objective, cells with a cytosolic distribution were 
brighter than cells with a punctate distribution (this is consistent with TMR being partially 
self-quenched when dfTAT is trapped inside endosomes; Figure 2-12), and this was used 
to quantify dfTAT’s cytosolic penetration as a function of time. Consistent with the notion 
that dfTAT penetrates the cytosolic space after endocytic uptake, the percentage of cells 
with cytosolic fluorescence increased from 4.3 % to 76.9 % over a period of 40 min 
(Figure 2-13). To further test whether dfTAT escapes from endocytic organelles, I 
incubated cells first with that dfTAT penetrates the cytosolic space after endocytic uptake, 
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Figure 2-11 Effect of endocytosis inhibitors on the cellular distribution of dfTAT. 
HeLa cells were pretreated with each inhibitor for 20 min, washed and incubated with 5 
μM dfTAT and inhibitor for 1 h. The percentage of cells displaying a cytosolic and nuclear 
fluorescence distribution was quantified as in Figure 2-6 (B). Inset, punctate distribution 
of dfTAT in the presence of bafilomycin (1,000 cells per experiment, experiments were 
performed in triplicates, mean ± s.d. represented). Scale bar: 10 μm. 
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Figure 2-12 Fluorescence emission spectra of dfTAT (5 μM) before and after 
reduction with the reducing agent TCEP (50 mM). The sample was excited at 556 nm 
and the emission was recorded between 570-750 nm. The emission spectra show that the 
fluorescence emission of dfTAT increases upon reduction of its disulfide bond. This is 
indicative of TMR self-quenching in the context of dfTAT. This evidence suggests that 
TMR fluorescence is quenched inside endosomes where, presumably, the peptide exists 
as a dimer. This behavior displayed by dfTAT allowed me to design the experiment 
performed in Figure 2-12.   
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Figure 2-13 Pulse-chase experiment showing the progressive cytosolic penetration of 
dfTAT. HeLa cells were incubated with dfTAT (5 μM) for 5 min, washed and imaged 
with a 20X objective (TMR fluorescence images are represented as inverted monochrome) 
(a schematic of the protocol is shown on the left). The imaging intervals and corresponding 
percentages of cells with a cytosolic signal are represented. Scale bars: 50 μm. 
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the percentage of cells with cytosolic fluorescence increased from 4.3 % to 76.9 % over a 
period of 40 min (Figure 2-13). To further test whether dfTAT escapes from endocytic 
organelles, I incubated cells first with DEAC-K9, a fluorescent peptide that accumulates 
inside endosomes (Figure 2-14)162. After washing, cells were incubated with dfTAT. 
Although only a punctate distribution of fluorescence was observed with cells incubated 
with DEAC-K9 alone, subsequent addition of dfTAT led to a bafilomycin-dependent 
redistribution of the DEAC-K9 signal throughout the cytosolic space and nucleus (Figure 
2-15). These data indicate that dfTAT accumulates inside endosomes already containing 
DEAC-K9 and that dfTAT endosomal escape is also accompanied by the leakage of 
luminal DEAC-K9. 
 
2.2.4 dfTAT-mediated endosomal leakage is efficient  
When endocytosed at similar levels, dfTAT escaped endosomes, whereas acfTAT 
did not, indicating that dfTAT is greatly more endosomolytic than acfTAT and is active 
inside endosomes as a dimer rather than as a reduced monomer (Figure 2-16). However, 
the cytosolic fluorescence of dfTAT possibly obscures the signal that remains inside 
endosomes. Under such a scenario, dfTAT endosomal escape would appear more dramatic 
than it really is. To establish more precisely the efficiency with which dfTAT mediates 
endosomal leakage, I co-incubated dfTAT with SNAP-Surface, a cell-impermeable green 
fluorophore that can react with the SNAP protein fusion tag242. The experiment was 
performed in cells expressing a SNAP-H2B histone construct so that SNAP-Surface 488  
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Figure 2-14 Structure and characterization of DEAC-K9. Structure and expected mass 
of DEAC-K9 (top). HPLC analysis and MALDI-TOF mass spectrum of pure DEAC-K9 
(rt = 14.4 min) (expected mass: 1412.97, observed mass: 1415.59) 
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Figure 2-15 dfTAT causes the cytosolic release of molecules trapped inside 
endosomes. Microscopy images showing dfTAT-mediated release of molecules trapped 
inside endosomes; a schematic of the process is included (top). HeLa cells were incubated 
with 5 μM DEAC-K9 for 1 h and washed. Cells were subsequently incubated with 5 μM 
dfTAT for 1 h. Images are represented as inverted monochromes. Scale bars: 10 μm.  
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Figure 2-16 dfTAT displays a high endosomolytic activity when compared to 
acfTAT. HeLa cells were incubated with dfTAT (5 μM) for 5 min and acfTAT (50 μM) 
for 1 h. After 1h, the cells were washed with PBS/heparin, imaged and lysed. The lysis 
buffer used in this experiment contains 2 mM DTT. The bulk fluorescence of cell lysates 
on a 96-well plate was measured using a plate reader. The fluorescence of each sample 
was normalized to total protein content in the cell lysate, as determined by a Bradford 
protein assay. Similarly, the fluorescence of solutions of acfTAT at different 
concentrations (0.1, 0.5, 1, 5 and 10 μM) was measured using a plate reader. A calibration 
curve of the peptide fluorescence intensity v.s. peptide concentration was established. 
These data was used to estimate the average concentration of acfTAT and dfTAT inside 
cells. Data shows higher fluorescence intensity for acfTAT than dfTAT inside cells. These 
data suggests that dfTAT is a dimer inside endosomes and that this peptide is more 
endosomolytic than acfTAT (Model 1).  
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Figure 2-16 Continued. 
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would label the nucleus of cells upon delivery, deplete the cytosolic signal and reveal the 
amount of probe remaining trapped inside endosomes. Cells incubated with dfTAT and 
SNAP-Surface 488 displayed a nuclear staining (Figure 2-17), whereas cells incubated 
with SNAP-Surface 488 alone did not (Figure 2-18). Cells with a brightly labeled nucleus 
also contained only a few dim endosomes. Analysis of the fluorescence signal indicated 
that 50–90 % of the fluorophore escaped endosomes. 
 
2.2.5 dfTAT-mediated delivery is not deleterious to cells 
By inducing efficient endosomal leakage, dfTAT might negatively affect cell 
physiology. In addition, endosomal leakage has been previously observed in cells 
undergoing apoptosis243. Endosomal leakage could therefore be either a cause or a 
consequence of cell death. To address these issues, I treated HeLa, MCH58, HDF and 
Neuro-2a cells with dfTAT for 1 h and established viability 1 and 24 h after incubation 
using a SYTOX® Green exclusion assay (Figure 2-19). Viability was >95 % after treating 
cells with 5 μM dfTAT for 1 h—conditions required to achieve cytosolic distribution of 
dfTAT in >80 % of cells. Cell morphology was also unaffected by dfTAT incubation 
(Figure 2-20). Likewise, dfTAT incubation did not affect the proliferation rates of HDF, 
HeLa or Neuro-2a cells (Figure 2-21), and cells containing a cytosolic fluorescence signal 
indicative of efficient dfTAT endosomal escape were observed to divide normally by 
microscopy (Figure 2-22). 
To characterize the physiological impact of dfTAT cytosolic penetration in greater 
detail, I performed transcriptome analysis on HDF cells incubated for 1 h in nrL-15  
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Figure 2-17 Endosomolytic efficiency of dfTAT. HeLa cells expressing SNAP-H2B 
were incubated with 5 μM dfTAT and 5 μM SNAP-Surface 488 (a schematic of the 
protocol followed is shown on the left). Representative fluorescence images (of 50 total) 
of SNAP-Surface are shown (dfTAT is in the inset). The SNAP-Surface 488 signal present 
in the nucleus is indicated as a percentage of the total signal. Scale bars: 10 μm. 
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Figure 2-18 SNAP-Surface 488 enters cells via endocytosis and does not escape 
endosomes in the absence of dfTAT. (A) HeLa cells were incubated with 5 μM SNAP-
Surface 488 for 1 h, washed and imaged. Inverted monochrome image shows a punctate 
distribution from SNAP-Surface 488 (right panel). (B) HeLa cells were incubated with 5 
μM SNAP-Surface 488 and 2.5 μM dfTAT (a concentration in which dfTAT incubation 
does not result in significant cytosolic release) for 1 h, washed and imaged. Inverted 
monochrome images show SNAP-Surface 488 accumulation in endocytic organelles 
(punctate distribution) (right panel) and colocalization with TMR signal. Bright field 
images show HeLa cells morphology did not change after uptake of SNAP-Surface 488 
and/or dfTAT (right panels). Scale bars: 10 μm. 
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Figure 2-19 dfTAT is not toxic to cells under conditions where efficient endosomal 
escape is achieved. (A) HeLa, MCH58, HDF and Neuro-2a cells were incubated with (1-
50 µM) dfTAT for 1 h. Cell viability was assessed by a SYTOX Green exclusion assay 
1, 24, and 48 h (for HeLa) after incubation (1,000 cells/experiment, experiments in 
triplicates, average and standard deviations represented). (B) Histogram of flow cytometry 
data. HeLa cells were incubated with 5 µM dfTAT or no peptide (control) for 1h, washed 
and then incubated in SYTOX Green (1 µM) for 15 min. Cells were then trypsinized for 
5 min, resuspended in a total of 200 µl of nrL-15, and analyzed by flow cytometry (BD 
Accuri C6 Flow Cytometer). Histograms show that only 2 % and 7.5 % of cells are stained 
with the cell impermeable dye SYTOX Green for untreated and treated cells, 
respectively. 
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Figure 2-20 The cellular localization of acfTAT and dfTAT is different after 
incubation with live cells but cell morphology is not changed. Fluorescence 
(monochrome) and brightfield images (100X objective) of HeLa cells incubated with 20 
μM acfTAT (left panel) and 5 μM dfTAT (right panel). The acfTAT peptide displays a 
fluorescence punctate distribution while dfTAT exhibits a cytosolic and nuclear 
fluorescence distribution. Brightfield images show no change in HeLa cell morphology 
upon peptide delivery.  
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Figure 2-21 dfTAT-mediated delivery does not significantly affect cell proliferation. 
HeLa, Neuro-2a and HDF cells were incubated with 5 μM dfTAT for 1 h or left untreated. 
Proliferation was assessed using a MTT assay (150,000 cells/experiment, experiments in 
triplicates, mean and standard deviations represented). 
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Figure 2-22 dfTAT-mediated delivery does not significantly affect cell division. 
Microscopy imaging showing that cells containing cytosolic dfTAT divide. HeLa cells 
were incubated with 5 µM dfTAT for 1 h, washed and imaged in a time-lapse experiment. 
Scale bars, 10 μm 
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medium with or without 5 μM dfTAT. Cells harvested immediately after dfTAT 
incubation showed 11 transcripts up- or downregulated more than twofold compared to 
those of untreated cells (twofold is used as a significance threshold; 47,321 total transcripts 
detected; Figure 2-23). Only two transcripts were dysregulated in cells incubated in 
DMEM for an additional 1 h and 24 h after treatment with dfTAT (Figure 2-23 and 2-
24). Together, these results indicate that dfTAT has a minimal impact on mRNA 
expression and that cells recover rapidly from dfTAT-mediated endosomal leakage 
(corroborated by quantitative proteomic profile experiments; Figure 2-25). 
If dfTAT perturbs many endosomes during a delivery step, I envisioned that 
endocytic trafficking might be a cellular process likely to be negatively affected following 
peptide incubation. In particular, I reasoned that dfTAT could cause endosomal leakage 
after an initial treatment but fail to be endocytosed or remain trapped inside damaged 
endocytic organelles after a second dfTAT incubation. I therefore tested the stepwise 
delivery of two different molecules (DEAC-K9 and SNAP-Surface 488). Cells were first 
incubated with dfTAT (5 μM) and DEAC-K9 (5 μM) for 1 h. As expected, this incubation 
resulted in the cytosolic distribution of both dfTAT and DEAC-K9 (data not shown). 
Twenty minutes later, cells were incubated with dfTAT (5 μM) and SNAP-Surface 488 (5 
μM) for 1 h. Cells treated with dfTAT using this two-step protocol displayed cytosolic and 
nuclear fluorescence of both DEAC-K9 and SNAP-Surface 488 (Figure 2-26). Delivery 
of SNAP-Surface 488 did not occur in the absence of dfTAT (Figure 2-18) and was 
inhibited by bafilomycin, consistent with the notion that the second delivery step is also 
mediated by the endosomolytic activity of dfTAT. Moreover, the fluorescence of SNAP- 
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Figure 2-23 dfTAT-mediated delivery does not significantly affect transcription in 
primary cells. Whole-genome microarray analysis of HDF cells treated with dfTAT. HDF 
cells were treated with 5 μM dfTAT for 1 h and transcriptome analysis was performed 
immediately, 1 h, or 24 h after dfTAT treatment. The plot displays microarray intensity 
values of treated vs. untreated (same incubation steps but without peptide) samples. The 
red lines represent 2-fold intensity change cut-offs and transcripts up or down-regulated 
above these cut-offs are circled for clarity. 
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Figure 2-24 mRNA expression analysis in the presence of staurosporine. (a) In order 
to establish a positive control for the microarray analysis, staurosporin was used to induce 
apoptosis in HDF cells. Cells were treated with staurosporine (0.1 µM) for 1h and mRNA 
levels were analyzed as described in Figure 3. The identity of transcripts related to 
apoptosis that were up-regulated (highlighted in red) and down-regulated (highlighted in 
green) upon treatment with staurosporin are listed. Notably, a total of 1830 transcripts 
were found to be up-or down-regulated out of 47321 transcripts detected. (b) Analysis of 
the microarray intensities of untreated HDF cells vs. those of HDF cells treated with 
staurosporine (0.1 µM) for 1h. The red lines represent the 2-fold cut-offs. (c) Table listing 
the identity of transcripts that are up-regulated (highlighted in red) and down-regulated 
(highlighted in green) in HDF cells incubated with dfTAT (5 µM) and analyzed 
immediately after incubation (1h), or 1h (1h+1h) and 24 h (1h+24h) after incubation. The 
11, 2, and 2 transcripts listed represent the total number of transcripts up or down-
regulated in the 1h, 1h+1h, and 1h+24h samples, respectively. 
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Figure 2-24 Continued. 
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Figure 2-25 Differential in gel electrophoresis (DIGE) proteomic analysis of HDF 
cells treated with dfTAT (5 μM) for 1 h. (a) Representative green and red fluorescence 
overlay of 2D gel of cells treated with or without dfTAT for 1h and incubated in fresh 
media for an additional 1h (1+1h samples, treated sample is labeled with Cy3 and 
untreated with Cy5). Green and red were used as pseudo colors for Cy3 and Cy5 dyes, 
respectively, and a yellow color is indicative of equal fluorescence intensities. (b) Table 
summarizing analysis results obtained from the DIGE using the DeCyder v6.5 suite of 
software tools (GE Healthcare). Data was obtained using a 2 standard deviation model 
(95% confidence). Each pair (treated vs. untreated) were individually analyzed based on 
the normalized volume ratio of each individual protein spot from Cy3- or Cy5- labeled 
sample. 
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Figure 2-26 dfTAT-mediated delivery does not significantly affect endocytosis. 
Microscopy images showing that dfTAT-mediated endosomal escape can be repeated. 
HeLa cells were co-incubated with dfTAT (5 μM) and DEAC-K9 (5 μM) for 1 h (step1) 
(images not shown). After washing, dfTAT (5 µM) and SNAP-Surface 488 (5 μM) were 
co-incubated in the absence (top panel) or presence (bottom panel) of bafilomycin (200 
nM) (step 3). Scale bars: 10 μm. 
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Surface 488 examined was comparable to that observed when SNAP-Surface 488 was 
delivered into untreated cells (one-step delivery) or simultaneously with DEAC-K9 
(Figure 2-27). Together these results establish that dfTAT-mediated delivery can be 
repeated. This suggests that the endocytic route employed by dfTAT is not dramatically 
compromised after dfTAT-mediated endosomal leakage. 
 
2.2.6 dfTAT delivers proteins by simple co-incubation 
To determine whether dfTAT could deliver large proteins into the cytosol of cells, 
I chose EGFP (26 kDa) as a model cargo. Cells were incubated with EGFP and dfTAT for 
1 h and examined by microscopy. EGFP was distributed into the cytosolic space and 
nucleus in more than 90 % of cells without observable toxicity (Figure 2-28). To estimate 
how much fluorescent and folded protein was delivered, cells were counted, harvested and 
lysed. The lysate was analyzed by PAGE, and the fluorescence of EGFP was quantified. 
On the basis of this analysis, approximately 34 μM and 23 μM of EGFP was present per 
HDF and Neuro-2a cell, respectively (Figure 2-29). As imaging confirmed that a large 
fraction of EGFP escaped endosomes (Figure 2-28), one can expect micromolar 
concentrations of proteins to be delivered in the cytosolic space of cells. 
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Figure 2-27 Simultaneous delivery of SNAP-Surface 488 and DEAC inside cells using 
a one step protocol. (a) HeLa cells were incubated with 5 μM dfTAT, 5 μM SNAP-
Surface 488 and 5 μM DEAC-K9. Inverted monochrome images show cytosolic and 
nuclear fluorescence localization of dfTAT (red fluorescence), DEAC-K9 (blue 
fluorescence) and SNAP-Surface 488 (green fluorescence). Scale bars: 10 μm. (b) HeLa 
cells were incubated with 5 μM dfTAT and 5 μM SNAP-Surface 488. Inverted 
monochrome images show cytosolic and nuclear fluorescence localization of dfTAT and 
SNAP- Surface 488. Scale bars: 10 μm. (c) HeLa cells were first incubated with 5 μM 
dfTAT and 5 μM DEAC-K9 for 1 h. Cells were then washed, incubated with 5 μM SNAP-
Surface 488 for 1 h and imaged. In one hand, inverted monochrome images show cytosolic 
and nuclear localization of TMR and DEAC but, in the other hand, SNAP-Surface 488 
display a fluorescence punctate distribution. Scale bar: 10 μm. 
92 
 
 
 
Figure 2-28 Delivery of intact and functional EGFP using co-incubation with dfTAT. 
Microscopy imaging showing that dfTAT delivers EGFP into the cytosol of live cells. 
HeLa, Neuro-2a and HDF cells were co-incubated with EGFP (10 μM) and dfTAT (5 μM) 
for 1 h. Scale bars: 100X objective, 10 μm; 20X objective, 100 μm. 
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Figure 2-29 Quantitation of the concentration of EGFP delivered into the cytosol of 
HDF and Neuro-2a. HDF and Neuro-2a cells were co-incubated with dfTAT (5 µM) and 
EGFP (10 µM) for 1 h. After 1 h, cells were washed with PBS/heparin and lysed. The cell 
lysate was treated with nucleases and an aliquot of 27 µL was analyzed by PAGE (top 
right panel). Similarly, samples of known EGFP concentrations (determined by measuring 
absorbance at 488 nm and using an extinction coefficient of 55,000 mol-1cm-1) were 
analyzed by PAGE (top left panel). A fluorescence imager was used to measure the EGFP 
fluorescence intensity from the cell lysates and EGFP calibration samples. Silver staining 
was used to detect all proteins in the lysate. A calibration curve of EGFP fluorescence 
intensity vs. EGFP concentration was established and used to estimate the average 
concentration of EGFP in the cell lysates. The data obtained was used to calculate the 
concentration of EGFP per cell. Important numbers: Cell number on well: 79,600 
(determined by flow cytometry); Cell volume: 2000 µm3 (bionumbers.hms.harvard.edu.) 
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To determine whether dfTAT needs to interact with a particular protein in order to 
successfully deliver it, I characterized the binding of dfTAT to EGFP. No fluorescence 
resonance energy transfer (FRET) between dfTAT and EGFP could be detected under 
conditions used for cellular incubation assays (Figure 2-30). Similarly, no interaction 
between dfTAT and EGFP could be detected by native gel electrophoresis (Figure 2-31). 
In contrast, dfTAT and BSA were found to interact in this assay (presumably through 
electrostatic interactions). Interestingly, addition of BSA (or fetal bovine serum or 
heparin) to cell incubation medium reduced the cytosolic penetration of dfTAT in a 
concentration-dependent manner (Figure 2-32). 
To further confirm that functional proteins can penetrate cells upon incubation 
with dfTAT, I tested delivery of Cre recombinase. In this assay, Cre induces 
recombination of a loxP-STOP-loxP sequence upstream of the EGFP-encoding gene of a 
reporter plasmid244. Therefore, cells transfected with the reporter plasmid express EGFP 
when Cre recombinase penetrates cells and excises the STOP signal sequence. Cells 
treated with TAT-Cre (1 μM) and dfTAT (5 μM) expressed EGFP (Figure 2-33), but the 
percentage of EGFP+ cells was greater in the presence of dfTAT (47 %) than in the 
presence of fTAT or when TAT-Cre was incubated alone (<5 %). 
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Figure 2-30 dfTAT and EGFP do not interact when co-incubated. (a) Fluorescence 
emission spectrum of EGFP (1 μM) (donor FRET pair) (EGFP, Ex/Em 488/508 nm) 
excited at 488 nm. The spectrum show an intense emission peak at around 510 nm and a 
small shoulder peak around 548 nm (b) Fluorescence emission spectrum of a solution of 
EGFP (1 μM) and dfTAT (5 μM) (acceptor FRET pair) (TMR, Ex/Em 556/580 nm) 
excited at 488 nm. The spectrum shows an intense emission peak at around 510 nm and a 
small shoulder peak around 548 nm. The contribution of TMR to the EGFP fluorescence 
spectrum (crossover fluorescence) was determined by measuring the fluorescence 
emission of a solution of dfTAT (5 µM) excited at 488 nm (not shown). The spectrum of 
the solution with EGFP and dfTAT is almost identical to the spectrum of EGFP alone 
(TMR fluorescence crossover signal was subtracted). (c) Fluorescence emission spectrum 
of ligated EGFP-CK(TMR). Using expressed protein ligation, EGFP was chemically 
ligated to CK(TMR) as described to produce EGFP-CK(TMR)7. EGFP-CK(TMR) was 
used a positive control for the FRET signal. Upon excitation at 488 nm, a dramatic increase 
in fluorescence between 560-630nm is observed (fluorescence max approximately 580 
nm), indicative of a FRET signal due the close proximity between fluorophores. This 
increase in fluorescence intensity was not observed in the spectrum in part b) (indicative 
of no interactions between EGFP and dfTAT). Emission of all samples was scanned from 
500 to 650 nm. 
Figure 2-31 dfTAT and EGFP do not interact. (a) Native gel electrophoresis was used 
to determine binding interaction between dfTAT and EGFP. Samples were prepared by 
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incubating dfTAT (5 μM) with either EGFP (10 µM) or BSA (10 µM, protein with a pI = 
4.7, used as a positive control) in nrL-15 for 30 min at 37 °C (pH 7.0, representing the pH 
of the extracellular milieu of the cell and pH 5.0 representing the lower pH that exists 
along the endocytic pathway). dfTAT alone, EGFP alone and BSA alone at the same 
concentration and pH were loaded on the same gel as controls. Fluorescence images of the 
gel were acquired using a Typhoon scanner. Green fluorescent bands corresponding to 
EGFP and a red fluorescence band correspond to dfTAT fluorescence. Red fluorescent 
bands corresponding to both dfTAT and BSA indicated binding between peptide and 
protein. In contrast, dfTAT fluorescence is not detected in bands corresponding to EGFP, 
indicating absence of binding. An image of the Commassie stained native gel is also 
shown (top left corner). (b) Coomassie staining, red fluorescence, and green fluorescence 
images of samples of dfTAT and EGFP at varying concentration and analyzed by native 
gel electrophoresis. Similar results were obtained with dmEGFP (EGFP not containing 
cysteine residues, data not shown). 
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Figure 2-31 Continued. 
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Figure 2-32 Effect of BSA, heparin and FBS on dfTAT cell penetration. (a) Co-
incubation of dfTAT with BSA results in a decrease in the percentage of cells displaying 
cytosolic release of dfTAT. HeLa cells were co-incubated with 5 µM dfTAT and 10 µM 
BSA for 1h. Cells show a punctate distribution of the peptide (monochrome 100X image) 
indicative of peptide being trapped in endocytic vesicles. In comparison, HeLa cells 
incubated with dfTAT (5 μM) alone show a homogenous cytosolic and nuclear 
distribution of peptide in a majority of cells. (b) Effect of FBS and heparin on dfTAT 
mediated cellular. HeLa cells were incubated with 5 μM dfTAT and heparin (1-100 
µg/mL) or FBS (0.1-10%) for 1 h. Cells were washed and imaged. The % cells with 
cytosolic and nuclear distribution was calculated as described in Figure 1(b). Scale bars: 
10 µm.  
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Figure 2-32 Continued. 
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Figure 2-33 Delivery of intact and functional Cre-recombinase using co-incubation 
with dfTAT. Assay showing that dfTAT improves the delivery of TAT-Cre. HeLa cells 
transfected with a plasmid containing egfp upstream of a loxP-STOP-loxP sequence were 
incubated for 1 h with either fTAT (5 µM) or dfTAT (5 µM) in the presence of TAT-Cre 
(1 µM). EGFP+ cells that result from successful TAT-Cre delivery were visualized and 
counted by microscopy (confirmed by flow cytometry). Scale bars: 100 µm. 
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I also delivered FITC–anti-ATP5A, a fluorescently-labeled antibody that 
recognizes the α-subunit of the mitochondrial ATP synthase. Cells treated with FITC–
anti-ATP5A (20 μg/ml) and dfTAT (5 μM) contained green fluorescent tubular structures 
(Figure 2-34). Colocalization with the blue fluorescent mitochondrial marker pTagCFP-
mito confirmed that these structures were mitochondria (Figure 2-35 (A)). Cells treated 
with FITC–anti-IgG, an antibody that does not target mitochondria, did not stain tubular 
structures (Figure 2-35 (B)). These experiments confirmed that dfTAT can deliver a 
functional antibody into live cells. 
The transcription factor HOXB4 can penetrate cells, activate transcription and 
induce hematopoietic stem cell expansion, either by itself or when fused to TAT245-247. I 
was therefore interested in determining whether dfTAT, by promoting cytosolic delivery, 
would enhance the transcriptional activity of this protein. NIH 3T3 cells were transfected 
with a vector containing the luciferase gene under a HOXB4-inducible promoter and with 
a β-galactosidase reporter as internal control. Cells were incubated with HOXB4 or TAT-
HOXB4, in the absence or presence of dfTAT, for 1.5 h. I assessed the expression of 
luciferase by measuring the luminescence of cell lysates (normalized to β-galactosidase 
activity, luciferase induction represents a ratio of treated versus untreated cells). HOXB4 
and TAT-HOXB4 (200 nM) alone induced a 2.2- and 5.0-fold increase in luciferase 
activity, respectively (Figure 2-36). In contrast, addition of dfTAT (3 μM) led to 53.1- 
and 307.4-fold luciferase induction, respectively. Neither dfTAT alone nor dfTAT 
incubated with TAT-mCherry led to the induction of luciferase, indicating that luciferase 
expression was dependent on the presence of HOXB4. 
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Figure 2-34 Delivery of an intact and functional antibody using co-incubation with 
dfTAT. Microscopy imaging showing that dfTAT mediates the delivery of an antibody. 
HeLa cells were co-incubated with FITC-anti-ATP5A (20 µg/mL) and dfTAT (5 µM) for 
1 h. FITC-anti-ATP5A (green) is delivered in the cytosol of cells and stains tubular 
mitochondria (more clearly visible in zoomed-in image). Absence of SYTOX® Blue 
staining indicates that the cells imaged do not have a compromised plasma membrane. 
Black arrows point to tubular mitochondria. Scale bars: 100X objective, 10 µm; zoomed-
in image, 2 µm. 
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Figure 2-35 The FITC-anti-ATP5a antibody co-localizes with a fluorescently labeled 
mitochondrial protein expressed in live cells after dfTAT-mediated delivery. (a) Cells 
expressing TagCFP-mito (left) were imaged using the FITC and CFP filters. Tubular 
mitochondria were clearly observed only in the CFP channel. In a separate experiment, 
dfTAT (5 µM) and FITC-anti-ATP5A (20 µg/mL) were incubated for 1 h with cells 
expressing TagCFP-mito. The inverted monochrome images show co-localization of 
FITC-anti-ATP5A (FITC channel) and TagCFP-mito (CFP channel). Scale bars: 2 µm. 
(b) To confirm that the mitochondrial staining is specific to FITC-anti-ATP5A, an 
antibody without an intracellular epitope, FITC-anti-IgG, was delivered with dfTAT. 
FITC-anti-IgG (20 µg/mL) and dfTAT (5 µM) were incubated with cells for 1 h. Inverted 
monochrome images show a homogenous cytosolic fluorescence distribution (top). In 
contrast, cells that were incubated with FITC-anti-ATP5A show fluorescence in tubular 
structures (bottom). Scale bars: zoom-in image, 2 µm; 100X objective, 10 µm. 
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Figure 2-36 dfTAT mediated delivery of HoxB4 and TAT-HoxB4 improves the 
expression of a luciferase reporter. NIH 3T3 transfected with a HoxB4-dependent 
luciferase reporter were incubated for 1.5 h with either HoxB4 or TAT-HoxB4 (200 nM) 
in presence or absence of dfTAT (3 μM). TAT-mCherry (200 nM) and dfTAT (3 μM) 
serve as negative controls (400,000 cells/experiment, experiments in duplicate). 
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Although increasing the transcriptional output of HOXB4 is valuable, precisely 
controlling the level and activity of HOXB4 inside cells is important to achieve desirable 
biological outcomes248. Because dfTAT appears to act independently of the molecules 
used for co-incubation in my assays, I hypothesized that it might be possible to titrate the 
amount of protein that penetrates cells by varying the protein concentration in the medium 
while keeping dfTAT concentration constant. Under this scenario, the efficiency of 
endosomal escape should remain unaffected, but the amount of material released from 
endosomes should change. Initial experiments with DEAC-K9 showed that the amount of 
fluorescent peptide delivered inside cells could be titrated using this protocol (Figure 2-
37 and 2-38). Consistent with these results, luciferase induction was proportional to the 
concentration of HOXB4 in the medium (Figure 2-39). 
 
2.3 Discussion 
By mediating endosomal leakage, dfTAT is remarkably efficient at delivering 
proteins and peptides into the cytosol of cells. Delivery is efficient because the amount of 
material that reaches the cytosol is substantial and the amount trapped inside endosomes 
is relatively low, and because cytosolic delivery occurs in most cells present in a sample. 
Endosomal escape appears to take place in most cells once dfTAT, which is intrinsically 
more endosomolytic than monomeric TAT, reaches a threshold concentration within 
endosomes. Future studies aimed at establishing the roles played by the two copies of the 
peptide TAT and of the fluorophore TMR, as well as their respective arrangement, should 
provide more molecular details about the activity of dfTAT. Establishing where dfTAT  
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Figure 2-37 The amount of DEAC-K9 delivered in the cytosol and nucleus of live 
cells can be titrated. HeLa cells were incubated with dfTAT (5 μM) and increasing 
amounts of DEAC-K9 (1, 2.5, 5, 10, 20 μM). The fluorescence intensity of cells displaying 
cytosolic release was assessed by microscopy (representative 20X images are shown using 
a pseudocolored colorscale: blue=lowest intensity, red=highest intensity) and by 
measuring to the bulk fluorescence of cell lysates (microscope: 1,000 cells/experiment, 
fluorometer: 300,000 cells/experiment; experiments in triplicates, average and standard 
deviations represented). Scale bars: 10 μm 
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Figure 2-38 Determination of the amount of DEAC-K9 delivered into cells. HeLa cells 
were incubated with dfTAT (5 µM) and different concentrations of DEAC-K9 (1, 2.5, 
5,10 and 20 µM) for 1 h. Cells were washed with PBS/heparin, imaged and lysed. The 
bulk fluorescence of cell lysates containing DEAC-K9 was measured using a fluorometer. 
Similarly, the fluorescence of solutions of DEAC-K9 at different concentrations (0.01. 
0.1, 1, 10 and 100 µM) was measured using a fluorometer. A calibration curve of DEAC-
K9 intensity vs. DEAC-K9 concentration was established. These data was used to estimate 
the average concentration of DEAC-K9 inside cells. Data shows a linear increase in the 
amount of DEAC-K9 delivered inside cells (top right panel). Consistent with these data, 
fluorescence images that show an increase in the fluorescence signal in the cytosol cells 
with increasing concentrations of DEAC-K9 incubated in the media (top left panel, and 
Figure 2-38). 
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Figure 2-39 The induction of luciferase expression by dfTAT-medited delivery of 
HoxB4 into cells can be controlled. NIH 3T3 cells were co-incubated with HoxB4 (25-
200 nM) and dfTAT (3 µM) and luciferase induction was measured as described in a 
(400,000 cells/experiment, experiments in duplicate). 
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escapes from the endocytic pathway should also provide valuable insights regarding its 
endosomolytic activity, which will be the focus of my next chapter. Notably, the 
membrane of endosomes can be lysed by fluorescently labeled cell-penetrating peptides 
upon light irradiation162, 163. dfTAT trapped inside endosomes (for example, after 
incubation at 2 μM) can indeed leak out of endosomes when TMR is continuously excited 
for several seconds (data not shown). Yet, all delivery experiments reported herein were 
performed in a dark room with a dim red light. The excitation of dfTAT, when required 
for fluorescence microscopy, was also minimized to less than 300 ms in all images shown. 
Overall, I conclude that the endosomal leakage mediated by dfTAT is light independent. 
A remarkable aspect of dfTAT-mediated delivery is the minimal cellular responses 
associated with the efficient endosomal leakage observed. This is surprising because 
endosomal lysis can be extremely toxic by causing the rapid release of calcium into the 
cytosol of cells249. In addition, the leakage of endolysosomal proteases could contribute to 
toxicity250-253. Yet, I observed that cells were not only viable but also healthy. These results 
are presumably valid for only the one hour dfTAT incubation used in my assays. 
Continuous endosomal leakage induced by particulate wear debris induces inflammatory 
responses and apoptosis254. dfTAT could therefore promote similar effects if administered 
to cells for long incubation times. Notably, membrane repair mechanisms have also been 
shown to mask the effect of debris-induced endosomal leakage254. This, in turn, could also 
explain why dfTAT-mediated delivery is relatively innocuous under the conditions tested. 
dfTAT delivers cell-impermeable molecules displaying diverse structures and 
properties. DEAC-K9, like dfTAT, is highly positively charged, and the isoelectric points 
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(pI) of Cre (9.4), and HOXB4 (9.8) are also not suggestive of favorable electrostatic 
interactions with dfTAT. EGFP, a protein with a lower pI (6.2), does not appreciably 
interact with dfTAT in vitro. It is therefore likely that dfTAT does not need to interact 
with a given protein outside the cell or within the lumen of endosomes to achieve cytosolic 
delivery of that protein. Instead, interactions that occur between dfTAT and a protein with 
low pI such as BSA are inhibitory. Similar inhibitory effects between arginine-rich cell-
penetrating peptides and negatively charged species have been observed74, 255. 
The co-incubation protocol used herein allows several cargos to be delivered 
simultaneously. Alternatively, delivery can be performed in successive steps, without 
complex sample preparations and, as exemplified by the delivery of SNAP-Surface 488 
or FITC–anti-ATP5A, is ideally suited for imaging applications. In addition, co-
incubation provides the opportunity to titrate the extracellular concentration of target 
molecules independently of dfTAT. The amount of protein delivered to the cytosol and 
the biological output achieved can in turn be modulated. Although my approach is likely 
not optimal for in vivo delivery of biologics, it could offer several advantages over existing 
reagents for delivery to tissue cultures and the ex vivo manipulation of cells. 
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2.4  Materials and Methods 
 
2.4.1 Peptide design, synthesis and purification 
 All peptides were synthesized in-house on the rink amide MBHA resin 
(Novabiochem) by solid-phase peptide synthesis (SPPS) using standard Fmoc protocols. 
Fmoc-Lys(Mtt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
Gln(Trt)-OH and Fmoc-Cys(Trt)-OH (Novabiochem) were used to assemble the peptides. 
Reactions were carried out in a SPPS vessel at room temperature using a stream of dry 
N2 to provide agitation. Fmoc deprotection was performed by addition of piperidine in 
dimethylformamide (DMF) (Fisher) (20 %, 10 mL) to the Fmoc-peptide resin (0.30 
mmol). Deprotection reactions were carried out once for 5 min (1 × 5 min) and 1 × 15 min 
with a washing step in between reactions. Amino acid coupling reactions were carried out 
for 4 h with a mixture of Fmoc-amino acid (1.2 mmol), HBTU (Novabiochem) (0.44 g, 
1.1 mmol) and di-isopropylethylamine (DIEA) (Sigma) (0.51 mL, 3.0 mmol) in DMF. 
Upon completion of the reactions, the resin was washed with DMF and dichloromethane 
(DCM) (Fisher). For DEAC-K9, the DEAC fluorophore (AnaSpec) was coupled to the N 
terminus of the peptide after coupling of the ninth Fmoc-Lys(Boc)-OH using a mixture of 
DEAC, HBTU and DIEA (4, 3.9 and 10 molar equivalents (eq) with respect to the peptide) 
in DMF. The reaction was carried out overnight using a stream of dry N2 to provide 
agitation. For CK(ε-NH-TMR)TATG (fTAT), the Mtt protecting group at the ε-amino 
group of Lys on CK(ε-NH-Mtt)TATG was cleaved with 2 % trifluoroacetic acid (TFA) 
(Fisher) and 2 % tri-isopropylsilane (TIS) (Sigma) in DCM, and the resin was washed 
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with DCM and DMF. A mixture of TMR, HBTU and DIEA (4, 3.9 and 10 eq with respect 
to the peptide) in DMF was added to the resin, and the reaction was carried out overnight 
using dry N2 to provide agitation. Following Fmoc-deprotection and peptide assembly, the 
resin was washed with DCM and dried in vacuo. The resin was then treated with TFA 
containing 2.5 % H2O, 2.5 % TIS and 2.5 % ethanedithiol (EDT) (Sigma) for 3 h at room 
temperature to achieve global deprotection and cleavage from the resin. The crude peptide 
products were precipitated and washed with cold anhydrous Et2O (Fisher). The 
precipitates were resuspended in water and lyophilized. The products obtained were then 
resuspended in 0.1 % aqueous TFA/acetonitrile. The peptides were analyzed and purified 
by reverse-phase HPLC. HPLC analysis was performed on a Hewlett-Packard 1200 series 
instrument and an analytical Vydac C18 column (5-μm particle size, 4 mm × 150 mm). 
The flow rate was 1 mL/min, and detection was at 214 nm and 550 nm. Semi-preparative 
HPLC was performed on a Vydac C18 10 × 250–mm column. The flow rate was 4 
mL/min, and detection was at 214 nm and 550 nm. All runs used linear gradients of 0.1% 
aqueous TFA (solvent A) and 90% acetonitrile, 9.9 % water and 0.1% TFA (solvent B). 
The correct identity of the peptides was confirmed by MALDI-TOF performed with a 
Shimadzu/Kratos instrument (AXIMA-CFR). fTAT expected mass was 2,041.17; 
observed mass was 2,040.66. DEAC-K9 expected mass, 1,412.97; observed mass, 
1,415.59. 
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2.4.2 Synthesis of acetamidated C(S-CH2CONH2)K(ε-NH-TMR)TATG (acfTAT) 
C(S-CH2CONH2)K(ε-NH-TMR)TATG was formed after addition of 
iodoacetamide (Sigma) (0.275 mg, 1.49 μmol) to CK(ε-NH-TMR)TATG (148 μg, 0.074 
μmol) in 25 mM HEPES, pH 7.5, under an atmosphere of N2. The product was purified 
using analytical reverse-phase HPLC. Expected mass (MALDI-TOF), 2,098.19; observed 
mass, 2,096.31. 
 
2.4.3 Generation of dfTAT by dimerization of CK(TMR)TATG (fTAT) 
 dfTAT was formed by dissolving (0.3 mg, 1.5 × 10−4 mmol) fTAT in aerated 
phosphate buffer saline (PBS), pH 7.4 (5 mL). Oxygen dissolved in the buffer acted to 
oxidize the thiol groups on the peptides and form a disulfide bond. The reaction was 
allowed to react overnight until completion (100 % yield according to HPLC analysis). 
The product was purified using analytical reverse-phase HPLC. Expected mass (MALDI-
TOF), 4,080.34; observed mass, 4,084.21. 
 
2.4.4 Generation of nrdfTAT using fTAT 
 Two fTAT peptides linked by the bis(maleimido)ethane (BMOE) (Pierce) linker 
(nrdfTAT) was formed by reacting pure fTAT (0.202 mg, 0.099 μmol) with BMOE (0.011 
mg, 0.0496 μmol) for 3 h in PBS buffer, pH 7.2, under an atmosphere of N2. The product 
was purified using analytical reverse-phase HPLC. Expected mass (MALDI-TOF), 
4,313.39; observed mass, 4,303. 
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2.4.5 Cloning, overexpression and purification of TAT-Cre, TAT-mCherry, HOXB4 
and TAT-HOXB4 
 The pTriEx-HTNC plasmid encoding His-tagged TAT-NLS-Cre (TAT-Cre) 
protein was purchased from Addgene. The TAT-Cre gene was then cloned into pTXB1 
vector and transformed into Escherichia coli BL21 (DE3) cells (Agilent Technologies). 
The protein was expressed and purified as described256. Briefly, TAT-Cre was expressed 
with 1 mM IPTG at 37 °C for 3 h. TAT-Cre was then purified to homogeneity using a Ni-
NTA resin (Qiagen) and cation-exchange chromatography (HiTrap SP HP) (GE 
Healthcare). 
pTXB1-TAT-mCherry was obtained by inserting the TAT DNA sequence into the 
pTXB1-mCherry plasmid. The oligonucleotides with sequences 5′-TAT GGG TCG TAA 
AAA ACG TCG TCA GCG TCG TCG TGG TCA-3′ and 3′-ACC CAG CAT TTT TTG 
CAG CAG TCG CAG CAG CAC CAG TAT-5′ (Integrated DNA Technologies) coding 
for the TAT sequence, which contain NdeI sites, were annealed to generate dsDNA. The 
pTXB1-mCherry plasmid was cut with NdeI (New England Biolabs) and ligated with TAT 
dsDNA. The pTXB1-TAT-mCherry plasmid was transformed into BL21 (DE3) cells, and 
protein expression was induced with 1 mM IPTG at 16 °C for 24 h. Cells were harvested 
and resuspended in lysis buffer containing 20 mM Tris-Cl (pH 7.5) and 200 mM NaCl. 
After cell lysis by sonication and high-speed centrifugation at 15,000 r.p.m. (rotor radius: 
23 cm) for 1 h, the soluble fraction was applied to chitin resin (New England Biolabs) pre-
equilibrated with lysis buffer and incubated overnight at 4 °C (the protein contains a C-
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terminal intein-chitin binding domain purification tag). The resin was washed with ten 
column volumes of lysis buffer. The protein was cleaved from the resin by incubating the 
beads with 1 column volume of cleavage buffer supplemented with 100 mM 2-
mercaptoethanesulfonic acid and for 24 h at 4 °C. The protein was further purified using 
cation-exchange chromatography. 
EGFP was cloned, expressed and purified as previously described257. The double-
mutant EGFP (dmEGFP) was obtained by introducing the mutations (C49S, C71V) in the 
EGFP plasmid using site-directed mutagenesis. Because dmEGFP does not contain any 
Cys residue, this protein is unable to form a disulfide bond with fTAT. In all assays, results 
obtained with EGFP were similar to those obtained with dmEGFP. In the text, both EGFP 
and dmEGFP are therefore referred to as EGFP for simplicity. 
The pTAT-HA-HOXB4 vector was generously provided by G. Sauvageau 
(Montreal University). His6-HOXB4 was produced by cloning the HOXB4 gene into pET-
28a. Briefly, the HOXB4 cDNA was first amplified from pTAT-HA-HOXB4 by using 
primers designed to introduce the NdeI and XhoI sites at the 5′ and 3′ ends, respectively 
(5′-GGC ATT CAT ATG GCT ATG AGT TCT TTT TTG ATC AAC TCA- 3′; 5′-GGT 
CAG TCT CGA GCT AGA GCG CGC GGG G-3′) (IDT). The PCR fragment was then 
inserted into the corresponding NdeI and XhoI sites of the 6xHis-tag vector, pET-28a. The 
fidelity of the reading frame was confirmed by sequencing. The procedure for the 
purification of both TAT-HOXB4 and HOXB4 is similar and has been previously 
described247. Briefly, BL21 (DE3) cells were transformed with either pTAT-HA-HOXB4 
or pET28a-HOXB4 and induced at 37 °C for 5 h with 1 mM IPTG. The pelleted cells were 
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lysed by sonication in buffer A (8 M urea, 20 mM HEPES, 200 mM NaCl, pH 8.0). 
Lysates, which were obtained via high-speed centrifugation (14,000 r.p.m., 30 min at 22 
°C), were then adjusted to 10 mM imidazole and incubated with Ni-NTA agarose beads 
for 60 min at room temperature. The nickel beads were then washed with buffer A 
containing 20 mM and 40 mM imidazole to eliminate the presence of any nonspecific 
products, and bound proteins were subsequently eluted with 100 mM and 250 mM 
imidazole in buffer A. Eluates from both concentrations of imidazole containing the 
proteins of interest (i.e., TAT-HOXB4 or HOXB4) were loaded on a HiTrap SP HP 
column at 4 °C in buffer B (4 M urea, 20 mM HEPES, 50 mM NaCl, pH 6.5) and eluted 
on the FPLC in a single-step at 4 °C with buffer C (20 mM HEPES, 1 M NaCl, pH 8.0). 
Both proteins were immediately desalted by diluting with 20 mM HEPES (pH 8.0) and 
concentrated using centrifugal filter units with 10K MWCO (EMD Millipore), divided 
into aliquots and flash frozen at –80 °C. Protein concentrations were determined using the 
Bradford protein assay (Bio-Rad). 
 
2.4.6 Cell lines 
 HeLa (ATCC CCL-2), HaCat258 (obtained from J. Massagué, Memorial Sloan-
Kettering Cancer Center), NIH 3T3 (ATCC CRL-1658), COLO 316259 (obtained from R. 
Burghardt, Texas A&M University), HDF (ATCC PCS-201-010), Neuro-2a (ATCC CCL-
131) and MCH58260 (obtained from E. Shoubridge, Montreal Neurological Institute and 
Hospital) were grown in Dulbecco's minimum essential medium (DMEM) (Fisher) 
supplemented with 10% fetal bovine serum (FBS) (Fisher) and 1× penicillin/streptomycin 
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(P/S) (Fisher) and kept at 37 °C in a humidified atmosphere containing 5 % CO2. Intestinal 
porcine epithelial cells (IPEC-1, obtained from G. Wu, Texas A&M University) were 
cultured in growth medium containing DMEM, 10 % FBS, insulin (5 μg/mL; Sigma), 
hydrocortisone (1 μg/mL; Sigma), EGF (5 ng/mL; BD Biosciences) and 1× P/S and kept 
at 37 °C in a humidified atmosphere containing 5% CO2
261. Cultures were tested 
for Mycoplasma contamination using the PCR Mycoplasma Test Kit II (PromoKine). 
HeLa cells were profiled using STR, by ATCC before purchase, but other cell lines were 
not. 
 
2.4.7  Delivery of peptides inside live cells 
 Cells were seeded in eight-well dishes so that the cells were 80–90 % confluent 
after 48 h. Each well was washed three times with PBS and Leibovitz's L-15 medium that 
did not contain the amino acid cysteine (nonreducing L-15, nrL-15). The medium (nrL-
15) used for incubation lacks cysteine to avoid reduction of the disulfide bond of dfTAT. 
Cells were then incubated with different concentrations of the acfTAT, fTAT, dfTAT or 
nrdfTAT at 37 °C for 5–60 min. Cells were washed three times with PBS and nrL-15 and 
placed on an inverted epifluorescence microscope (Model IX81, Olympus) equipped with 
a heating stage maintained at 37 °C. Images were collected using a Rolera-MGI Plus back-
illuminated electron-multiplying charge-coupled device (EMCCD) camera (Qimaging). 
Images were acquired using bright-field imaging and three standard fluorescence filter 
sets: CFP (excitation (Ex) = 436 ± 10 nm/emission (Em) = 480 ± 20 nm), RFP (Ex = 560 
± 20 nm/Em = 630 ± 35 nm) and FITC (Ex = 488 ± 10 nm/Em = 520 ± 20 nm). The 
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fluorescence intensities of different cells were measured with the SlideBook 4.2 software 
(Olympus), and the average fluorescence intensity was determined for each condition. Our 
laboratory has previously reported that cell-penetrating peptides labeled with fluorophores 
such as TMR can photosensitize membranes and cause endosomal leakage upon light 
irradiation162, 163. To minimize the role played by light irradiation in the activities reported 
herein, I performed all delivery experiments under conditions of minimal light irradiation 
(dark room with dim red light). When fluorescence imaging was required, probes (for 
example, SNAP-Surface 488 and EGFP) were imaged before dfTAT images were 
acquired. dfTAT was also excited for only a maximum of 300 ms. In contrast, the light 
dose required to observe light-induced endosomal leakage was typically 10- to 20-fold 
greater than that used for imaging. For experiments performed with Cre and HOXB4, cells 
were not imaged and not exposed to light during delivery (cells incubated with HOXB4 
were never exposed to light, and cells incubated with Cre were imaged 12 h after 
incubation). 
 
2.4.8 Delivery of peptides and proteins inside live cells by co-incubation with dfTAT 
 HeLa, HDF and Neuro-2a cells were seeded in eight-well dishes, grown and 
washed as described in the prior section. Cells were then co-incubated with 5 μM delivery 
peptide and with the cargo at the corresponding concentration for 1 h at 37 °C. Cells were 
washed three times with PBS and nrL-15 and placed on the microscope. Images were 
acquired as described before. For transfection and expression of SNAP-H2B and TagCFP-
mito, plasmids were mixed with Lipofectamine 2000 reagent in opti-MEM medium and 
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incubated at room temperature for 30 min. The DNA complex was added to previously 
seeded HeLa cells (80 % confluent) on an eight-well dish, and cells were kept at 37 °C for 
24 h. After 24 h, the wells were washed three times with PBS and nrL-15 before 
performing the delivery experiments using the SNAP-Surface 488, FITC goat anti-mouse 
IgG (Life Technologies, Cat. No. F2761) or mouse monoclonal FITC–anti-ATP5A 
(Abcam ab119688). The SNAP-Surface 488 fluorescence is known to be quenched (80 
%) before reacting with the SNAP fusion tag242. Consequently, I considered the signal of 
SNAP-Surface 488 to be 80 % quenched when the molecule is trapped inside endosomes 
or distributed in the cytosol of cells, but fully fluorescent when localized in the nucleus of 
cells (where it reacts with SNAP-H2B). To estimate the amount of SNAP-Surface 488 
that escapes from endosomes after dfTAT-mediated delivery, I analyzed the SNAP-
Surface 488 fluorescence signal obtained after imaging using the SlideBook software. The 
total signal intensity of the cytoplasmic region was multiplied by 5 and compared to the 
total signal intensity of the nuclear region. 
 
2.4.9 Quantitative determination of peptide and macromolecule uptake inside cells 
         HeLa cells were seeded in a 48-well dish, grown and washed as described above. 
For the peptide uptake experiment, each well was incubated for 1 h with varying 
concentration of acfTAT, fTAT or dfTAT (range: 5–25 μM peptide concentration). For 
the titration experiment, cells were incubated with dfTAT (5 μM) and varying 
concentration of DEAC-K9 (range: 1–20 μM) or EGFP (10 μM) for 1 h. Cells were then 
washed with PBS with heparin (1 mg/mL) and nrL-15 and imaged. To lyse cells, I 
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removed nrL-15 from the wells, and a total of 100 μl of lysis buffer (50 mM Tris, pH 7.5, 
2 mM EDTA, 2 mM DTT, 0.1 % Triton X-100) were incubated with cells for 5 min 
(alternatively, cells were trypsinized and counted as described in the flow cytometry 
section). Cells were scraped off the dish, and the cell lysate was pipetted into a 1.5-mL 
microcentrifuge tube and centrifuged at 13,000 r.p.m. for 25 min (rotor radius: 8.4 cm). 
For uptake measurement, 70 μl of supernatant were collected and placed in a 96-well plate. 
The fluorescence emission intensity was measured using a plate reader equipped with a 
fluorescence module (Ex = 525 nm, Em = 580–640 nm) (GloMax-Multi+ Detection 
System, Promega). Alternatively, 80 μL of supernatant were diluted to a total volume of 
100 μl, and the bulk fluorescence was measured using a SLM-8000C fluorometer (Ex = 
435 nm, Em = 465–475 nm) (SLM Instruments). Fluorescence intensities were normalized 
to total protein concentration in each well (determined by Bradford protein assay, wherein 
10 μl of each cell lysate is added to 200 μl of a 1× protein assay reagent and then incubated 
at room temperature for 30 min; absorbance at 600 nm is measured using the plate reader). 
To determine the amount of EGFP uptake, I mixed cell lysates (27 μl) with 3 μl of 5× 
SDS-PAGE loading buffer lacking DTT and analyzed them by SDS-PAGE (the sample 
was not boiled so as to avoid EGFP unfolding; SDS-PAGE does not unfold EGFP, as 
described in 262 ; DTT was not included to avoid cleavage of the disulfide bond that might 
form between fTAT and EGFP). Calibration curves were established for EGFP and 
DEAC-K9 by analyzing samples of known concentrations using SDS-PAGE gel and 
fluorescence, respectively. All experiments were performed in triplicate. 
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2.4.10 Quantitative analysis of TAT-HOXB4 and HOXB4 delivery with fTAT and 
dfTAT using a luciferase reporter 
The murine fibroblast cell line (NIH 3T3, stably transfected with the E2A-PBX 
vector), the luciferase reporter vector, pML (5xHOX/PBX; contains a promoter with 
binding sites for HOXB4 and PBX) and the β-gal internal control vector used in the 
following studies were kindly provided by P. Zandstra (University of Toronto). The cells 
were initially cultured in 100-mm dishes at 37 °C with 5 % CO2 in DMEM supplemented 
with 10% FBS. For experimental purposes, however, cells were seeded in 24-well plates 
at a density of 5 × 104–6 × 104 cells per well for 24 h. Subsequently, cells were 
cotransfected with 0.8 μg/ml of pML (5xHOX/PBX) and of the β-gal internal control 
vector using Lipofectamine 2000. Twelve hours post transfection, cells were washed and 
incubated with TAT-HOXB4 or HOXB4 (both at 200 nM, unless, otherwise noted; see 
below) with or without fTAT or dfTAT in nrL-15 for 90 min. Some cells were also 
incubated with TAT-mCherry (200 nM) with and without the peptides. After incubation, 
all cells were washed with PBS and lysed according to the manufacturer's protocol for the 
reporter lysis buffer (RLB) (Promega). For titration experiments, the same protocol was 
followed, with the exception that HOXB4 concentrations were varied (25, 50, 100, 150 
and 200 nM). In order to quantitate the luciferase reporter activity, I added 100 μl of 
luciferase assay reagent (Promega) to 20 μl of cell lysate and bioluminescence was 
immediately measured using a SpectraMaxL luminometer (Molecular Devices). For the 
purposes of measuring transfection efficiency, 180 μl of β-gal assay buffer were mixed 
with 20 μl of cell lysate in a 96-well plate and incubated at 37 °C for 30 min. The β-gal 
assay buffer is composed of 75 % 0.1 M sodium phosphate, pH 7.5, 24 % o-nitrophenyl 
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β-D-galactopyranoside (ONPG made at a concentration of 4 mg/mL in 0.1 M sodium 
phosphate) (Sigma) and 1% 100-fold solution (10 % 1 M magnesium chloride solution, 
32 % β-mercaptoethanol and 58 % distilled water). Absorbance was then measured at 450 
nm using the plate reader. As the absorption spectrum of the chromophore (TMR) 
conjugated to the peptide used in this study overlaps with that of β-gal, 20 μl of cell lysate 
containing the peptide were also diluted with 180 μl of the lysis buffer, and absorbance 
values obtained at 450 nm were subtracted from those of the β-gal. The luciferase activity 
of all samples was determined as a ratio of the luciferase activity to the β-gal activity, and 
the fold-increase in luciferase activity was established by normalizing the luciferase 
activity of each sample to that of cells, which were transfected but had no protein 
delivered. 
 
2.4.11 Cell viability assays 
In order to determine cells that had compromised plasma membranes, I treated 
cells with SYTOX® green (SYTOX® blue in some cases) and Hoechst (Invitrogen). 
SYTOX® dyes are cell impermeable and stain the DNA of cells with compromised plasma 
membranes. The Hoechst dye is cell permeable and stains the DNA of all cells. Images 
were acquired using the green and blue filter. The green and blue images were used to 
count cells with a blue- or green-stained nucleus. ImageJ was used to count the dead 
(green) and total cells (blue). Cytotoxicity was determined from the ratio of SYTOX® 
green–positive cells/total number of cells. An MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay was performed to determine the effect of the peptide 
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on cell proliferation. Cells were seeded in a six-well dish, grown and washed as described 
above. One well from the dish was incubated with 5 μM dfTAT at 37 °C for 1 h. A second 
well was left untreated and served as control. Cells were washed three times with PBS and 
nrL-15. Cells were trypsinized and seeded into 96-well dishes containing 200 μl of 
DMEM. The cells were then allowed to attach to the bottom of the dish for 12 h. The MTT 
assay was then performed at specific time points to measure cell proliferation. The DMEM 
was removed and replaced with 100 μl of nrL-15, and 10 μl of a 12 mM MTT stock 
solution were added to the wells. The 96-well dish was incubated at 37 °C for 4 h. After 
the incubation, 100 μl of a 10 mM SDS-HCl solution were added to each well. The solution 
was mixed thoroughly by pipetting up and down and was incubated for 13 h. After the 
incubation each sample was mixed, and the absorbance at 600 nm was measured. Controls 
included a negative control where 10 μl MTT was added to 100 μl of nrL-15 alone (no 
cells). A second control consisted of cells treated with the delivery peptide but to which 
no MTT was added to subtract the contribution of TMR from the measured absorbance. 
The absorbance of the negative control was subtracted from all samples. The final time 
point measurement for each cell type corresponded to 100 % cell confluency. 
 
2.4.12 Whole-genome microarray analysis 
HDF cells were cultured in 24-well dishes and incubated with nrL-15 (untreated 
cells), nrL-15 supplemented with dfTAT (5 μM, treated cells) or nrL-15 supplemented 
with staurosporine (0.1 μM) for 1 h. Cells were trypsinized immediately after washing 
with PBS or nrL-15 (1-h time point). Alternatively, cells were trypsinized after 1 h (1 h + 
124 
 
1 h) or 24 h (1 h + 24 h) incubation in 10 % FBS/DMEM. Cells were removed from each 
well by gentle pipetting and spun down at 12,000 r.p.m. for 4 min at 4 °C. The cell pellets 
were preserved in 1 mL Trizol (Ambion, Life Technologies) and shipped frozen to the UT 
Southwestern microarray facility, where total RNA was extracted and analyzed on an 
Illumina Human HT-12 v4 sequencer using reported protocols 
(https://microarray.swmed.edu/protocols/protocol/illumina-gene-expression-probe-
labeling). 
 
2.4.13 Differential in gel electrophoresis (DIGE) proteomic analysis 
HDF cells were treated with or without dfTAT as described in the whole-genome 
microarray analysis assay. A volume of 150 μl of lysis buffer (10 mM Tris, pH 7.5, 1 % 
CHAPS and 1× protease inhibitor cocktail) was added to each well. After 5 min, the 
solution was transferred to an Eppendorf tube, and 20 μl of nuclease cocktail were added 
to the cell lysates and incubated on ice for 30 min. The lysate was spun down at 13,000 
r.p.m. for 10 min at 4 °C. The supernatant was saved, and an aliquot was used in Bio-Rad 
protein assay for quantification of total protein in the cell lysates. Methanol-chloroform 
precipitation was performed on the remaining sample263. All DIGE experiments were 
performed with pH 3–10 NL gradients. Each sample (~50 μg of protein) was resuspended 
in 30 μl of labeling buffer (7 M urea, 2 M thiourea, 4 % CHAPS, 30 mM Tris, 5 mM 
magnesium acetate). All samples were individually labeled with Cy3 or Cy5 (GE 
Healthcare) for 30 min on ice and in the dark (200 pmol), after which the reaction was 
quenched by the addition of 10 mM lysine for 10 min followed by the addition of an equal 
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volume of 2× rehydration buffer (7 M urea, 2 M thiourea, 4 % CHAPS, 4 mg/mL DTT). 
The combined samples were brought up to 250 μl with 1× rehydration buffer (7 M urea, 2 
M thiourea, 4 % CHAPS, 2 mg/mL DTT, 0.5 % IPG buffer, pH 3–10). All strips were 
subjected to isoelectric focusing for 25,000 V h, according to manufacturers' 
recommendations. DIGE-associated instrumentation was manufactured by GE 
Healthcare. Electrophoresis instrumentation was from Hoefer. Cy2/3/5-specific 16-bit 
data files were acquired at 100-μm resolution separately by dye-specific excitation and 
emission wavelengths using a Typhoon Trio Variable Mode Imager in a manner that 
greater than 90% of the proteins were in the linear range of detection. 
 
2.4.14  Determination of dfTAT and EGFP interaction by FRET 
Fluorescence emission spectra were obtained using an SLM-8000C fluorometer 
upgraded with the Phoenix package (ISS) and Vinci v.1.6 PC software (ISS). The 
experiments were conducted using a quartz cuvette at room temperature. The samples 
were excited at 488 nm (slit width = 1 mm), and the fluorescence emission was scanned 
from 500 to 650 nm (slit width = 1 mm). All samples (1 μM EGFP or dmEGFP and 5 μM 
dfTAT) were prepared using nrL-15. A 12% native gel was run using Tris-glycine running 
buffer at 100 mV for 2 h. Samples containing dfTAT (5 or 10 μM) were co-incubated with 
either varying concentration of dmEGFP (10–20 μM) or BSA (10 μM) in nrL-15 (pH 5.0 
and 7.0) for 30 min at 37 °C before gel loading. Fluorescence images of dfTAT and EGFP 
bands on the gel were detected using a fluorescence scanner (Typhoon, GE Healthcare). 
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(dfTAT fluorescence detection: Ex, 568 nm; Em, 620 nm. EGFP fluorescence detection: 
Ex, 488 nm; Em, 525 nm.) Gels were then stained with Coomassie blue. 
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3. AN L- TO D- AMINO ACID CONVERSION IN AN ENDOSOMOLYTIC 
ANALOG OF THE CELL-PENETRATING PEPTIDE TAT INFLUENCES 
PROTEOLYTIC STABILITY, ENDOCYTIC UPTAKE, AND ENDOSOMAL 
ESCAPE264 
 
3.1 Introduction 
In this chapter, I use dimeric fluorescence TAT developed in the previous chapter 
as a model CPP to explore the broader consequences of L- to D-stereochemical 
conversion. In particular, I determine the impact of chirality on endosomal escape during 
the cell penetration process and how an unnatural D-CPP affects cell physiology once 
inside a cell. I hypothesize that inversion of stereochemistry of dfTAT, allows for 
protection against degradation from endocytic proteases, and therefore promotes enhanced 
endosomal escape activity. In this work, I show that the inversion of chirality provides 
protease-resistance without altering the overall mode of cellular entry, a process involving 
endocytic uptake followed by endosomal escape and cytosolic entry. However, while 
inversion of chirality reduces endocytic uptake, the D-peptide (D-dfTAT), once in the 
endosome, is significantly more prone to escape than its L counterpart. Moreover, the D-
peptide is retained in the cytosol of cells for several days while the L-peptide is degraded 
within hours. Notably, while the L-peptide is relatively innocuous to cells, the D-peptide  
 
 
*This chapter is reprinted with permission from “An l- to d-Amino Acid Conversion in an Endosomolytic 
Analog of the Cell-penetrating Peptide TAT Influences Proteolytic Stability, Endocytic Uptake, and 
Endosomal Escape” by Najjar, K., Erazo-Oliveras, A., Brock, D.J., Wang, T.-Y. & Pellois, J.-P. Journal of 
Biological Chemistry 292, 847-861 (2017). Doi:10.1074/jbc.M116.759837. Copyright (2017) by Kristina 
Najjar 
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exerts a prolonged anti-proliferative activity. Together, my results establish connections 
between chirality, protease- resistance, cellular penetration, and intracellular activity that 
may be useful for the development of future delivery agents with improved properties. 
 
3.2 Results 
Cell-penetrating peptides (CPPs) have become important tools for the delivery of 
macromolecular cargoes inside cells 17, 265, 266. These delivery agents show promise in 
therapeutic applications and are useful reagents for cell biology assays 23, 247, 267. For 
instance, CPPs (TAT, Penetratin, etc.) are currently tested in several pre-clinical and 
clinical trials 71, 268. However, CPPs exposed to cells or serum are rapidly degraded and 
this can consequently render these compounds less effective in vivo or in vitro 269-273. To 
protect CPPs from degradation, a common strategy has been to employ D-amino acids 
instead of their L-amino acid counterparts. D-peptides are protease resistant and this 
approach has been applied to CPPs such as TAT, R9, penetratin, hLF, pVEC, and Sweet 
Arrow Peptide 270, 274-277. In addition, the extended in vivo half-lives of D-peptides over L-
peptides have contributed to the successful development of D-polyarginine CPPs as cancer 
contrast agents 74, 278. How inversion of chirality impacts the multifaceted functions of 
CPPs, however, remains unclear.  
Several reports have indicated that cellular uptake of CPPs is independent of 
peptide backbone chirality 276, 279. Uptake of the CPPs studied was thought to involve 
direct plasma membrane translocation. This is because uptake persisted at 4 °C, a 
condition that typically abolishes endocytosis 276. In many cases, however, the penetration 
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of CPPs into cells involves different routes of cellular entry 280. Instead of crossing the 
plasma membrane directly, certain CPPs are first internalized by endocytosis and 
accumulate inside endosomes. In a second step, CPPs escape from endosomes to penetrate 
the cytosolic space 110, 233. The effect of chirality on endocytosis has been reported for the 
CPPs R9, penetratin, and hLF. Preferential uptake of L-CPPs over D-CPPs was observed, 
suggesting that chirality is important for the interactions between these compounds and 
cell surface partners that induce endocytosis 281. Together, these studies reveal conflicting 
results that highlight how L- to D-amino acid conversion may lead to CPP-dependent 
results.   
To date, several questions related to the effect of chirality on CPPs’ activities 
remain unanswered. In particular, how chirality impacts endosomal escape during the cell 
penetration process and how an unnatural D-CPP affects cell physiology once inside a cell 
are still unclear 282. The issue of endosomal escape is important because this step is critical 
for the successful delivery of molecules of interest into a cell 230. Similarly, the issue 
concerning the physiological impact of cell penetration is of significance when one 
considers, for instance, using cellular delivery protocols as a tool for cell biology and 
therapeutic applications (i.e. most applications would benefit from delivery protocols that 
only minimally disrupt cells).  
In this report, I address these questions by using dfTAT (dimeric fluorescent TAT) 
as a model CPP. dfTAT is a disulfide bonded dimer of the prototypical CPP TAT. dfTAT 
is capable of escaping from endosomes with extremely high efficiency 157. For instance, 
while TAT escapes endosomes with an estimated efficiency of less than 1% (i.e. 1% of 
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peptide present in a cell reaches the cytosol while 99% remains trapped inside endosomes), 
the endosomal escape efficiency of dfTAT exceeds 90% 134, 157, 244. Mechanistically, 
cytosolic penetration of dfTAT involves egress from late endosomes (it does not involve 
escape from other endocytic organelles or direct plasma membrane translocation) 283. This 
egress appears to be mediated by the leaky fusion of late endosomal membranes and 
involves interactions between the positively-charged CPP and the anionic lipid 
bis(monoacyl)glycerophosphate (BMP)283. From a delivery point of view, the mode of cell 
penetration by dfTAT is useful because macromolecules, endocytosed along with dfTAT 
after co-incubation with cells, can also be released into the cytosol of cells (i.e. by leaking 
out of late endosomes along with the endosomolytic CPP). This approach has been used 
to deliver an enzyme, a transcription factor, peptides, and cell-impermeable small 
molecules with high efficiencies157. Importantly, the leakage induced by dfTAT appears 
to be relatively innocuous to cells as dfTAT-mediated delivery does not lead to changes 
in cellular proliferation or transcriptional responses. dfTAT therefore represents a CPP 
with desirable properties and with an activity sufficiently high to enable mechanistic 
studies.  
Herein, I investigate the cell penetration of a D-amino acid analog of dfTAT to 
establish the impact of chirality on cytosolic access. I establish that a L- to D-amino acid 
substitution, by inhibiting peptide degradation from endocytic proteases, promotes 
enhanced endosomal escape activity. I also establish that the D-CPP, after successful 
cytosolic entry, gives rise to perturbations in proliferation and transcription more severe 
than L-CPP. This can be attributed to the prolonged intracellular retention of the D-
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peptide. For the first time, I therefore report on an anti-proliferative effect of a D-CPP and 
reveal additional advantages and disadvantages inherent to conferring protease-resistance 
to an endosomolytic agent. I envision these findings are relevant to other cell-permeable 
molecules (e.g. stapled peptides, peptoids, CPPs, etc.), in particular those that, like dfTAT, 
have high arginine residue content. 
 
3.2.1 Generation of D-dfTAT: a protease resistance cell-penetrating peptide 
dfTAT (i.e. L-dfTAT) and D-dfTAT were prepared by synthesis of the peptide 
CK(TMR)RKKRRQRRRG or ck(TMR)rkkrrqrrrG, respectively, on solid-phase followed 
by disulfide bond formation of the cysteine residue in solution (Figure 3-1, Figure 3-2; 
Figure 3-3). TMR is the red fluorophore carboxytetramethylrhodamine and is conjugated 
to the ε-NH2 of the lysine side chain. 
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Figure 3-1 Schematic representation of the amino acid sequence of dfTAT (top) and 
D-dfTAT (bottom). 
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Figure 3-2 Characterization of dfTAT. a) HPLC and b) MALDI-TOF MS spectrum of 
dfTAT (retention time, rt=12.94 min). Mass Spectrum of dfTAT: observed [M+H]+ = 
4080.87, [M+2H]/2+ = 2042.56 predicted Exact Mass (M) = 4078.27 Da. 
b
b
b 
a 
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Figure 3-3 Characterization of D-dfTAT. a) HPLC and b) MALDI-TOF MS spectrum 
of D-dfTAT (rt=12.91 min). Mass Spectrum of D-dfTAT: observed [M+H]+= 4078.87, 
[M+2H]/2+= 2042.50 predicted M = 4078.27 Da 
b
b
b 
a 
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3.2.2 D-dfTAT is protease resistant and capable of penetrating cells 
To confirm that the incorporation of D-amino acids confers protease resistance to 
D-dfTAT, the peptide was exposed to trypsin in vitro. Consistent with the high Arg and 
Lys content of the TAT sequence, the parent compound dfTAT was degraded by trypsin 
within minutes as evidenced by HPLC analysis (Figure 3-4). In contrast, D-dfTAT 
remained intact for the duration of the experiment (48h).To determine whether the cell 
penetration activity of dfTAT is retained after a L-to D-amino acid substitution, HeLa and 
human dermal fibroblast (HDF) cells were incubated with 1 or 5 μM dfTAT or D-dfTAT 
for 1h and examined by fluorescence microscopy. At 1 μM, both peptides show a punctate 
distribution indicative of endosomal entrapment (as previously reported for dfTAT). In 
contrast, at 5 μM peptide incubation, cells displayed a diffuse cytoplasmic fluorescent 
signal accompanied with a nucleolar staining observable immediately after incubation 
(Figure 3-5). These fluorescence staining are consistent with successful entry of each 
peptide into the cell’s cytosolic space as cytosolic entry presumably precedes targeting to 
nucleoli16, 157, 284. In addition, the fluorescence signal of D-dfTAT was low in the nucleus 
(apart from the nucleoli), and a sharp contrast was observed with the 
cytoplasmic/nucleolar signal. The fluorescence staining of cells was monitored for 24 h to 
establish how the fluorescence signal of each peptide changes overtime (Figure 3-6). The 
nucleolar staining of dfTAT disappeared within 2 hours. The diffuse signal of dfTAT also 
progressively disappeared overtime and was replaced by a punctate distribution in less 
than 24h (Figure 3-6). In contrast, the fluorescence signal of D-dfTAT remained  
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Figure 3-4 HPLC analysis of dfTAT and D-dfTAT before and after treatment with 
trypsin.  The peptides (10 µM) were each analyzed before (0 min time point) and after 
incubation with trypsin (0.025%) for the indicated times. Reactions were quenched at 
different time intervals with 0.01% TFA in water (1 min, 1 h and 48 min). Peaks are 
detected by monitoring the absorbance of the TMR chromophore at 550.8 nm. 
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Figure 3-5 Cellular distribution of dfTAT and D-dfTAT after 1 hr incubation. HeLa 
cells were incubated with dfTAT or D-dfTAT at 1 or 5 µM for 1 h, washed and then 
stained with the cell permeable Hoechst nuclear stain (1µg/mL). Live cells were imaged 
with a 100X objective. Fluorescence images are overlays of the TMR emission at 560 nm 
(pseudocolored red) and Hoechst emission at 460 nm (pseudocolored blue). Insets to the 
left show a zoom in into the nucleolar staining of each peptide (white arrowheads). Scale 
bars, 10 µm. 
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Figure 3-6 Cellular distribution of dfTAT and D-dfTAT immediately after delivery 
and after 24h. HDF cells were incubated with dfTAT or D-dfTAT at 5 µM for 1 h and 
washed. Cells were imaged with a 100X objective either immediately after treatment or 
after an additional 24 h incubation. Fluorescence images are overlays of the TMR emission 
at 560 nm (pseudocolored red) and Hoechst emission at 460 nm (DNA stain added during 
imaging, pseudocolored blue). Scale bars, 10 µm. 
 
139 
 
unchanged and a strong nucleolar staining was retained throughout the duration of the 
experiment (Figure 3-6).  
To assess the stability of each peptide in cellulo, an analysis of cellular extracts 
was performed using gel electrophoresis. A high percentage acrylamide gel was used to 
separate the full-length peptides from smaller degradation fragments (the peptides are 
reduced with DTT to simplify the analysis; consequently the monomeric peptides fTAT 
and D-fTAT are detected in this assay). The fluorescence signal of TMR, a moiety 
presumably not readily degradable by cells, was used to detect all the species generated 
upon cellular exposure. Cells were incubated with dfTAT or D-dfTAT (5 M) for 1 h, 
washed, and incubated with fresh media (media not containing peptide) for up to 24h. 
Incubation medium and cell lysates were extracted at various time points. The samples 
recovered from the medium immediately after incubation of cells with dfTAT and D-
dfTAT display a single species comparable in size to that of the pure control peptide fTAT 
(reduced dfTAT) (Figure 3-7). The cell lysates obtained from cells incubated with D-
dfTAT show a similar band, independent of incubation time. In contrast, the lysate of cells 
incubated with dfTAT for 1 h show a band corresponding to fTAT and a smear 
corresponding to smaller degradation species. Analysis of the band intensities by 
densitometry shows that approximately 25% of the peptide is intact while 75% is 
degraded. This ratio remains relatively unchanged after an additional 1 and 3 hours of 
incubation in fresh media. However, the band corresponding to fTAT is not present 
anymore at the 24 h time point. Overall, these data indicate that dfTAT is rapidly degraded 
during incubation with cells and during the delivery process. The degradation of dfTAT  
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Figure 3-7 Analysis of peptide degradation by Tris-Tricine gel electrophoresis of cell 
lysates. HeLa cells were incubated with 5 µM dfTAT or D-dfTAT for 1 h and lysed either 
immediately (1 h), or at 1 h, 3 h or 24 h after peptide incubation. Cells lysates were 
analyzed by electrophoresis along with an aliquot of the peptide solution incubated with 
cells (medium 1 h) and with a sample of pure peptide. The gel was imaged on a 
fluorescence scanner. The fluorescent bands were quantified by densitometry to generate 
the graph presented. The data reported represent the average and corresponding standard 
deviations of biological triplicates. 
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continues after cellular penetration, however on a slower time scale. In contrast, D-dfTAT 
resists degradation throughout the duration of the experiment. 
 
3.2.3 Both dfTAT and D-dfTAT deliver macromolecules inside cells and access the 
cytosol of cells by using a similar endocytic route 
The utility of dfTAT is based on the fact that this reagent renders endosomes leaky and 
that, consequently, it can mediate the efficient cytosolic delivery of macromolecules into 
live cells by a simple co-incubation protocol157. To determine whether D-dfTAT displays 
a similar activity, a Cre recombinase delivery assay was performed. In this assay, 
successful nuclear delivery of Cre recombinase (38 kDa) results in the expression of an 
EGFP reporter. I used TAT-Cre, a Cre recombinase fused to the protein transduction 
domain (PTD) TAT. TAT-Cre has previously been shown to enter cells and I therefore 
used this reagent to assess how dfTAT-mediated delivery compares to the commonly used 
PTD approach 285. As shown in Figure 3-8, incubation of cells with TAT-Cre led to 
expression of EGFP in approximately 10 % of the cell population. In contrast, addition of 
5 µM of dfTAT or D-dfTAT peptide during incubation led to more than 70% of cells 
positive for EGFP expression. Similar results were obtained for co-incubation of cells with 
dfTAT and D-dfTAT with the DEAC-k5 peptide (Figure A-1). These data suggest that 
both dfTAT and D-dfTAT are capable of delivering a macromolecule inside the cytosol 
and nucleus of live cells at a level superior to that observed with a PTD fusion alone. 
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Figure 3-8 dfTAT and D-dfTAT deliver Cre recombinase into live cells. HeLa cells 
were transfected with a plasmid containing EGFP upstream of a loxP-STOP-loxP 
sequence. The cells were then co-incubated with dfTAT or D-dfTAT (5 μM) and 4 μM 
Cre recombinase. Cells positive for EGFP expression were counted 24 h after the protein 
delivery treatment.*** represents P≤0.001 and **** represents P≤0.0001 compared to 
control (TAT-Cre). Bracket indicates comparison of P-values obtained using t-test 
analysis of dfTAT and D-dfTAT treatments (ns = P>0.05) 
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dfTAT penetrates the cytosol of cells by escaping from late endosomes via 
interactions with the lipid BMP 283 .To examine whether D-dfTAT follows the same route 
for cellular entry, D-dfTAT was incubated with cells transfected with a dominant-negative 
Rab7 (DN-Rab7), a construct known to block endocytic trafficking between early and late 
endosomes 286, 287. The effect of Rab7 and DN-Rab7 on peptide endocytic uptake was 
established by measuring the overall fluorescence of cell lysates. The cytosolic penetration 
activity of D-dfTAT was established by counting the number of cells displaying a distinct 
nucleolar staining by the peptide. Notably, this assay does not directly measure how much 
peptide remains trapped inside endosomes versus how much escapes endosomes. Instead, 
it is a binary assay that establishes whether or not endosomal leakage is achieved above a 
detection threshold determined by the fluorescence microscopy set-up. As previously 
observed with dfTAT the overall endocytic uptake of D-dfTAT was not significantly 
altered by overexpression of the Rab7 constructs, indicating that DN-Rab7 does not 
prevent D-dfTAT from accumulating inside endosomes. However, DN-Rab7 inhibited 
cytosolic penetration of D-dfTAT while wild-type did not (Figure 3-9). These results 
indicate that DN-Rab7 blocks the endosomal escape of D-dfTAT and that, consequently, 
D-dfTAT escapes from endocytic organelles that are downstream of early endosomes in 
the endocytic pathway. In addition, to further test the involvement of endocytic trafficking 
in cell penetration, cells were pre-incubated with anti-BMP (50 μg/ml), an antibody 
previously shown to block membrane fusion within late endosomes 128, 288, 289. As in the 
case of DN-Rab-7, the cell penetration of dfTAT and D-dfTAT was inhibited by this 
treatment to a similar extent (Figure 3-10). Overall, these data support the model that both  
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Figure 3-9 Cytosolic penetration of D-dfTAT is blocked by expression of dominant-
negative Rab7. HeLa cells were transfected with Rab7 or dominant negative Rab7 (DN-
Rab7). dfTAT or D-dfTAT (3 μM) was then incubated with cells for 1 h and cell 
penetration was quantified. The total fluorescence of cell lysates was also measured to 
assess the impact of each treatment on peptide endocytic uptake. The uptake for cells 
transfected with Rab7 or DN-Rab7 was normalized to the uptake of cells treated with 
dfTAT or D-dfTAT respectively. *** represents P≤0.001 and **** represents P≤0.0001 
compared to control. 
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Figure 3-10 D-dfTAT major route of cellular entry is via endocytosis followed by 
endosomal escape in a manner similar to dfTAT. a) Cytosolic penetration of D-dfTAT 
is blocked by the anti-BMP antibody. HeLa cells were pre-incubated with anti-BMP mAb 
or the control anti-IgG mAb for 30 min. dfTAT or D-dfTAT (3 μM) was then incubated 
with cells for 1 h and cell penetration was quantified. The total fluorescence of cell lysates 
was also measured to assess the impact of each treatment on peptide endocytic uptake. b) 
Given the possibility of a secondary mode of penetration in a minority of cells (<5%, as 
described in Figure 2), the uptake data presented in Figure 4 may include endocytosis-
dependent and endocytosis-independent uptake. In order to address how much signal may 
be contributed by endocytosis-independent cytosolic entry, the fluorescence intensity of 
cells positive for peptide penetration in the presence of DN-Rab7 was estimated (these are 
the cells in which uptake cannot be fully accounted for by endocytosis). HeLa cells were 
transfected with Rab7 or dominant negative Rab7 (DN-Rab7). Cells were then incubated 
with D-dfTAT at 3 µM. Images are pseudocolored based on the fluorescence intensity of 
D-dfTAT in the cells (Scale bars, 100 µm). These representative data confirm that the 
number of cells positive for peptide penetration decreases when DN-Rab7 is expressed (as 
shown in Figure 2b). However, the overall fluorescence intensity of the few cells positive 
for peptide penetration in the presence of DN-Rab7 is equivalent (as shown by the 
pseudocolored scale) to the fluorescence intensity of cells positive for peptide penetration 
in the presence of wild type Rab7 (as exemplified with cells highlighted with a white box; 
this observation was made in 10 images taken of the DN-Rab7 condition, the fluorescence 
intensity of 30 cells surveyed). Therefore, I estimate that endocytosis-independent uptake, 
if present in 5% of cells, may contribute 5% or less of the total signal reported.   
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Figure 3-10 Continued. 
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dfTAT and D-dfTAT reach the cytosol by an endocytic route in a majority of cells. It is 
important to note that penetration persisted in approximately 5% of cells in the presence 
of DN-Rab7 or anti-BMP. On one hand, it is possible that the inhibitors did not work 
effectively in these cells (i.e. maybe because of low expression, degradation, etc…). On 
the other hand, these results may suggest that a secondary route of entry (e.g direct plasma 
membrane translocation) is also plausible, albeit much less predominant than endosomal 
escape.  
In principle, the previous results indicate that the peptide escapes from either late 
endosomes or lysosomes is possible 290. In the case of dfTAT, I have previously ruled out 
the involvement of lysosomes by establishing that dfTAT does not release material loaded 
inside lysosomes 283 . Yet, D-dfTAT might differ significantly from dfTAT in this 
instance. In particular, one can envision how dfTAT might be rendered inactive inside 
lysosomes because it is extensively degraded. In contrast, by being protease-resistant, D-
dfTAT could remain membrane-disrupting in this milieu. To test this idea, the endosomes 
of HeLa cells were preloaded with DEAC-k5, a fluorescent and protease-resistant 
polylysine peptide (Figure 3-11). As shown in exp 1 of Figure 3-12, endosomes loaded 
with DEAC-k5 are observed by fluorescence microscopy as puncta inside cells 
(endosomal entrapment is confirmed by co-localization with lysotracker). Cells were then 
washed and treated with D-dfTAT immediately (Figure 3-12, exp 2) or 2 hours (Figure 
3-12, exp 3) after DEAC-k5 incubation. The additional incubation time in the latter 
experiment was used to allow lysosomal accumulation of DEAC-k5. Microscopy images 
show that D-dfTAT is able to redistribute the fluorescence of DEAC-k5 inside cells after  
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Figure 3-11 Characterization of DEAC-k5. a) Structure and expected mass of DEAC-
k5. b) The HPLC spectrum of DEAC-k5 (rt= 11.8 min) and the MALDI-TOF mass 
spectrum are shown. Observed mass are [M]+= 900.84 and [M+Na]+ = 922.88, predicted 
mass of 900.59 Da. 
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Figure 3-12 D-dfTAT causes the release of a peptide preloaded into endosomes but 
not that of peptide preloaded into lysosomes. In experiment 1, cells were incubated with 
DEAC-k5 (20 µM) for 1h and washed. Cells were then incubated with lysotracker during 
imaging to establish the accumulation of DEAC-k5 inside endosomes. In experiment 2, 
cells were incubated with DEAC-k5 (20 µM) for 1 h, washed and then incubated with D-
dfTAT (5 µM) for 1 h. Experiment 3 was performed as experiment 2 with the exception 
of a 2 h waiting time between incubation with DEAC-k5 and D-dfTAT. Fluorescence 
images represented are either monochromatic or pseudocolored green for lysotracker and 
blue for DEAC-k5. Scale bars, 10 µm. 
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immediate incubation (like D-dfTAT, DEAC-k5 stains nucleoli because it is positively 
charged and presumably binds nucleolar nucleic acids). This is presumably because D-
dfTAT is capable of causing the leakage of late endosomes that still contain DEAC-k5.In 
contrast, D-dfTAT was not able to cause cytosolic release of DEAC-k5 in exp 3. In 
particular, D-dfTAT still displayed a nuclear/cytosolic distribution but the DEAC-k5 
fluorescent distribution remained punctate (exp3 in Figure 3-12). This in turn suggests 
that D-dfTAT, like dfTAT, does not cause the release into the cytosol of material that has 
accumulated inside lysosomes. Overall, these data also indicate that dfTAT and D-dfTAT 
use an identical route of cellular entry involving late endosomes. To further confirm that 
the membrane of these organelles is the site of peptide penetration, the activity of dfTAT 
and D-dfTAT towards liposomes mimicking late endosomes (i.e. BMP, PC, PE, 
cholesterol) was assessed in vitro. In particular, both peptides were capable of inducing 
liposome leakage with equivalent efficiencies (Figure 3-13). Furthermore, the affinity of 
the peptides to BMP containing liposomes were similar (Figure A-2). In addition, dfTAT 
and D-dfTAT are partitioned into hexane by the presence of BMP to a similar extent 
(Figure A-2). This establishes that the chirality of the peptide is not an important 
determinant in its interaction with lipids found in late endosomes. 
 
 
 
 
151 
 
 
 
Figure 3-13 D-dfTAT causes leakage of liposomes with a lipid composition 
mimicking that of late endosomes. Liposomes loaded with calcein (500 µM) were 
incubated with dfTAT or D-dfTAT (0.1, 1 or 10 M). The fluorescence signal of free 
calcein was quantified after peptide treatment. ns represents P >0.05.   
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3.2.4 L- to D- substitution negatively impacts endocytosis but favors endosomal 
escape 
The previous experiments indicate that dfTAT and D-dfTAT share similar cell 
penetration properties, at least qualitatively. In order to establish whether the two peptides 
differ in their respective efficiencies quantitatively, the penetration activity of each 
compound was determined as a function of peptide concentration. First, cells were 
incubated with increasing concentrations of each peptide. Cells were then examined by 
fluorescence microscopy. Cells displaying a distinctive nucleolar staining are counted as 
positive for penetration (the cells counted are also negative for SYTOX Blue staining, 
indicating that their plasma membrane is not compromised and that these cells are not 
dead). At any given concentration of peptide in the incubation media, the number of cells 
positive for penetration was similar between the two peptides (with the exception of 10 
μM, where D-dfTAT is more active than dfTAT) (Figure 3-14). Cells negative for cell 
penetration typically display a punctate distribution consistent with endosomal entrapment 
of the peptide and weak endosomal escape 291. This assay is however only binary in nature 
and only reveals whether penetration is achieved above a detection threshold dictated by 
the fluorescence microscope. To quantify the activity of each peptide in greater detail, 
overall peptide uptake was also measured (Figure 3-15). 
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Figure 3-14 Evaluation of the cytosolic delivery efficiency of dfTAT and D-dfTAT as 
a function of peptide concentration in incubation media. HeLa cells were incubated 
with peptides (1-10 M) for 1 h. The percentage of cells detected as positive for 
penetration was established by microscopy (ns represents P >0.05, ** = P≤0.01). 
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Figure 3-15 Quantification of whole cell uptake by dfTAT and D-dfTAT as a function 
of the peptide concentration in incubation media. HeLa cells were incubated with 
peptides (1-10 μM). The overall amount of peptide internalized by cells (endosomal + 
cytosolic) was assessed by measuring the bulk fluorescence of cell lysates. The illustration 
summarizes the protocol used for this assay. 
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Figure 3-15 Continued. 
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This was performed by measuring the bulk fluorescence emission of cell lysates. This 
assay was chosen because the fluorescence of the dimeric CPPs is partially quenched in 
comparison to that of their monomeric counterparts (Figure 3-16). In addition, one may 
expect that once inside cells, the CPP might give rise to multiple species, including the 
intact dimer, the reduced monomer, and degradation fragments. Consequently, cell lysis 
enabled us to chemically reduce the pool of dimeric CPPs present in cells so as to generate 
unquenched species that can be better quantified (Figure 3-16). This analysis shows that 
the overall cellular fluorescence is 3 to 4 fold higher for cells treated with dfTAT than for 
cells treated with D-dfTAT (Figure 3-15; preferential uptake of the L-CPP over the D-
CPP were corroborated by flow cytometry and fluorescence microscopy, although these 
assays suffer from the possible caveat of partial fluorescence quenching described above, 
Figure 3-17). Control experiments indicated that none of the fluorescence detected was 
associated with extracellular membrane binding (Figure 3-18). Notably, it is conceivable 
that there would be less D-dfTAT inside cells than dfTAT if the export of the peptides 
from inside to outside of cells was greater for the D-CPP than for the L-CPP. To test this 
possibility, cells were treated with both CPPs for 1 h and washed using protocols that 
remove extracellular peptides (Figure 3-18). The media of cells incubated for up to 6 
hours were then collected and the presence of the TMR signal was subsequently detected 
by fluorescence spectroscopy (Figure 3-19). Based on this assay, significantly more 
fluorescent species are released into the medium after delivery with dfTAT than after 
delivery with D-dfTAT (where no to little fluorescence is detected). Therefore, 
preferential export of D-dfTAT does not account for the differences observed in  
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Figure 3-16 The fluorescence emission of dfTAT and D-dfTAT increases upon 
reduction of the disulfide bond. a) HPLC analysis of purified dfTAT and D-dfTAT in 
absence and presence of the reducing agent tris(2-carboxyethyl)phosphine (TCEP). Pure 
dfTAT and D-dfTAT was mixed with a solution of TCEP (50 mM) in water and allowed 
to react for 15 min. The HPLC chromatogram show a peak with rt = 12.9 min for both 
dfTAT and D-dfTAT and rt= 9.7 min for the reduced peptides. b) Bar graph of the 
fluorescence emission of dfTAT and D-dfTAT (1.25 µM) in the absence and presence of 
the reducing agent TCEP (50 mM). The samples were excited at 556 nm and the emission 
was scanned between 560-760nm. c) Quantification of the uptake fluorescence intensity, 
with or without DTT, in cells treated with dfTAT and D-dfTAT. HeLa cells were 
incubated with 5 µM dfTAT or D-dfTAT. Cells were then trypsinized and lysed in 
presence or absences of DTT (2mM). The overall amount of peptide internalized by cells 
(endosomal + cytosolic) was assessed by measuring the bulk fluorescence of cell lysates.  
 
Together, these results indicate that the fluorescence of dfTAT and D-dfTAT is 
partially quenched when the peptides are in their dimeric form. As indicated in the main 
text, we therefore concluded that the reduction of cell lysates was necessary to obtain 
quantitative data of peptide uptake into cells. However, the contribution of the dimer 
fluorescence is relatively small (see -/+ DTT comparison), indicating that the peptides are 
presumably already reduced after entry into the cytosolic space (this is consistent with the 
observation that disulfide bonds are reduced in a matter of second by once inside cell 134. 
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Figure 3-16 Continued. 
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Figure 3-17 Comparison of the cellular uptake of dfTAT and D-dfTAT. a) The overall 
amount of peptide internalized by cells (endosomal + cytosolic) was measured using flow 
cytometry. HeLa cells were incubated with dfTAT or D-dfTAT at different concentrations 
(1-10 µM). Cells were then analyzed and fluorescence intensity was quantified as a 
function of concentration. b) The overall amount of peptide internalized by cells was 
quantified using fluorescence microscopy. HeLa cells were incubated with dfTAT or D-
dfTAT at 5 µM. Images are pseudocolored based on the fluorescence intensity of dfTAT 
and D-dfTAT in the cells. Scale bars, 100 µm. 
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Figure 3-17 Continued. 
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Figure 3-18 The uptake fluorescence intensity of dfTAT and D-dfTAT is not a 
consequence of extracellular membrane binding. Cells were treated with dfTAT and 
D-dfTAT at 5 µM for 1 h. The cells were then washed using three separate protocols that 
insure removal of peptide bound extracellularly. For all protocols, cells were first washed 
three times with L-15 supplemented with heparan (1 mg/mL) and once with nrL-15. 
Sample 1: control cells were then trypsinized and resuspended in nrL-15 for flow 
cytometry. For sample 2: The cells were then washed again three times with L-15 
supplemented with heparan (1 mg/mL) and once with nrL-15. For sample 3: The cells 
were then trypsinized and resuspended in nrL-15 and centrifuged. The supernatant was 
removed and the cell pellet was trypsinized (50 µL) and resuspended once again in nrL-
15 for flow cytometry analysis. The bar graph shows the average mean fluorescence 
intensity values from the flow cytometry (each condition was performed in triplicate). An 
example of the flow cytometry histogram for each condition is shown below the bar graph.  
 
 Because the cell fluorescence is independent of the various treatments used, I 
conclude that portion of extracellular peptide that could potentially contribute to signal is 
negligible.  
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Figure 3-18 Continued. 
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Figure 3-19 Determination of the contribution of peptide export after dfTAT or D-
dfTAT treatment. HeLa cells were incubated with 5 µM dfTAT or D-dfTAT for 1h. The 
cells were washed and the media in all wells was replaced. The media for each time point 
condition was removed at the indicated times (0, 0.25, 0.5, 1, 3, and 6 hours post 
incubation). The fluorescence intensity of the media collected form treated cells was 
measured and normalized to the media obtained from untreated cells. All the data reported 
in this figure represent the average and corresponding standard deviations of biological 
triplicates. 
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Figure 3-15. Overall, considering that intracellular fluorescence signals detected in Figure 
3-15 are proportional to initial endocytic uptake (i.e. step 1 in Figure 3-14), these results 
indicate that an L to D conversion reduces endocytosis of the CPP. 
 Given that D-dfTAT is endocytosed less efficiently than dfTAT and yet leads to 
equivalent numbers of cells positive for penetration, the previous data indicated that D-
dfTAT might be able to escape from endosomes at lower concentrations than dfTAT. 
Using microscopy analysis of cells treated with lysotracker green, a fluorescent markers 
of late endosomes and lysosomes, I found that the number of endosomes present in cells 
treated with dfTAT is similar to that present in cells treated with D-dfTAT (Figure 3-20). 
I therefore reasoned that the overall uptake measured in Figure 3b is proportional to the 
concentration of peptide present inside endosomes prior to endosomal escape. To estimate 
the relative endosomal escape efficiency of each peptide, the penetration activities of D-
dfTAT and dfTAT were therefore plotted as a function of overall uptake (Figure 3-21). 
These data show that the ability of D-dfTAT to escape from the endocytic pathway 
increases dramatically within a narrow range of intracellular concentrations. In contrast, 
dfTAT achieves similar cell penetration activities but requires a larger intracellular 
concentration to do so. Notably, the plot of dfTAT appears to plateau at high levels of 
peptide uptake, indicating that significant increases in intracellular concentration only lead 
to minor improvements in penetration. Moreover, under low intracellular uptake 
conditions, the percentage of penetration positive cells for dfTAT is approximately 7 fold 
less than in the case of D-dfTAT (e.g. uptake of ~3). Overall, these data indicate that D-
dfTAT is capable of escaping endosomes more effectively than dfTAT (for a discussion  
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Figure 3-20 The number of endosomes present in cells treated with dfTAT is similar 
to that present in cells treated with D-dfTAT. HeLa cells were treated with 2 µM dfTAT 
or D-dfTAT respectively for 1h. Cells were then washed and incubated with 500 nM 
lysotracker green for 10 min. The fluorescent images show a punctate distribution for both 
the peptide and lysotracker green. Scale bar, 10 µm.  
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Figure 3-21 Evaluation of the endosomal escape activity of dfTAT and D-dfTAT as 
a function of the total amount of peptide internalized by cells (rationale highlighted 
in scheme). The data represented combines the peptide penetration and uptake measured 
in Figure 3-14 and 3-15. 
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on the possible yet small contribution of peptide uptake by an endocytosis-independent 
process, please see Figure 3-10). 
In order to assess whether the differences in endosomal activity detected between 
the two peptides might arise from the partial endosomal proteolytic degradation of dfTAT, 
cell penetration activities were quantified in the presence of protease inhibitors. First, 
HeLa cells were pre-incubated with the cysteine-protease inhibitor E-64D and the 
cysteine, serine and threonine proteases inhibitor leupeptin 292, 293. To establish whether 
this cocktail may protect the peptide from degradation prior to endosomal escape, cells 
were treated with 5 µM dfTAT for only 10 min and lysed immediately. This condition 
allows for peptide accumulation in the endocytic pathway (i.e. cells display a punctate 
peptide distribution under this condition) without providing sufficient time for endosomal 
escape. The cell lysates were analyzed by gel electrophoresis and densitometry analysis 
was performed on bands representing intact and degraded peptide fractions. As shown in 
Figure 3-22, a 20% increase in the amount of intact peptide was achieved in the presence 
of inhibitors. While these results do not pinpoint the site of action of the inhibitors within 
the cell (e.g. plasma membrane vs endocytic organelles), they nonetheless indicated that 
an increase of the amount of intact peptide present within endosomes could be achieved. 
This inhibitor cocktail was then used to determine whether protection against endosomal 
proteolytic degradation could impact the cell penetration activity of dfTAT. HDF cells 
were pre-treated with E-64D and leupeptin and then treated with D-dfTAT and dfTAT (2 
µM) for 1h. The percentage of cells positive for penetration was then measured (Figure 
3-23). The penetration activity of D-dfTAT was not impacted by the presence of  
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Figure 3-22 A protease inhibitor cocktail protects dfTAT from proteolytic 
degradation prior to cytosol delivery. HeLa cells were pre-incubated (40 min) with E-
64D (40 µM) and leupeptin (28 µM). Cells were then treated with dfTAT (5µM) in 
presence of E-64D for 10 min. Cells lysates were analyzed by gel electrophoresis. Bands 
corresponding to intact and degraded peptide, detected using a fluorescence scanner, were 
quantified by densitometry to generate the bar graph presented. The data reported 
represent the average and corresponding standard deviations of biological triplicates. P-
values are obtained using t-test analysis (*= P ≤0.01) between dfTAT with or without 
inhibitors. 
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Figure 3-23 A protease inhibitor cocktail increases the penetration activity of dfTAT 
but not of D-dfTAT. HDF cells were pre-incubated (40 min) with the protease inhibitor 
cocktail (40 µM E-64D and 28 µM leupeptin). The cells were then treated with dfTAT or 
D-dfTAT (2µM) in presence of E-64D for 1h. The percentage of cells detected as positive 
for penetration was established by microscopy. 
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inhibitors, indicating that these compounds do not indirectly affect endocytosis and 
endosomal escape. In contrast, the activity of dfTAT was significantly increased by the 
inhibitor cocktail (approximately 2-fold increase at 2 µM). These data therefore suggest 
that proteolytic degradation along the trafficking pathway of the peptide might reduce its 
overall penetration activity. 
 
3.2.5 Endosomal scape is not toxic to cells, but intracellular retention of D-dfTAT 
inhibits cells proliferation and impacts transcription  
The viability of cells, determined using a SYTOX BLUE exclusion assay, was 
95% and 98% after treatment with dfTAT and D-dfTAT (5 µM), respectively. dfTAT did 
not impact the proliferation of HDF or MCH58 cells. Likewise, D-dfTAT was innocuous 
to HDF and HeLa. However, the proliferation of MCH58 cells was blocked by this peptide 
(Figure 3-24; Figure 3-25; Figure A-4). Consistent with these results, bright field images 
of MCH58 cells treated with D-dfTAT for 1 h show no appreciable change in confluency 
over a period of 48 h (Figure 3-26). In order to gain a more detailed insight into how cells 
respond to each peptide, a microarray analysis was performed. I have previously reported 
that, despite causing extensive leakage of endocytic organelles, dfTAT does not 
dramatically impact the transcriptional program of cells treated with the peptide for one 
hour (analysis was performed one hour after incubation) 157. Herein, I repeated this 
analysis 24 h after incubation to compare the effects of dfTAT and D-dfTAT. This choice 
was made based on the fact that dfTAT is completely degraded inside cells at this time  
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Figure 3-24 D-dfTAT impacts cellular proliferation more dramatically than dfTAT 
after cytosolic delivery. Proliferation assays. HDF and MCH58 cells were incubated with 
5 µM dfTAT or D-dfTAT for 1h. Cells were then incubated in growth media 
(DMEM/10%FBS) and cellular proliferation was monitored over a period of 72 h using a 
MTT assay. Experiments were performed in triplicates with average and standard 
deviation indicated. 
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Figure 3-25 Proliferation assay. dfTAT treated HDF cells proliferate at a similar rate 
to untreated cells. HDF cells were incubated with 5 µM dfTAT or D-dfTAT in nrL-15 
for 1h. Cells were then incubated in growth media (DMEM/10%FBS) and cellular 
proliferation was monitored over a period of 72h using a MTT assay. Experiments were 
done in triplicates with average and standard deviation indicated. 
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Figure 3-26 The effect of dfTAT and D-dfTAT treatment on cell growth was 
monitored by microscopy. MCH58 cells were grown to 50-60% confluency and 
incubated with 5 µM dfTAT or D-dfTAT for 1h. Cells were washed and imaged. The cells 
were then incubated in growth media (DMEM/10%FBS) and imaged again at 48 h. Bright 
field images of live cells taken immediately after incubation and after 48 h are shown 
using a 20X objective. Insets show fluorescence images of dfTAT and D-dfTAT treatment 
pseudocolored in red (emission 560 nm) and Hoechst emission pseudocolored in cyan 
(emission 480 nm). Scale bars, 100 µm. 
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point while D-dfTAT remains intact (Figure 3-7). Cells were images before mRNA 
extraction to insure efficient dfTAT or D-dfTAT delivery (Figure A-5). As previously 
observed, HDF cells treated with dfTAT were virtually identical to untreated cells 
(1/47000 transcript being overexpressed over a 2-fold threshold). MCH58 cells were 
slightly more perturbed with a total of 20 transcripts dysregulated. In contrast, D-dfTAT 
caused the dysregulation of 215 and 551 transcripts in HDF and MCH58 cells, respectively 
(Figure 3-27). These data establish that the transcriptional response induced by D-dfTAT 
is cell-dependent, yet consistently more severe than in the case of dfTAT. Notably, the 
level of transcriptional dysregulation induced by D-dfTAT also correlates with the effect 
of the peptide on proliferation (dysregulation of pro-apoptotic, as well as pro-survival 
genes, is identified in the microarray data; a list is provided in Table 3-1).   
 
3.3 Discussion  
dfTAT is a multitasking molecule utilizing the endocytic pathway to access the 
cytosolic space of cells (Figure 3-28) 157. On the cell surface, it interacts with cell 
components that facilitates endocytic uptake. In the lumen of late endosomes, it interacts 
with BMP to induce membrane leakage 283 . Upon cytosolic access, dfTAT is reduced to 
monomeric fTAT. fTAT then accumulates at nucleoli. Throughout this pathway, dfTAT 
is presumably subjected to proteolysis. The results clearly establish that substituting L-
amino acids for their D- isomers protects the peptide from degradation. In particular, based 
on intracellular peptide distribution and gel analysis, D-dfTAT is stable for a minimum of 
24 h after cell penetration. In contrast, dfTAT is already partially degraded after 1 h  
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Figure 3-27 RNA-seq analysis of HDF and MCH58 cells treated with D-dfTAT or 
dfTAT (5µM) in L-15 for 1 h. Untreated cells were incubated without peptide in L-15 
for 1 h. After 24 h in growth media (DMEM/10%FBS), cells were pelleted for total RNA 
extraction. The scatter plots shown display the microarray intensity values of 47,000 
transcripts in treated cells (dfTAT or D-dfTAT, Y-axis) vs. untreated cells (x-axis). 
Analyses were performed in duplicate from two independent cell cultures. Both sets of 
microarray analyses yielded similar results. A representative set of results is shown (both 
sets are deposited in GEO accession bank). The red lines indicate the 2-fold intensity 
thresholds. The number of genes up and down-regulated beyond these thresholds are 
indicated with a red or green arrow respectively.  
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Table 3-1 Table showing the list of names of gene transcripts related to cell death 
and proliferation that are affected after treatment with D-dfTAT. The upward red 
arrow indicates an up regulation compared to control while the downward green arrow 
indicates a down regulation using a two-fold threshold. Data were analyzed through the 
use of QIAGEN’s Ingenuity ® Pathway Analysis (IPA®, QIAGEN Redwood City, 
www.qiage.com/ingenuity). 
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Table 3-1 Continued. 
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incubation and fully degraded at 24 h. The degradation observed at 1 h is presumably a 
combination of proteolysis within the lumen of endosomes and cytosolic proteolysis after 
entry into cells.   
 While inversion of chirality protects the delivery peptide from protease 
degradation, a change in stereochemistry should also impact the interaction of this 
compound with other chiral molecules281. My assays suggest that an inversion of chirality 
does not impact the overall mechanism of cell penetration. Like dfTAT, D-dfTAT enters 
cells by endocytosis followed by escape from late endosomes via interactions with BMP. 
At first glance, both peptides also appear to enter cells with relatively equal efficiencies. 
Overall, this suggests that chirality in not a critical aspect of the interaction between the 
CPP and molecules involved in its intracellular transport. Yet, upon closer examination, 
the results reveal that the individual steps of endocytosis and endosomal escape are 
impacted in opposite ways by chirality; endocytosis is reduced while endosomal escape is 
increased (Figure 3-28). Based on my results, the reduction in endocytosis could not be 
explained by a preference in D-dfTAT export during incubation. The export of D- dfTAT 
was significantly lower than dfTAT during the time course of the experiment, presumably 
due to stability and retention of D-dfTAT at the nucleoli. 
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Figure 3-28 Schematic representation modeling the similarities and differences 
observed in the cellular penetration of dfTAT and D-dfTAT. dfTAT is internalized by 
endocytosis at a higher level than D-dfTAT. Along the endocytic pathway, dfTAT is 
partially degraded by proteolytic enzymes while D-dfTAT is not. Upon reaching the late 
endosome both dfTAT and D-dfTAT induce the leakage of BMP-containing membranes. 
Due to proteolytic degradation, the endosomal escape efficiency of dfTAT is, however, 
diminished compared to D-dfTAT. Upon escaping from late endosomes, D-dfTAT and 
intact dfTAT are represented as being reduced to their monomer counterparts in the 
cytosol (e.g. by action of glutathione). The peptide then diffuses into the cytosolic space 
and accumulate at nucleoli. The degradation products of dfTAT contribute to a diffuse 
cytosolic fluorescent distribution. D-dfTAT remains intact inside cells for several days 
and impacts the physiology of cells negatively. In contrast, cytosolic enzymes degrade 
dfTAT in a matter of hours. This in turn leads to a dramatically diminished physiological 
impact.  
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D-dfTAT is significantly less prone to internalization by endocytosis than dfTAT. The 
parent compound TAT is known to interact with negatively-charged heparan sulfate 
proteoglycans on the cell surface 104, 294. The role played by these interactions with respect 
to endocytosis remains, however, unclear: proteoglycans might act as docking sites for the 
peptide and might or might not be directly involved in inducing endocytosis. In in vitro 
binding assays, Brock and co-workers have found no differences in the binding of L-CPPs 
or D-CPPs to heparan sulfate 281. Yet, they have also reported a decrease in endocytic 
uptake by D-CPPs (CPPs tested were r9, D-penetratin, and D-hLF) when compared to 
their L counterpart. Overall, these data suggest that interactions with chiral species other 
than heparan sulfate might play an important role in endocytosis. The identities of these 
chiral species, however, have yet to be established.  
Given that dfTAT and D-dfTAT differ in the extent to which they accumulate into 
endocytic organelles, comparing these peptides with respect to the subsequent step of 
endosomal escape is challenging. Nonetheless, to address this issue, I compared the 
propensity of the peptides to reach the cytosol of cells under conditions where the same 
amount of peptide is endocytosed (rather than conditions where incubation is performed 
at the same concentration). Based on this analysis, D-dfTAT induces endosomal leakage 
at a luminal concentration significantly lower than that required for dfTAT. Yet, dfTAT 
reaches the cytosol of cells in a degraded form. In addition, protease-inhibitors increase 
the endosomal escape activity of dfTAT, Finally, dfTAT and D-dfTAT have similar 
membrane leakage-inducing activities in vitro. Overall, my interpretation is therefore that 
dfTAT is not necessarily less capable of inducing endosomal leakage per se, but that 
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instead it is degraded by proteases while trafficking within the endocytic pathway. As a 
result, the amount of membrane-active dfTAT present inside endosomes represents only 
a portion of what is measured in the fluorescence measurements (intact dfTAT might 
represent approximately ~25% of total signal based on Figure 1c). Overall, D-dfTAT 
therefore appears to gain activity simply because, unaffected by proteolysis, it can 
accumulate inside late endosomes at concentrations higher than dfTAT. 
 I have previously shown that dfTAT is not toxic to cells157 .This is confirmed in 
this report as dfTAT does not significantly impact the proliferation of two cell lines. Cells 
treated with dfTAT are also virtually indistinguishable on a transcriptional level from 
untreated cells at 24 h. Overall, this indicates that dfTAT-mediated endosomal leakage is 
well tolerated by cells. This is in sharp contrast to D-dfTAT, which has a deleterious 
impact on both proliferation and transcription. Based on the notion that both dfTAT and 
D-dfTAT share a similar mechanism of cell penetration, I interpret the impact of D-dfTAT 
on cellular proliferation not to be associated with the delivery process per se but that it is 
instead a result of interactions with cytosolic and nucleolar partners that take place post-
delivery. In particular, one can speculate that the positively charged peptide interacts with 
negatively charged nucleic acid in the nucleoli and disrupts ribosome-associated 
processes. While dfTAT could potentially have similar interactions and lead to similar 
deleterious effects, this peptide is degraded rapidly and its effects are minimized. In 
contrast, the protease-resistant D-dfTAT remains intact in the cytosol and nucleoli of cells 
for a prolonged time and cellular responses become detectable.  
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Overall, my data reveal several insights relevant to the design of future cell-
permeable peptide-based agents (e.g. stapled peptides, retro-inverso peptides, peptoids, 
CPPs, etc.). One is that conferring protease resistance to a CPP helps promote its activity 
inside endosomes. This is important as such approach might help generate agents that are 
cell-permeable at sub-micromolar concentrations and, thereby, more relevant to in vivo 
applications. Additionally, I infer that proteolytic degradation inside the endocytic 
pathway acts as a major determinant of peptide activity. For instance, one can envision 
how certain CPPs might appear relatively ineffective at escaping endosomes not because 
of low membrane-permeation activity per se, but rather because of a high propensity to be 
degraded and inactivated in this environment. Furthermore, for the first time, I establish 
that protease-resistance has a significant impact on the cytosolic activity of CPPs. In 
particular, our results highlight that a protease-resistant CPP can reside in the cytoplasm 
and nucleus of cells for an extended period of time and consequently induce numerous 
cellular responses. This is problematic for in vitro applications that aim at delivering 
bioactive cargos to probe or manipulate biological processes (ideally, cells should not be 
perturbed by the delivery agent itself if one is to investigate the intracellular effects of a 
cargo). In addition, one can speculate that this could be equally problematic for in vivo 
applications given that extended cellular retention of a delivery agent often leads to off-
target effects 267. When considering these issues, it is apparent that the strategy of all-L to 
all-D residue conversion is not an ideal strategy to improve CPP properties. However, my 
results now point toward the idea of conferring protease-resistance to endosomolytic 
agents in an environment dependent manner. In particular, I envision that delivery agents 
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that are protease resistant inside endosomes but degradable in the cytosol should provide 
clear improvements. Therefore, establishing the feasibility of such strategy will be the 
focus of future studies. 
 
3.4 Materials and Methods 
 
3.4.1 Peptide design, synthesis, and purification  
All peptides were synthesized on the rink amide MBHA resin (Novabiochem, San 
Diego, CA) by solid phase peptide synthesis (SPPS). Fmoc-Lys(Mtt)-OH, Fmoc-
Lys(Boc)-OH, Fmoc-D-Lys(Boc)-OH, Fmoc-D-Lys(Dde)-OH, Fmoc-Gly-OH, Fmoc-
Arg(Pbf)-OH, Fmoc-D-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-D-Gln(Trt)-OH, Fmoc-
Cys(Trt)-OH (Novabiochem) were used to assemble the peptides using standard Fmoc 
protocols. Boc-D-Cys(Trt)-OH (Novabiochem) was added to the N-terminus of D-fTAT 
(single chain monomeric peptide) and the Boc protecting group was removed upon TFA 
cleavage. All reactions were performed at room temperature in a SPPS vessel. Reactions 
were agitated using a stream of dry N2. For each amino acid coupling the reaction was 
agitated for 4 h with a mixture of Fmoc-amino acid (1.6 mmol), HBTU (Novabiochem) 
(1.5 mmol) and di-isopropylethylamine (DIEA) (sigma) (4.0 mmol) in 
dimethylformamide (DMF) (Fisher). After addition of each amino acid, Fmoc 
deprotection was performed by addition of 20% piperidine in DMF. The reaction was 
carried out twice: 1x 5 min followed by 1x 15 min with a DMF washing step between 
reactions. Upon completion of the linear chain assembly, the peptidyl-resin was washed 
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with DMF and dichloromethane (DCM) (Fisher). DEAC-k5 was synthesized by coupling 
five Fmoc-D-Lys(Boc)-OH. The DEAC (Anaspec) fluorophore was conjugated to the N-
terminus of the peptide by reaction of DEAC, HBTU and DIEA (4, 3.9 and 10 eq.) in 
DMF overnight. CK(-NH-TMR)TATG (L-fTAT) was synthesized as described 
earlier157. Briefly, MTT protecting group was removed using 1% trifluoroacetic acid 
(TFA) (Fisher) and 2% triisopropylsilane (TIS) (Sigma) in DCM. The peptidyl-resin was 
washed with both DMF and DCM between each reaction. For ck(-NH-Dde)rkkrrqrrrG 
(D-TAT), the Dde protecting group was removed using 2% Hydrazine (sigma) in DMF. 
The peptidyl resin for both peptides was then reacted with a mixture of TMR, HBTU and 
DIEA (4, 3.9 and 10 eq.) and agitated overnight. For L-fTAT, the resin was washed and 
Fmoc-deprotection was performed to remove the N-terminal Fmoc moiety. For D-fTAT 
and L-fTAT, the peptide (and remaining protecting groups) were then cleaved from the 
resin by treatment with 92.5% TFA, 2.5% H2O, 2.5% TIS and 2.5% ethanedithiol (EDT) 
(Sigma) for 3h at room temperature. The crude peptide was precipitated in cold anhydrous 
ether (Fisher). The precipitate was resuspended in water and lyophilized. The lyophilized 
product was dissolved in 0.1%TFA/water. The peptides were analyzed and purified by 
reverse-phase HPLC. HPLC analysis was performed on a Hewlett-Packard 1200 series 
instrument and an analytical Vydac C18 column (5 μm, 4 x 150 mm). The flow rate was 
1 mL/min, and detection was at 214 nm and 550 nm. Semi-preparative HPLC was 
performed on a Vydac C18 10 x 250 mm column. The flow rate was 4 mL/min, and 
detection was at 214 nm and 550 nm. All runs used linear gradients of 0.1% aqueous TFA 
(solvent A) and 90% acetonitrile, 9.9% water, and 0.1% TFA (solvent B). The correct 
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identity of the peptides was confirmed by MALDI-TOF performed with a 
Shimadzu/Kratos instrument (AXIMA- CFR, Shimadzu, Kyoto). fTAT, expected mass: 
2041.17, observed mass: 2040.66. DEAC-k5, expected mass: 900.59, observed mass: 
900.84   
 
3.4.2 Generation of D-dfTAT by dimerization of D-dfTAT 
fTAT or D-fTAT (0.3 mg, 1.5 x 10-4 mmol) were dissolved in 5 mL of aerated 
phosphate buffer saline (PBS) at pH 7.4. The reaction was agitated on a nutator overnight 
(100% yield based on HPLC analysis). dfTAT and D-dfTAT were purified using 
analytical reverse-phase HPLC. Expected mass (MALDI-TOF): 4078.27, observed mass 
dfTAT and D-dfTAT were 4080.87 and 4078.87 respectively. 
 
3.4.3 Cell culture and transfection 
HeLa (ATCC CCL-2), MCH58 and HDF(ATCC PCS-201-010) cells were grown 
in Dulbecco’s Minimum Essential Media (DMEM, Fisher) supplemented with 10% fetal 
bovine serum (FBS) (Fisher) and 1X penicillin/streptomycin (P/S) (Fisher) and incubated 
at 37 C in a humidified atmosphere containing 5% CO2. 
For transfection experiments, rab7 (GFP-rab7 WT, Addgene plasmid # 12605) and 
DN-rab7 (GFP-rab7 DN, Addgene plasmid # 12660) were a gift from Richard Pagano. 
For transfection of the TAT-Cre experiment, loxp-stop-loxp-EGFP (pPCALNL-GFP, 
Addgene plasmid # 13770) and gWiz GFP (ALDEVRON LOT# 35237) were purchased. 
186 
 
Each plasmid (250 ng) was mixed with Lipofectamine 2000 (1 µL) in opti-MEM medium 
and allowed to incubate for 10 min at room temperature. The DNA/lipofectamine complex 
was then incubated for 18h at 37°C with HeLa cells seeded in an eight-well dish. 
 
3.4.4 dfTAT and D-dfTAT degradation  
An in vitro proteolysis assay was performed by addition of 1 µL of 0.5% trypsin 
to 19 µL of either dfTAT or D-dfTAT (10 µM) and incubated at room temperature. 
Reactions were quenched at specific time points by addition of 80 µL of 0.1% TFA in 
water. The samples were analyzed on a reverse phase HPLC using a 15-40% gradient 
(0.1% TFA/90% Acetonitrile). 
For the in cellulo assay, HeLa cells were seeded in a 24 well dish and allowed to 
grow to 90% confluency. The wells were washed three times with PBS and once with 
Leibovitz’s L-15 medium that does not contain the amino acid cysteine (non reducing L-
15, nrL-15). nrL-15 is used for incubation since it lacks cysteine and avoids the reduction 
of the disulfide bond of dfTAT. Cells were then incubated with dfTAT or D-dfTAT (5µM) 
for 1 h. The cells were washed three times with PBS, lysed at different time point as 
indicated in the text using a lysis buffer (50 mM Tris, pH7.5, 2 mM EDTA, 2mM DTT, 
0.1% Triton X-100 and protein inhibitor cocktail; 75 µL per well). The samples were then 
treated with DNAse (3 μL, Genesse) for 15 min on ice. The samples were centrifuged at 
4C, 13,000 RPM for 20 min. The supernatant (cell lysate) (39 µL) was added 6 µL of 
loading dye. The samples were boiled for 10 min at 100C. The samples were run on a 
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16.5%Tris-Tricine gel (Bio Rad, Cat# 3450063) using a running buffer composed of 100 
mM Tris, 100 mM Tricine, 0.1% SDS pH 8.3.  
 
3.4.5 Delivery of peptides and proteins into live cells 
HeLa, HDF and MCH58 cells were seeded in an 8-well dish. The cells were grown 
to 80-90% confluency in a 37C humidified atmosphere containing 5% CO2. The wells 
were washed three times with PBS and once with nrL-15. Cells were incubated with 
dfTAT or D-dfTAT (5 µM) at 37C for 1 h (unless otherwise specified). The cells were 
then washed three times with L-15 supplemented with heparin (1 mg/mL) once with nrL-
15. Cells were treated with the cell impermeable nuclear stain SYTOX® BLUE or 
SYTOX ® GREEN to identify cells with a compromised plasma membrane (i.e. dead 
cells). Alternatively, cells were incubated with cell permeable Hoechst for nuclear 
staining. Cells were imaged using an inverted epifluorescence microscope (Model IX81, 
Olympus, Center Valley, PA) equipped with a heating stage maintained at 37 °C. Images 
were collected using a Rolera-MGI Plus back-illuminated EMCCD camera (Qimaging, 
Surrey, BC, Canada). Images were acquired using bright field imaging and three standard 
fluorescence filter sets: CFP (Ex = 436 ± 10 nm / Em= 480 ± 20 nm), RFP (Ex = 560 ± 20 
nm / Em= 630 ± 35 nm). For viewing and processing individual fluorescent images, the 
SlideBook 4.2 software (Olympus, Center Valley, PA) was used. Cells that displayed a 
cytosolic and nucleolar peptide staining were considered positive for cytosolic penetration 
(penetration(+)).The percentage of penetration (+) cells was calculated by dividing the 
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number of cells that displaying a fluorescent nuclear staining (20X images) by the total 
number of cells present (acquired using bright field imaging). Cells negative for cytosolic 
penetration typically display a punctate distribution consistent with endosomal entrapment 
of the peptides. Cells with plasma membrane compromised stained by SYTOX dyes were 
considered dead and excluded from the analysis. For each experiment, an average of three 
20X pictures were taken, representing 300-400 cells. The reproducibility of all the 
experiments was assessed by performing experiments with independent batches of cell 
cultures on three different days (i.e. biological triplicates). 
 To monitor the intracellular localization of dfTAT and D-dfTAT after cell 
delivery (1 h incubation), cells were washed and incubated in fresh growth media 
(DMEM/10% FBS). The dish was placed at 37 C in a humidified atmosphere containing 
5% CO2. Cells were imaged after 24 and 48h.  
For delivery of TAT-Cre, HeLa cells were co-transfected with pCALNL-GFP 
andgWiz-GFP (control plasmid for transfection efficiency) for 18h. Cells were then 
washed and co-incubated with dfTAT or D-dfTAT and TAT-Cre (4 µM) for 1 h. The cells 
were washed again and the media was re-placed with fresh DMEM. The cells were placed 
back in the incubator for 24h. The cells were then imaged as described above. To quantify 
the results, EGFP+ cells were counted and divided by the total number of cells that were 
transfected (control cells that were transfected with gWiz GFP (250 ng)) in each 20X 
image. 
To investigate the process of cellular entry, HeLa cells were incubated in L-15 
with DEAC-k5 (20 µM) for 1 h. Cells were then washed three times with PBS and 
189 
 
incubated either immediately or after 2h in nrL-15 with D-dfTAT (5 µM) or without 
peptide (control cells) for 1h. The cells were then washed three times with L-15 
supplemented with heparin (1 mg/mL). Alternatively, the incubation steps were inverted. 
HeLa cells were first incubated with D-dfTAT for 1h and then washed as described above. 
Cells were then incubated in nrL-15 for 20 min. The cells were then incubated with 
DEAC-k5 (20 µM in L-15) for 1 h. Cells were washed and imaged as described earlier.  
To establish the involvement of BMP in cellulo, HeLa cells were incubated with 
50µg/ml anti-BMP mAb (mouse, Z-PLBPA) or anti-IgG mAb (mouse, ab99763) in L-15 
for 30 min at 37C. Cells were washed and incubated with D-dfTAT (3 μM). Cells were 
then imaged as previously described.  
To assess whether endosomal proteolytic degradation could play a role in the 
difference in cell penetration activity observed between dfTAT and D-dfTAT, protease 
inhibitor were used. In particular, HDF cells were pre-incubated with the 40 µM E-64D 
(sigma) and 28 µM leupeptin (sigma) in nrL-15 for 40 min. The treatment was removed 
and the cells were incubated with D-dfTAT or dfTAT (2 µM) in the presence of 40 µM 
E-64D. The cells were then washed and imaged as described above. For determination of 
the amount of intact peptide remaining prior to cytosolic access, HeLa cells were pre-
incubated with the 40 µM E-64D (sigma) and 28 µM leupeptin (sigma) in nrL-15 for 40 
min. The treatment was removed and the cells were incubated with dfTAT (5 µM) in the 
presence of 40 µM E-64D for 10 min. The control cells were treated with dfTAT (5 µM) 
for 10 min in absence of inhibitors. The cells were then washed, lysed and processed as 
described above for preparation to run on a 16.5% Tricine gel (Bio Rad, Cat# 3450063).  
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3.4.6 Quantitative determination of peptide uptake 
HeLa cells were seeded in a 48-well dish and grown to 80% confluency. Cells were 
treated with dfTAT and D-dfTAT for 1h at various concentrations (range: 1-10 µM). Total 
peptide uptake was measured in two ways: Fluorescence measurements of a cell lysate 
assay or flow cytometry. For whole cell lysate analysis, cells were washed with heparin 
(1mg/mL) and then trypsinized (50 µL) for 3 min. Cells were resuspended in nrL-15 (350 
µL) and centrifuged at 4°C, 2,500 rpm for 10 min. The supernatant was removed and the 
cell pellet was resuspended in nrL-15 (50 µL). An aliquot of the resuspended cells (3 µL) 
was removed and used through flow cytometry to normalize for total number of cells per 
sample. The remaining resuspended cells were lysed by addition of 50 µL of a lysis buffer 
(components: 50mM Tris, pH7.5, 2 mM EDTA, 4mM DTT, 20% Triton X-100 and 
protein inhibitor cocktail) and vortexing. For the whole cells lysates in the absence of 
DTT, the lysis buffer prepared and used lacked DTT (components: 50mM Tris, pH7.5, 2 
mM EDTA, 20% Triton X-100 and protein inhibitor cocktail). The samples were vortexed 
and a volume of 80 µL of supernatant for each condition was placed in a 96 well plate. 
The fluorescence emission intensity was measured using a plate reader equipped with a 
fluorescence module (Ex=525, Em=580-640 nm) (GloMax®-Multi+ Detection System, 
Promega, Fitchburg, WI). To normalize the aliquot of cells (3 µL) was resuspended in 
nrL-15 (97 µL) and the total amount of cells per samples was determined using flow 
cytometry. 
For fluorescence measurement using the flow cytometer, cells were trypsinized 
and resuspended in nrL-15 medium. Cells were analyzed using a BD Accuri C6 flow 
191 
 
cytometer equipped with the FL2 filter (Ex = 488 nm/Em = 533 ± 30 nm). All data was 
acquired at flow rate of 66 µL/min with detection of a minimum of 40,000 events. The 
geometric mean of the FL2 signal for each experiment was determined using the Flowjo 
software. The data reported represent the average and corresponding standard deviations 
of three independent experiments for each peptide concentration.  
For export measurements, HeLa cells were seeded in a 48-well dish and grown to 
80% confluency. Cells were treated with dfTAT and D-dfTAT at 5 µM for 1 h. Cells were 
washed according to protocol and the medium was replaced with fresh new media (200 
µL, DMEM+FBS+P/S). The extracellular media from separate wells was removed at 
specific time points. The media was centrifuged at 8,000 rpm for 8 min. The media 
samples from each time point were aliquoted into a 96 well plate. The fluorescence 
intensity was measured as mentioned above using a plate reader. The data was normalized 
by comparison to the fluorescence of the extracellular media of the untreated cells.  
To determine whether the peptide remained bound to the cell surface after the 
initial wash, HeLa cells were seeded in a 48-well dish and grown to 80% confluency. Cells 
were treated with dfTAT and D-dfTAT at 5 µM for 1 h. The cells were then washed in 
three different ways. For all conditions, cells were first washed three times with L-15 
supplemented with heparin (1 mg/mL) and once with nrL-15. Sample 1: control cells were 
then trypsinized and resuspended in nrL-15 for flow cytometry. For sample 2: The cells 
were then washed again three times with nrL-15 supplemented with heparin (1 mg/mL) 
and once with nrL-15. For sample 3: The cells were then trypsinized and resuspended in 
nrL-15 and centrifuged at 4°C, 2,500 rpm for 10 min. The supernatant was removed and 
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the cell pellet was trypsinized (50 µL) for 3min. The trypsinized cells were then 
resuspended in nrL-15 for flow cytometry analysis.  
 
3.4.7 Liposome Preparation and leakage assays 
Lipids used in the experiments consisted of: 1,2-dioleoyl-s-glycero-3-
phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), sn-
(3-oleoyl-2-hydroxy)-glycerol-1-phospho-sn-1’-(3’-oleoyl-2’-hydroxy-glycerol) (BMP), 
cholesterol (chol) (Avanti Polar Lipids). Liposomes were prepared by first transferring 
various volumes of lipids dissolved in chloroform (stock solutions of know 
concentrations) into scintillation vials. For liposomes mimicking the intraluminal late 
endosomes vesicles (L.E.) the molar ratios of lipids consisted of 77:19:4 BMP:PC:PE. For 
liposomes mimicking the plasma membrane, the lipid mixture was 65:15:20 PC:PE:Chol. 
The lipid film was prepared by removing the chloroform from the lipid mixture using a 
stream of N2 and then placing the vial in a desiccator for 24h. A buffer containing 100 
mM NaCl, 10 mM NaH2PO4 pH7.4, and 60 mM calcein was added to the lipids film for 
hydration. The lipids were then mixed vigorously and swelled for 1 h at 42C under N2 to 
obtain multilamellar vesicles (MLVs). For production of unilamellar vesicles (LUVs), the 
MLVS were extruded (20 passes) through a 100 nm pore size polycarbonate membrane 
(Whatman) using a Mini-Extruder (Avanti Polar Lipids). Dynamic light scattering was 
used to determine the average diameter size distribution of the liposomes using a Zeta 
Sizer (Malvern instrument). The liposomes were purified by gel filtration using a 
Sephadex G-50 (GE Healthcare) column (2.5 x 17.5 cm) to separate the liposomes from 
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free calcein. The eluate was collected in a 96 well plate and the plate was read using a 
Promega GloMax-Multi plate reader (Promega) at 450 nm and 750 nm corresponding to 
the wavelength of detection for calcein and liposome respectively. 
Purified calcein-loaded LUVs were mixed with D-dfTAT or dfTAT at different 
ratios for 1 h at room temperature in 100 mM NaCl, 10 mM NaH2PO4 pH5.5. Samples 
were centrifuged for 1 min at 4,000 rpm. To measure the amount of leaked calcein and 
separate soluble liposomes from released calcein, the supernatants were purified using an 
illustra NAP-10 Sephadex G-25 column (GE Healthcare) (the elution volumes of 
liposomes and free calcein were determined independently with pure samples). Fractions 
were collected in a 96-well plate and the fluorescence of calcein was measured using a 
Promega GloMax-Multi plate reader (Ex 490nm, Em 520-560nm). The percent leakage 
was calculated using the following equation: 
% Leakage = 100 × 
Flt − Fl0
Flmax − Fl0
 
 
where Flt is the free calcein fluorescence intensity of a sample at a specific peptide:lipid 
ratio measured after 1 h, Fl0 is the free calcein fluorescence intensity of a untreated 
sample and Flmax is the free calcein fluorescence intensity of a sample after treatment 
with 0.2 % Triton X-100. 
 
3.4.8 Cell proliferation assays  
A MTT assay was performed to compare the effect of dfTAT to D-dfTAT on the 
proliferation rate of MCH58 and HDF. Cells were seeded and grown in a 6-well dish and 
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treated as described earlier. Each well was incubated with either 5 µM dfTAT or D-dfTAT 
at 37 C for 1 h. Cells were washed, trypsinized and seeded into 96-well dishes containing 
100 µL of DMEM/10%FBS. The cells were then allowed to adhere to the bottom of the 
dish for 12 h. The DMEM was removed, replaced with 100 µL of fresh DMEM/10%FBS 
and 10 µL of a 12 mM MTT stock solution was added to the wells. The 96-well dish was 
incubated at 37 C for 4 h, followed by addition of 100 µL of SDS-HCl (10 mM). The 
cells were then allowed to incubate with this solution for 12 h. After the incubation each 
sample was mixed and the absorbance at 560 nm was measured. Controls included a 
negative control where 10 µL MTT was added to 100 µL of DMEM alone (no cells). A 
second control consisted of cells treated with the delivery peptide but to which no MTT 
was added to subtract the contribution of TMR from the measured absorbance. The 
absorbance of the negative control was subtracted from all samples. Assays were 
performed at multiple time points to obtain a cellular proliferation curve.  
 
3.4.9  Whole genome microarray analysis 
MCH58 and HDF cells were seeded in 24-well dishes and incubated with dfTAT 
or D-dfTAT (5µM) or nrL-15 (untreated cells), for 1h. Cells were then washed and the 
media was replaced by DMEM. The cells were then placed back into the 37°C humidified 
atmosphere containing 5% CO2 incubator for 24 h. After 24hr, the cells were then 
trypsinized after washing with PBS or nrL-15 (1h + 24h time point). Cells were pipetted 
into an eppendorf tube and spun down at 12k RPM for 4 min at 4°C. The cell pellets were 
preserved in 1 mL TRIzol (Ambion®, Life Technology) and shipped frozen to the 
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UTsouthwestern microarray facility for total RNA extraction and analysis using Illumina 
Human HT-12 v4 sequencer. The protocol is described in this link 
(https://microarray.swmed.edu/protocols/protocol/illumina-gene-expression-probe-
labeling/). Data sets are deposited in GEO accession bank, GSE90575. 
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4. THE ENDOSOMAL ESCAPE PROPERTY OF POSITIVELY CHARGED 
CELL-PENETRATING PEPTIDES IS DEPENDENT ON THE NUMBER OF 
ARGININE RESIDUES PRESENT IN THE SEQUENCE  
 
4.1 Introduction 
 The chemical properties that confer dfTAT its endosomolytic activity and that 
distinguish it from its far less active monomeric counterpart are currently not understood. 
Understanding the features that provide high cell-penetration activity to dfTAT may 
therefore guide the development of analogs possessing better performance and 
consequently that are more therapeutically relevant. In addition, cell-penetration rules 
learned with this lead compound may also be applicable to other delivery systems that 
utilize the endocytic pathway as a route of cellular entry, including liposomes and 
nanoparticles. In this chapter, I aim to establish the role associated with the peptide 
sequence of dfTAT on cellular delivery. Previous reports have attributed the 
internalization activity of TAT predominantly to its arginine-residues32-34. However, given 
the low efficiency of this CPP, most studies have measured endocytic uptake without 
quantifying the process of endosomal escape directly. In contrast, the unusually high 
endosomolytic activity of dfTAT allowed me to characterize the residues important for 
this activity. I hypothesize that the endosomolytic activity of dfTAT is dependent on the 
arginine content and specifically the number of arginine residues present.  
In this work, I show that the polyarginine peptides can recapitulate the observed 
endosomolytic activity of dfTAT; while a polylysine construct cannot. Interestingly, a 
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minimum number of 12 arginines is required to achieve cytosolic penetration, however 
peptides containing less arginines remained entrapped in endocytic vesicles. Furthermore, 
I show that the difference in cellular penetration is not due to a decrease in amount of 
peptide internalized. Using in vitro assays, I demonstrate that while all polyarginine 
peptides are able to bind to late endosomal liposomes to the same extent, the membrane 
leakage observed increases as a function of arginine content. Together, my results provide 
insights into the molecular parameters required for efficient cellular penetration of 
arginine-rich CPPs, information that is important to consider when generating new 
delivery agents.  
 
4.2 Results  
 
4.2.1 Generation of dfRn and dfKn reagents 
Polyarginine or polylysine analogs of dfTAT were synthesized. In particular, given 
that dfTAT contains 16 basic residues, dfR8 (16 arginine residues) and dfK8 (16 lysine 
residues) were produced to evaluate the importance of charge (Figure 4-1). Additionally, 
a series of dfRn peptides, where n= 4,5,6 or 7, were synthesized to determine the minimum 
number of arginine residues required to recapitulate the endosomolytic activity of dfTAT.  
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4.2.2 The positive charge in dfTAT is necessary but not sufficient for its cell 
penetration activity 
 dfTAT induces leakage from late endosomes by interacting with the lipid BMP283. 
dfTAT is cationic while BMP is anionic, suggesting that electrostatic interactions may be 
important for activity. To establish whether charge alone is a determining factor for 
endosomal escape, polyarginine or polylysine analogs of dfTAT were synthesized. In 
particular, given that dfTAT contains 16 basic residues, dfR8 (16 arginine residues) and 
dfK8 (16 lysine residues) were first produced (Figure 4-1). Cells were incubated with 
each peptide for 1h and the cellular penetration of each compound was assessed by live 
cell fluorescence microscopy. The measurements are based on the fact that, when 
endosomal escape fails, a distinct punctate fluorescence can be observed103, 295, 296. 
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Figure 4-1 HPLC and ESI MS spectrum of dfK8 and dfRn series. The expected and 
observed masses for the corresponding peptides can be found in the material and methods 
section. 
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Figure 4-1 continued.  
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This is a result of endosomal entrapment of the fluorescent peptides. In contrast, upon 
endosomal escape, a diffuse cytosolic fluorescence can be detected157, 194. Moreover, 
because polycationic peptides tend to accumulate at nucleoli upon cytosolic entry, 
nucleolar staining can also be observed16, 284. While the cytosolic signal is admittedly 
unreliable because of possible out-of-focus contributions, the nucleolar signal is useful 
because it validates that the compounds have indeed penetrated cells. Therefore, I use a 
binary assay in which cells are counted as either positive or negative for nucleolar staining. 
When compared to dfTAT, dfK8 showed no cell penetration activity (Figure 4-2). More 
precisely, dfK8 appears trapped in the endocytic pathway at all concentrations tested 
(Figure 4-2). In contrast, dfR8 appears to be more active than dfTAT. dfR8 displays an 
increased number of penetration positive cells at 3 and 5 µM when compared to both 
dfTAT and dfK8. Notably, the level of endocytic uptake of dfK8 was also lower than both 
dfTAT and dfR8 at all concentrations tested (Figure 4-3). To insure that peptide 
penetration was not associated with cellular toxicity, I conducted a Sytox ® Blue exclusion 
assay. To my surprise, cell treatment with dfR8 at 5 and 10 µM resulted in 13% and 47% 
decrease in cell viability respectively (Figure 4-4). The cytotoxic effect of dfR8 treatment 
could be attributed to the increased number of arginine and not the charge since both dfK8 
and dfTAT showed no cellular toxicity at all concentrations tested.  
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Figure 4-2 Comparison of cellular distribution of the peptides after 1 h incubation. 
a) HeLa cells were incubated with dfTAT, dfR8 and dfK8 at 5 µM for 1 h, washed and 
then stained with the cell permeable Hoechst nuclear stain (1µg/mL). Live cells were 
imaged with a 20X and 100X objective. Fluorescence images are overlays of the TMR 
emission at 560 nm (pseudocolored red) and Hoechst emission at 460 nm (pseudocolored 
blue). Scale bars, 10 and 100 µm for 100X and 20X respectively. b) Evaluation of the 
cytosolic penetration efficiency of dfTAT, dfR8 and dfK8 as a function of peptide 
concentration present in the incubation media. HeLa cells were incubated with peptides 
(1-5 M) for 1 h. The percentage of cells detected as positive for penetration was 
established by microscopy. 
b
b
b 
a 
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Figure 4-3 Quantification of total cellular uptake by dfTAT, dfR8 and dfK8 as a 
function of the peptide concentration in incubation media. HeLa cells were incubated 
with peptides (1 and 5 μM) as in figure 4-2). The overall amount of peptide internalized 
by cells (endosomal + cytosolic) was assessed by measuring the bulk fluorescence of cell 
lysates.  
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Figure 4-4 dfR8 is cytotoxic at high peptide concentrations. HeLa cells were incubated 
with dfR8 or dfK8 for 1h at specified peptide concentrations. Cell viability was assessed 
by a SYTOX Blue exclusion assay immediately after the incubation.  
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4.2.3 A peptide with the same number of arginine’s found in dfTAT mimics its 
endosomolytic activity 
Although dfR8 recapitulated the endosomolytic activity displayed by dfTAT, it did 
however exhibit increased cytotoxicity. I decided to test how the number of arginine 
residues present impacts cell penetration. To test this, a series of dfRn peptides, where n= 
4, 5, 6 or 7 were synthesized. The peptide dfR4, the smallest compounds of the series, 
displays no detectable cell penetration, regardless of the concentration tested (from 1 to 5 
µM). Instead, the peptide appears to exclusively accumulate inside endosomes, as 
indicated by co-localization with Lysotracker Green (Figure 4-5 and Figure 4-6). The 
activity of dfR5 was similarly poor. In contrast, dfR6, dfR7, and dfR8 displayed a robust 
cytosolic penetration, comparable to that of dfTAT at all concentrations tested (Figure 4-
5 and Figure 4-7). While the cytosolic penetration assay establishes whether a peptide 
can reach the cytosolic and nucleolar space (above the detection threshold of the imaging 
set-up), it does not address how much peptide enters cells. To test how the dfRn peptides 
compare to dfTAT in that regard, the total fluorescence of cells incubated with 5 µM of 
each reagent was measured. In particular, to avoid artifacts that could arise from the 
peptides having different fluorescence intensities depending on whether they localize in 
endosomes or in the cytoplasm, cell lysates were analyzed (the fluorescence intensities 
measured are normalized to the number of cells present in the incubation dish)157. As 
shown in Figure 4-8, the overall cellular uptake increases with the number of arginine 
residues, with dfR8 showing almost 3 fold more peptide inside cells than dfR4. Overall,  
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Figure 4-5 Comparison of cellular distribution of the polyarginine peptides after 1 h 
incubation. HeLa cells were incubated with dfTAT, dfRn constructs (n= 4, 5, 6, 7 or 8) 
at 5 µM for 1 h, washed and then stained with the cell permeable Hoechst nuclear stain 
(1µg/mL). Live cells were imaged with a 100X objective. Fluorescence images are 
overlays of the TMR emission at 560 nm (pseudocolored red), Hoechst emission at 460 
nm (pseudocolored cyan). Scale bars, 10 µm. 
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Mander's 
overlap 
coefficients (M) 
M1 M2 
dfR4 0.7099 0.5789 
dfR5 0.7991 0.5906 
dfK8 0.7117 0.9115 
 
Figure 4-6 dfR4, dfR5 and dfK8 co-localize with LysoTracker green, a marker of 
acidified endocytic organelles. HeLa cells were incubated with the specified peptides at 
5 µM for 1 h. The cells were washed and then incubated with lysotracker green and 
imaged. Images are overlays of either peptide/ lysotracker (pseudocolor: red for peptide 
and green for lysotracker) or peptide/ bright field. Mander’s overlap coefficients were 
determined using Image J software. M1 is a ratio of the sum of the red pixels (peptide) 
where the green pixel (lysotracker) is above 0 (true signal) divided by the total red pixels.  
M2 is a ratio of the sum of the green pixel where the red pixel is above zero (true signal) 
divided by the total green pixels.   
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Figure 4-7 Quantitative determination of the cytosolic delivery efficiency of dfRn 
constructs in comparison to dfTAT as a function of peptide concentration present in 
the incubation media. HeLa cells were incubated with peptides (1, 3 and 5 M) for 1 h. 
The percentage of cells detected as positive for penetration was established by 
microscopy. 
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Figure 4-8 Comparison of the total cellular uptake of peptide as a function of the 
number of arginine. HeLa cells were incubated with peptides (5 μM). The overall amount 
of peptide internalized by cells (endosomal + cytosolic) was assessed by measuring the 
bulk fluorescence of cell lysates. All fluorescence measurements were normalized to the 
lowest averaged fluorescence measurements obtained (ie. dfRn where n=4).  
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these results suggest a threshold behavior where 12 arginine residues is a cutoff required 
for cytosolic access. Notably, dfTAT also contains 12 arginine residues.  
 
4.2.4 Differences in endocytic uptake are not solely responsible for differences in cell 
penetration 
The cytosolic penetration of dfR6, dfR7 and dfR8 is endocytosis dependent 
(Figure 4-9). Consistent with the mechanistic studies performed with dfTAT, this 
suggests that cytosolic penetration involves endocytic uptake followed by endosomal 
escape. Conceptually, the peptides dfR4 and dfR5, which stay trapped inside endosomes, 
could therefore fail to reach the cytosolic space because their uptake is poor and does not 
permit sufficient accumulation of peptide inside endosomes for escape. To test this idea, 
I looked for peptide incubation concentrations that would lead to similar uptake for dfR4, 
dfR5, and dfR6. I found that cell incubation with 20 µM dfR4 and 10 µM dfR5 yielded a 
peptide uptake comparable to that of 5 µM dfR6, as measured by the total fluorescence of 
cell lysates (Figure 4-10). Yet, under these conditions, dfR4 remained unable to reach the 
cytosol and deliver cargo into cells (Figure 4-10). dfR5, although slightly more active, 
was also unable to reproduce the activity of dfR6. Together, these results suggested that 
differences in how much peptide is endocytosed by cells cannot account for the differences 
in cytosolic penetration observed between dfR4/5 and dfR6/7/8.  
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Figure 4-9 dfR6, dfR7 and dfR8 penetrate the cytosol by escaping from the endocytic 
pathway. a) Pulse-chase assay showing the progressive cytosolic penetration of the 
peptides. HeLa cells were incubated with either dfR6 (5 µM), dfR7 (3 µM) or dfR8 (3 
µM) for 5 min. The cells were washed and imaged with a 20X objective. The number of 
cells that were positive for penetration were counted at the specified time interval after 
delivery. b) dfR6 and dfR8 can release a peptide that is preloaded into endosomes. In 
experiment 1 (exp 1), cells were incubated with DEAC-k5 (20 µM) and then imaged. In 
exp 2, cells were incubated with DEAC-k5 for 1 h, washed and then incubated for 1 h with 
either dfR6 or dfR8 (5 µM). Cells were then imaged using a 100X objective. Fluorescence 
images represented are pseudocolored cyan for DEAC-k5 and red for TMR. Scale bars, 
10 µm.  
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Figure 4-9 Continued. 
a 
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 Figure 4-9 Continued. 
 
 
b 
214 
 
Figure 4-10 The endocytic uptake does account for the difference observed in the 
endosomolytic activity of polyarginine peptide. a) Evaluation of the total cellular uptake 
of dfR4, dfR5 and dfR6. HeLa cells were incubated with either 20 μM dfR4, 10 μM dfR5 
or 5 μM dfR6. The overall amount of peptide internalized by cells was assessed by 
measuring the bulk fluorescence of cell lysates. All fluorescence measurements were 
normalized to the lowest averaged fluorescence measurements obtained (ie. dfRn where 
n=4). b) Determination of the cytosolic delivery efficiency of peptides. HeLa cells were 
incubated with peptides dfR4, dfR5 and dfR6 as described in part a. The percentage of 
cells detected as positive for penetration was established by microscopy. c) dfRn 
constructs with the number of arginine less than 12 (n<6) cannot deliver cargo to the 
cytosolic space of cells. HeLa cells were incubated with either 20 μM of dfR4 or 5 μM 
dfR6 in the presence of 10 μM of DEAC-k5. Cells were washed and imaged with a 20X 
objective. Fluorescence images of the TMR emission at 560 nm (pseudocolored red) and 
CFP emission at 436 nm (pseudocolored cyan). Scale bars, 100 µm.  
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Figure 4-10 Continued. 
 
b
b
b 
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4.2.5 A non-linear response for cell penetration of polyarginine peptides can be 
explained by the ability of the peptides to induce leakage of late endosomal 
compartments 
In order to compare the membrane disruption activity of the dfRn compounds, 
liposomes with a lipid composition mimicking the lipid bilayers of the plasma membrane 
and late endosomes were prepared. The liposomes were prepared with PC:PE:chol 
(65:15:20) to model the plasma membrane and early endosomes (PM/E.E. LUVs) and 
with BMP:PC:PE (77:19:4) to model late endosomes (L.E. LUVs)128, 288, 289. Calcein was 
encapsulated inside the liposomes and peptide-induced liposome disruption was 
quantified by measuring calcein leakage. When incubated with PM/E.E. LUVs, the 
peptides dfTAT and dfRn did not cause significant leakage. However, when incubated 
with L.E. LUVs, dfRn peptide induced leakage in a manner linearly proportional to 
arginine content (R2=0.99) (Figure 4-11). Notably, the activity of dfTAT was similar to 
that of dfR6 and dfR7, indicating again that the membrane disruption activity of dfTAT is 
mainly mediated by its arginine residues. 
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Figure 4-11 The in vitro leakageactivity of dfRn increases as a function of n. a) 
Comparison of liposomal leakage activity caused by dfRn constructs and dfTAT. L.E or 
PM mimicking liposomes (500 µM) loaded with calcein were incubated with peptides at 
10 M. The fluorescence signal of free calcein was quantified after peptide treatment. b) 
Determination of the affinity of dfRn and dfTAT to PM and LE LUVs. L.E or PM 
mimicking liposomes (500 µM) were incubated with peptides at 10 M. The samples were 
spun down at 13,000 RPM and the fluorescence signal in the supernatant corresponding 
to the unbound peptide was quantified.  
 
 
 
 
 
b a 
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4.3 Discussion 
My results indicate that the arginine residues of dfTAT account for its endocytic 
uptake and for its endosomal escape activity. In particular, the activities of dfTAT and 
dfR6 are very comparable. This would therefore suggest that the residues other than 
arginine, namely 4 lysine residues and 2 glutamine residues, are not contributing 
significantly to the cytosolic penetration of dfTAT. The data also indicate that a content 
of 12 arginine residues is an approximate threshold necessary for high endosomal escape 
efficiency. Below this threshold, the peptides tested are mostly inactive and trapped inside 
endosomes. In contrast, above this threshold, a clear increase in cytosolic egress is 
achieved. However, this was also associated with an increase in cellular toxicity at higher 
concentrations. Interestingly, both the endocytic uptake and the leakage activity of the 
dfRn peptides are proportional to the number of arginine residues present (n × 2). It is 
therefore likely that, in the case of shorter peptide such as dfR4 and dfR5, a relatively 
lower endocytic uptake and a weaker membrane disrupting activity lead to conditions 
under which there is simply not enough peptide inside endosomes to cause any detectable 
endosomal leakage. It should be noted however that the peptides tested can be partially 
degraded during their transit in endocytic organelles264. In principle, differences in their 
propensity for proteolysis could therefore also contribute to the non-linear cytosolic 
release response observed.      
If dfTAT can be simplified to dfR6, why not simply use R12, a peptide with similar 
arginine content but with a linear structure? Interestingly, fluorescently labeled R12 CPPs 
have already been reported to penetrate cells73, 297, 298. However, these peptides seem to 
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enter cells by a mechanism that involves direct translocation at the plasma membrane. In 
our laboratory, this is a process that we have also detected and attributed in part to the 
membrane oxidation of cells grown under 20% oxygen (e.g. ambient air)297. Overall, it 
would appear that CPPs with different structures but with similar arginine content take 
different routes into the cells. Investigating how this is possible may in turn reveal how to 
favor specific delivery pathways. Notably, it is worth noticing that dfR6 differs form a 
linear R12 peptide in several ways. First, a disulfide bond separates two R6 peptides. In 
the context of dfTAT, I have already established that a non-reducible linker could replace 
this disulfide bond without causing a loss of activity, indicating that the presence of 
disulfide group is not necessary per se157. However, it is possible that the presence of a 
spacer between two R6 sequences is somehow making the peptide behave differently than 
a peptide with 12 contiguous arginine residues. Consistent with this idea, Schepartz and 
co-workers have reported that arginine topology played a determining role in the 
intracellular trafficking of minimally cationic proteins, including their endosomal 
escape136. Alternatively, it is important to note that dfR6 contains two 
tetramethylrhodamine moieties while the R12 previously studied were labeled with only 
a single copy of this fluorophore. It is therefore possible that the addition of an extra 
fluorophore contributes to changing how the peptides interact with cells. Overall, further 
structure-activity relationship studies are required to provide a more detailed molecular 
understanding of the parameters that dictate the behavior of these CPPs.   
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4.4 Material and Methods 
 
4.4.1 Peptide design, synthesis, and purification  
All peptides were synthesized on the rink amide MBHA resin (Novabiochem, San 
Diego, CA) by solid phase peptide synthesis (SPPS). Fmoc-Lys(Mtt)-OH, Fmoc-
Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-
Cys(tbuthio)-OH (Novabiochem) were used to assemble the peptides using standard Fmoc 
protocols. All reactions were performed at room temperature in a SPPS vessel. Reactions 
were agitated using a stream of dry N2. For each amino acid coupling, the reaction was 
agitated for 4 h with a mixture of Fmoc-amino acid (1.6 mmol), HBTU (Novabiochem) 
(1.5 mmol) and di-isopropylethylamine (DIEA) (sigma) (4.0 mmol) in 
dimethylformamide (DMF) (Fisher). Fmoc deprotection was performed by addition of 
20% piperidine in DMF. The reaction was carried out twice: 1x 5 min followed by 1x 15 
min with a DMF washing step between reactions. After generation of the linear peptidyl 
chain, the peptidyl-resin was washed with DMF, followed by dichloromethane (DCM) 
(Fisher) for storage. DEAC-k5 (D-amino acid) was synthesized by coupling five Fmoc-
D-Lys(Boc)-OH. The DEAC (Anaspec) fluorophore was conjugated to the N-terminus of 
the peptide by reaction of DEAC, HBTU and DIEA (4, 3.9 and 10 eq.) in DMF overnight. 
CK(-NH-TMR)RnG peptides (n=4, 5, 6, 7 or 8) where generated similar to work 
described earlier for CK(-NH-TMR)TATG (L-fTAT)157.  Briefly, the MTT group found 
on C(tbuthio)K(-NH-MTT)RnG was removed using 1% trifluoroacetic acid (TFA) 
(Fisher) and 2% triisopropylsilane (TIS) (Sigma) in DCM. The peptidyl-resin was washed 
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with both DMF and DCM between each reaction. The peptidyl-resin was then reacted with 
a mixture of TMR, HBTU and DIEA (4, 3.9 and 10 eq.) and allowed to react overnight. 
The peptidyl-resin was washed and Fmoc deprotection was performed to remove the N-
terminal Fmoc moiety. To remove the tbuthio protecting group on the side chain of 
cysteine, the peptidyl-resin was then incubated in presence of tributylphosphine (PBU3) 
(180 μL PBU3, 500 μL DMF and DCM and 50 μL H2O; 3 times the volume is used for a 
full cleavage resign>100 mg).  The peptides with the remaining protecting groups were 
cleaved from the resin by treatment with 92.5% TFA, 2.5% H2O, 2.5% TIS and 2.5% 
ethanedithiol (EDT) (Sigma) for 3h at room temperature. The crude peptides were 
precipitated in cold anhydrous ether (Fisher). The precipitates were resuspended in 
0.1%TFA/water and lyophilized. The lyophilized product was dissolved in 
0.1%TFA/water. The peptides were analyzed and purified by reverse-phase HPLC. HPLC 
analysis was performed on a Hewlett-Packard 1200 series instrument and an analytical 
Vydac C18 column (5 μm, 4 x 150 mm). The flow rate was 2 mL/min, and detection was 
at 214 nm and 550 nm. Semi-preparative HPLC was performed on a Vydac C18 10 x 250 
mm column. The flow rate was 4 mL/min, and detection was at 214 nm and 550 nm. All 
runs used linear gradients of 0.1% aqueous TFA (solvent A) and 90% acetonitrile, 9.9% 
water, and 0.1% TFA (solvent B). The correct identity of the peptides was confirmed by 
electrospray ionization mass spectrometry (ESI) performed with an exactive plus orbitrap 
mass spectrometer instrument (Thermo Fisher Scientific). 
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4.4.2 Generation of dfRn and dfKn peptides by dimerization reactions 
fRn (where n=4, 5, 6,7 or 8), fK8 and fTAT (0.3 mg, 1.5 x 10-4 mmol) was each 
dissolved in 5 mL of aerated phosphate buffer saline (PBS) at pH 7.4. The reaction was 
left to incubate overnight (100% yield based on HPLC analysis). dfRn (where n=4, 5, 6,7 
or 8), dfK8 and dfTAT were purified using reverse-phase HPLC. Expected masses were: 
dfTAT: 4078.27, dfR4: 2683.48, dfR5: 2995.7, dfR6: 3307.92, dfR7: 3620.14, dfR8: 
3932.36, dfK8: 3484.25. The calculated observed masses based on ESI were dfTAT: 
4076.24, dfR4: 2682.36, dfR5: 2994.6, dfR6: 3306.8, dfR7: 3619.28, dfR8: 3932.16, 
dfK8: 3484.08. 
 
4.4.3 Cell culture  
HeLa cells (ATCC CCL-2) were grown in Dulbecco’s Minimum Essential Media 
(DMEM, Fisher) supplemented with 10% fetal bovine serum (FBS) (Fisher) and 1X 
penicillin/streptomycin (P/S) (Fisher) and incubated in a humidified atmosphere 
containing 5% CO2 at 37 C. 
 
4.4.4 Delivery of peptides into live cells 
HeLa cells were seeded in an 8-well dish or a 48-well dish and were grown to 80-
90% confluency in a 37C humidified atmosphere containing 5% CO2. The cells were 
washed three times with PBS and once with nrL-15. Cells were incubated with each 
peptide (dfRn, dfKn or dfTAT) at 37C for 1 h (unless otherwise specified). This was 
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followed by washing the cells three times with L-15 supplemented with heparin (1 
mg/mL) and an extra nrL-15 wash. Cells were treated with the cell impermeable nuclear 
stain SYTOX® BLUE or SYTOX ® GREEN to take into account cells that had a damaged 
plasma membrane (i.e. dead cells). Alternatively, the cell permeable Hoechst was used for 
nuclear staining. Cells were imaged using an inverted epifluorescence microscope (Model 
IX81, Olympus, Center Valley, PA) equipped with a heating stage maintained at 37 °C. 
Images were collected using a Rolera-MGI Plus back-illuminated EMCCD camera 
(Qimaging, Surrey, BC, Canada). Images were acquired using bright field imaging and 
three standard fluorescence filter sets: CFP (Ex = 436 ± 10 nm / Em= 480 ± 20 nm), RFP 
(Ex = 560 ± 20 nm / Em= 630 ± 35 nm), FITC (Ex = 488 ± 10 nm / Em= 520 ± 20 nm). 
For viewing and processing individual fluorescent images, the SlideBook 4.2 software 
(Olympus, Center Valley, PA) was used. Cells that displayed a cytosolic and nucleolar 
peptide staining were considered positive for cytosolic penetration (penetration(+)).The 
percentage of penetration (+) cells was calculated by dividing the number of cells that 
displaying a fluorescent nuclear staining (20X images) by the total number of cells present 
(acquired using bright field imaging). Cells that displayed a punctate distribution 
consistent with endosomal entrapment of the peptides, were considered negative for 
penetration and were not counted. Cells stained by SYTOX dyes were considered dead 
and were excluded from the analysis. For all quantitative experiments performed, an 
average of at least three 20X pictures were taken, representing 300-400 cells. The 
reproducibility of all the experiments was assessed by performing experiments with 
independent batches of cell cultures on three different days (i.e. biological triplicates). 
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4.4.5 Determination of mechanism of cellular entry 
To investigate the process of cellular entry, HeLa cells were incubated in L-15 
with DEAC-k5 (20 µM) for 1 h. Cells were then washed three times with PBS and then 
incubated with dfRn peptide (5 µM) or in nrL-15 (control cells) for 1h. Cells were washed 
and imaged as described earlier.  
 
4.4.6 Quantitative determination of peptide uptake 
HeLa cells were seeded in a 48-well dish and grown to 80% confluency. Cells were 
treated with peptides for 1h at various concentrations (range: 1-10 µM). The total amount 
of peptide uptake was measured by a whole cell lysate analysis. Cells were washed with 
heparin (1mg/mL) and then trypsinized (50 µL) for 3 min. Cells were resuspended in nrL-
15 (350 µL) and centrifuged at 4°C, 2,500 rpm for 10 min. The supernatant was discarded 
and the cell pellet was resuspended in nrL-15 (50 µL). An aliquot from the resuspended 
cells (3 µL) was removed to determine the total number of cells per sample by analysis 
using flow cytommetry. The remainder of resuspended cells were lysed by addition of 50 
µL of a lysis buffer (components: 50mM Tris, pH7.5, 2 mM EDTA, 4mM DTT, 20% 
Triton X-100 and protein inhibitor cocktail) and 3 min of vortexing. A volume of 70 µL 
of the lysed cells for each condition was placed in a 96 well plate. The fluorescence 
emission intensity was measured using a plate reader equipped with a fluorescence module 
(Ex=525, Em=580-640 nm) (GloMax®-Multi+ Detection System, Promega, Fitchburg, 
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WI). To normalize the aliquot of cells (3 µL) was resuspended in nrL-15 (197 µL) and the 
total amount of cells per samples was determined using flow cytometry. 
 
4.4.7 Liposome Preparation 
The lipids used in the experiments consisted of: 1,2-dioleoyl-s-glycero-3-
phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), sn-
(3-oleoyl-2-hydroxy)-glycerol-1-phospho-sn-1’-(3’-oleoyl-2’-hydroxy-glycerol) (BMP), 
cholesterol (chol) (Avanti Polar Lipids). Liposomes were prepared by first transferring 
various volumes of lipids dissolved in chloroform (stock solutions of known 
concentrations) into scintillation vials. For liposomes mimicking the intraluminal late 
endosomes vesicles (L.E.) the molar ratios of lipids consisted of 77:19:4 BMP:PC:PE. For 
liposomes mimicking the plasma membrane, the lipid mixture was 65:15:20 PC:PE:Chol. 
The lipid film was prepared by removing the chloroform from the lipid mixture using a 
stream of N2 and then placing the vial in a desiccator for 24h. A buffer containing 100 
mM NaCl, 10 mM NaH2PO4 pH7.4, with or without 60 mM calcein was added to the 
lipids film for hydration. The lipids were then mixed vigorously and swelled for 1 h at 
42C under N2 to obtain multilamellar vesicles (MLVs). For production of unilamellar 
vesicles (LUVs), the MLVS were extruded (20 passes) through a 100 nm pore size 
polycarbonate membrane (Whatman) using a Mini-Extruder (Avanti Polar Lipids). 
Dynamic light scattering was used to determine the average diameter size distribution of 
the liposomes using a Zeta Sizer (Malvern instrument). The liposomes were purified by 
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gel filtration using a Sephadex G-50 (GE Healthcare) column (2.5 x 17.5 cm) to separate 
the liposomes from free calcein. The eluate was collected in a 96 well plate and the plate 
was read using a Promega GloMax-Multi plate reader (Promega) at 450 nm and 750 nm 
corresponding to the wavelength of detection for calcein and liposome respectively. 
 
4.4.8 Liposome leakage assays 
Purified calcein-loaded LUVs were mixed with different peptides at a 1:50 
peptide: lipid ratio for 1 h at room temperature in 100 mM NaCl, 10 mM NaH2PO4 pH5.5. 
Samples were centrifuged for 1 min at 4,000 rpm. To measure the amount of leaked calcein 
and separate soluble liposomes from released calcein, the supernatants were purified using 
an illustra NAP-10 Sephadex G-25 column (GE Healthcare) (the elution volumes of 
liposomes and free calcein were determined independently with pure samples). Fractions 
were collected in a 96-well plate and the fluorescence of calcein was measured using a 
Promega GloMax-Multi plate reader (Ex 490nm, Em 520-560nm). The percent leakage 
was calculated using the following equation: 
% Leakage = 100 × 
Flt − Fl0
Flmax − Fl0
 
 
where Flt is the free calcein fluorescence intensity of a sample at a specific peptide:lipid 
ratio measured after 1 h, Fl0 is the free calcein fluorescence intensity of a untreated sample 
and Flmax is the free calcein fluorescence intensity of a sample after treatment with 0.2 % 
Triton X-100. 
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4.4.9 Liposome binding assays 
To determine the difference in the binding affinity of peptides to LUVs of different 
lipid compositions. The LUVs were incubated for 1 h with either peptide at the same 
peptide to lipid ratio as the leakage assay (1:50) using the buffer composition of 100 mM 
NaCl, 10 mM NaH2PO4 pH 5.5. Samples were centrifuged at 13,000 rpm for 3 min. The 
supernatant was removed to measure the amount of unbound peptide (using the 
fluorescence emission of TMR). To insure that quenching due to the proximity of the TMR 
fluorophore in the dfTAT constructs would not affect my results, the supernatant was 
reduced with TCEP (50 mM). The TMR fluorescence was measured using the red channel 
(Ex= 525nm, Em=580-640 nm) of a Promega GloMax-Multi plate reader (Promega). The 
amount of peptide bound to the MLVs was determined according to the following 
equation: 
𝑃𝑏 =  𝑃𝑡𝑜𝑡 – 𝑃 
 
Where Ptotal is the amount of peptide from the supernatant in the absence of MLVs, P is 
the fraction of unbound peptide at a particular lipid concentration and Pb is the fraction of 
bound peptide at a particular lipid concentration. 
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5. SUMMARY AND CONCLUSIONS 
 
dfTAT: a highly efficient cellular delivery agent 
Over two decades of research in the field of macromolecular delivery have been 
dedicated to enhancing the endosomal escape property of CPPs. Various approaches to 
improving this activity have been proposed; however, to date the efficiency remains sub-
optimal. Multivalency is one methodology that has been suggested. Multivalent 
compounds are generated by attaching multiple copies of their functional unit to a single 
scaffold. It has been suggested that this results in a higher local concentration of the active 
peptide/protein at the membrane. In this research, I used this approach to generate a 
dimeric version of the TAT peptide called dfTAT (dimeric fluorescent TAT) and 
established that it has an unprecedented level of endosomolytic activity. I show that dfTAT 
was able to penetrate the cytosolic space of cells more efficiently than its monomeric 
counterpart, TAT. Interestingly, the monomeric TAT could not recapitulate dfTAT’s 
activity, even when the same amount of peptide was present inside the endocytic vesicles. 
This work, therefore, confirms the important role that multivalency plays in cellular 
penetration. The viability, proliferation and gene expression data show that the high 
endosomal disruption generated by dfTAT is well tolerated by the cells, as no negative 
impact was observed. This result was unexpected, since the efficient disruption of 
endosomes could result in the release of proteases, toxic enzymes and calcium ions into 
the cytosolic space of cells. It is possible that this observation is a result of the slow 
kinetics of the peptide release, allowing for ample of time for the cells to recuperate and 
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repair the disrupted membrane. Both the high endosomal escape efficiency and low 
toxicity, make dfTAT an ideal delivery agent, unique from what has been previously 
reported. I show that dfTAT can be used to efficiently deliver a variety of macromolecules 
inside cells. Some examples include: the biologically active enzyme TAT-Cre, the 
mitochondrial targeting antibody anti-ATP5a, and the transcription factor HOXB4, the 
latter which is important for hematopoietic stem cell expansion. I also demonstrated that 
the amount of HOXB4 delivered could be tightly controlled by modulating the amount of 
protein that was administered extracellularly. This is important for many therapeutic 
applications, since opposing effects have been observed by altering the dose of the 
molecule administered. Furthermore, multiple molecules could be administered either 
simultaneously or sequentially. The latter suggests that while dfTAT disrupts endocytic 
vesicles, it does not negatively impact this pathway. Overall, the properties mentioned 
make dfTAT a unique delivery agent, and unveiling the structural characteristics required 
for this highly efficient endosomolysis is important for developing new and improved 
delivery agents.  
Impact of chirality and protease-resistance on endosomal escape 
While multivalency was shown to clearly impact the endosomal escape efficiency 
of CPPs, I sought further insights into additional parameters that could influence CPP 
activity. In particular, I wanted to determine how CPP chirality and proteolytic 
degradation impacted its cell penetration property. The latter, in particular, is important 
many CPPs show promise as delivery tools, however upon exposure to cells or serum, 
CPPs are rapidly degraded. This innate property renders CPP activity less effective. One 
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way to overcome degradation is by substituting L-amino acids for D-amino acids. In doing 
so, the change in chirality results in a proteolytically stable CPP. How chirality impacts 
the endosomal escape property of CPPs however is not clear. This is in part due to the fact 
that most studied CPPs remain extremely inefficient at escaping these vesicles. Therefore, 
I used dfTAT as the proto-type and standard for a highly efficient endosomal reagent. I 
generated a reagent, D-dfTAT or D-amino acid dfTAT, which combines the parameters 
of inversing chirality and increasing protease resistance. I then determined that dfTAT 
was degraded in an hour, upon incubation with cells. However, D-dfTAT remained stable 
over all time points tested (over 48 h). Also, I showed that D-dfTAT, in a fashion similar 
to dfTAT, is capable of penetrating cells via the same endocytic route. However, by 
measuring the total fluorescence of a cell lysate, I determined that dfTAT was endocytosed 
three to four- fold higher than D-dfTAT. Conversely, under conditions in which the same 
amount of each peptide was found in the endosomes, D-dfTAT was more efficient at 
escaping the late endosome than dfTAT.  
Interestingly, these findings shed light on the dependency of peptide 
internalization based upon peptide chirality. Conversely, in vitro assays using late 
endosomal liposomes showed no changes in lipid binding or calcein leakage between both 
peptides. These assays suggest that the interaction of the peptide with BMP in LE is 
independent of the peptide’s chirality. Furthermore, my results indicate that 
supplementing cells with endocytic protease inhibitors increased the endosomal escape 
efficiency of dfTAT. Therefore, the reduced dfTAT activity observed could in part be due 
to the extensive degradation it experiences along the endocytic pathway. Therefore, D-
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dfTAT portrays an overall enhanced endosomal escape property, which is ideal for both 
in cellulo and in vivo experiments. However, by performing viability and proliferation 
assays, I have shown that MCH58 cells treated with D-dfTAT proliferate at a slower rate 
than untreated or dfTAT- treated cells. Interestingly, this was not observed in HDF cells, 
which could be explained by a difference in the amount of peptide internalized. In order 
to gain detailed insights into how cells respond to the peptides, I performed a microarray 
analysis. Using dfTAT, I had previously shown that neither the peptide treatment nor the 
endosomal leakage had a negative impact on cellular proliferation. Interestingly, the D-
dfTAT treatment resulted in the dysregulation of 215 and 551 genes in the HDF and 
MCH58 cells, respectively. Since both D-dfTAT and dfTAT penetrate the cells via the 
same mechanism, I attributed this difference in behavior to be attributed to the retention 
of D-dfTAT in the cells. This retention could result in D-dfTAT interaction with many of 
the cytosolic and nucleolar proteins necessary for cellular homeostasis. It is known that 
TAT localizes in the nucleolus due to its high positive charge. In fact, fluorescent images 
of cells treated with D-dfTAT show a clear nucleolar staining that persists over 48 h. This 
indicates that D-dfTAT could in particular be interacting with nucleic acids in this 
compartment, and thus be disrupting important processes. While dfTAT could have 
similar interactions, the peptide is rapidly degraded and therefore its effects on the cells 
are minimized. These results highlight that while increasing peptide stability is important 
to improving CPP activity, this might come at the costs of negatively impacting cellular 
physiology. This issue is particularly important when considering the use of CPPs for in 
vivo applications.  
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The role of cationic residues in endosomal escape 
The importance of the arginine residues for cellular internalization in cationic-
based CPPs has been established by many pioneers in the field; however, it remains to be 
determined whether this extends to endosomal escape. As mentioned above, this is due to 
the inefficient endosomal escape property of most well-studied CPPs. Therefore, I again 
used dfTAT as a prototype for highly endosomoloytic CPPs in an effort to answer this 
question. dfTAT also shares some similarities with other molecules that display enhanced 
endosomal escape activities. For instance, recent reports have suggested that proteins with 
a very high density of positive charges can escape from endosomes. This is for instance 
the case for supercharged GFP (scGFP), a GFP variant engineered with 36 surface exposed 
cationic residues (+1.3/kDa)299. It is also the case for viral capsid proteins that naturally 
display charge density as high as +2/kDa and that can either directly participate in the viral 
entry into host cells or that can be used to deliver exogenous cargos300. Notably, dfTAT, 
has a charge density of +4.4/kDa, may also be considered a “supercharged” species.  
My work shows that the polylysine construct, dfK8, while containing the same 
number of positive charges as dfTAT (the monomer TAT has 6 Arg and 2 Lys, a total of 
8 positive side chain charges, and therefore the dfTAT dimer would have 16 side chain 
positive charges), was unable to escape the endocytic pathway at any concentration tested. 
Conversely, dfR8 (also containing 16 side chain positive charges) recapitulated and 
surpassed the observed penetration activity of dfTAT. This suggests that the positive 
charge is not sufficient for the endosomal escape of CPPs. It appears that endosomal 
escape is dependent on the presence of arginine residues. This can be explained by the 
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bidentate nature of the arginine residue, in comparison to the monodentate lysine. For 
example, arginine could engage in a higher level of interaction with BMP in the late 
endosome, due to its ability to form two hydrogen bonds with the phosphate polar head 
group. However, I also observed that dfR8 was associated with cytotoxicity at higher 
concentrations. Interestingly, dfR8 and dfTAT contain the same number of positive 
charges, however differ in arginine content (dfTAT:12 Arg, dfR8: 16 Arg). It is currently 
unclear why dfR8 is more toxic than dfTAT and whether dfR8 expresses this deleterious 
effect from the outside or inside of cells or both. Similar toxicity was also observed with 
the dfR7 peptide. Future work will also be required to fundamentally understand why the 
presence of the extra arginine’s result in a more toxic peptide. However, I reasoned that 
since dfR8 had a similar penetration activity as dfTAT, it is possible that by decreasing 
the amount of arginine, I could find an active compound that was not cytotoxic. In fact, 
dfR6 (12 Arg per dimer), a peptide containing the same total number of arginines as 
dfTAT, was able to recapitulate its penetration activity and shows similar extremely low 
cytotoxicity. Interestingly, peptides with an arginine content less than 12 (per dimer) such 
as dfR4 (8 arginines) and dfR5 (10 arginines) remain entrapped in the endocytic pathway 
at any concentration tested. Furthermore, both the endocytic uptake and the endosomal 
release activity of the dfRn peptides was proportional to the number of arginine residues 
present in the peptide. This suggested that the peptide constructs such as dfR4 and dfR5 
(total arginine content less than 12) has a lower endocytic uptake and a weaker membrane 
disrupting activity which ultimately results in not enough peptide present in the endosome 
for sufficient endosomal leakage. Interestingly, even at concentration inside the 
234 
 
endosomes in which dfR4 and dfR5 were higher than dfR6, dfR4 and dfR5 still remained 
entrapped endosomes while dfR6 escapes and reaches the cytosolic space. This data 
showed that peptides with less than 12 arginines are weak at disrupting membranes and it 
endosomal escape is not simply dependent on the concentration of peptide present. The 
number of arginine residues per peptide play an important role in the endosomal escape 
activity. The in cellulo assays were also complemented with an in vitro liposome leakage 
assay. My results show that the leakage of these liposomes is dependent on the peptides 
total arginine content. This indicates that there is a minimum amount of arginine required 
in the peptide to interact with BMP and result in leakage.  
Current model for dfTAT mechanism and implications 
Taken together, my work suggests that chirality plays an important role in cell 
surface internalization. However, my data also demonstrates that the exact peptide 
sequence is not necessary. For example, dfTAT is comprised of six noncontiguous 
arginines per monomer (12 per dimer) and dfR6 contains the same number of arginines in 
a contiguous stretch, are internalized with the same efficiency. At first glance, this data 
might seem contradictory. In particular one might ask how the interaction of the peptide 
could depend on chirality but not on the specific peptide sequence. The uptake of CPPs 
has been reported to involve interactions with HSPGs on the cell surface. However, it has 
been reported that the interaction of the CPP with heparan sulfate (HS) is independent of 
chirality199. Therefore, I hypothesize that in addition to HS, there are co-attachment factors 
or receptor proteins that may mediate the internalization of cationic CPPs inside cells. In 
particular, the interaction with these receptors would be dependent on stereochemistry. 
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This suggests that dfTAT’s cellular entry occurs via two mutually inclusive pathways: 
chirality dependent and independent. In support of this hypothesis, Futaki and colleagues 
used a photo- crosslinking approach to demonstrate that the CPPs R8 and R12 interact 
with Syndecan-4 and CXCR4 receptors, respectively105, 301. These receptors have also 
been shown to trigger endocytosis. Hence, I concluded that D-dfTAT triggers endocytosis 
via its interaction with HS. However, it cannot interact with the chiral-dependent protein 
receptors involved in endocytosis. This decreases the total amount of D-dfTAT entering 
cells to a greater extent than does dfTAT, since one pathway is essentially shut down. To 
understand how the receptor is sequence independent, I hypothesized that the peptides 
would adopt a secondary structure that exposes the minimum recognition motif required 
for the peptide to activate the receptor for endocytosis. The minimum number of arginines 
that would be required for binding would be arginine number two through six on each 
monomer of dfTAT (TAT=R1XXR2R3XR4R5R6). This would suggest that in dfR6, the 
third arginine in each monomer would not be involved in this interaction 
(R6=R1R2R3R4R5R6). This R2R3XR4R5R6 construct would be the minimum motif per 
monomer required for activation of the protein receptor. Furthermore, dfR7 and dfR8 
result in enhanced internalization because the extra arginines provide surplus electrostatic 
interactions in addition to the minimum required sequence. This results in a higher affinity 
of dfR7/8 to the protein receptor. Future structural analysis of the peptide constructs with 
membranes would be required to test this hypothesis.  
After internalization, dfTAT is initially entrapped inside endocytic vesicles. 
dfTAT travels along the endocytic pathway and reaches the late endosome. Experiments 
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have shown that dfTAT escapes from the late endosome by interaction with BMP. By 
altering dfTAT’s chirality using D-amino acid (Chapter 3), I was able to show that the 
interaction of dfTAT with BMP is independent of chirality. Both dfTAT and D-dfTAT 
bind and cause the leakage of liposomes containing high BMP content to a similar extent. 
Therefore, this interaction BMP/dfTAT interaction would presumably be an electrostatic 
interaction of the phosphate backbone with the positively charged arginine residues. My 
work also highlights the importance of the 12 total arginines found in dfTAT, which are 
necessary for its endosomolytic activity. Furthermore, my data shows that dfTAT is 
degraded by proteases along the endocytic pathway that ultimately diminish its 
endosomolytic activity. dfTAT is also degraded in the cytosolic space of cells. It is 
currently unknown which proteases or pathways are occurring in the cells that result in the 
degradation of dfTAT. Identification of these process will be important as they can be 
modulated to enhance dfTAT’s in cellulo activity. However, it is important to note that 
the susceptibility of dfTAT to degradation could be an important and ideal feature. My 
work shows that cells treated with dfTAT shows no observable impact on the cell’s 
physiology or transcriptional regulation. On the contrary, the non-degradable version D-
dfTAT shows a dramatic negative impact on the cells growth and transcriptome levels. 
Future work will be necessary to identify peptides that are proteolytically resistant inside 
endosomes (which results in increased endosomolysis), however are readily degraded in 
the cytosolic space.  
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Figure 5-1 Model of dfTAT entry and escape from the endocytic pathway. dfTAT 
enters cells via two simultaneous pathways: Chirality independent and Chirality 
dependent. In the first pathway, dfTAT interacts electrostatically with the sulfates and 
carboxylates on Heparan sulfate present on the cell surface. In the chirality dependent 
pathway, it is possible that open interaction with the membrane a conformational change 
in dfTAT allows for a chirality dependent interaction with proteins found on the cell 
surface. In both scenarios, an induction of endocytosis occurs, in which dfTAT is initially 
entrapped inside endocytic vesicles until reaching the late endosomes. dfTAT escapes 
from the late endosome via electrostratic interaction with BMP and this interaction is 
independent of peptide chirality. Furthermore, due to proteases found along the endocytic 
pathway dfTAT is degraded inside endosomes and is further degraded in the cytosolic 
space. The intracellular degradation of this peptide is important as it results in a peptide 
that shows no observed impact on the cell’s physiology. 
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Future work 
As described above, experiments designed to determine the structure of dfTAT 
and the identification of its cell-surface membrane interacting partners are necessary to 
gain further insight into the mechanism of dfTAT’s cellular penetration. In addition, 
studies are necessary to further elucidate the structural characteristics that are important 
for dfTAT’s activity.  
The work detailed in this thesis is part of a broader project that aims at establishing 
the structure-activity relationships that will reveal the molecular properties required for 
efficient endosomal escape. This is work that I have started as part of my thesis project 
however additional work is still required. The original working hypothesis for dfTAT was 
that multivalency (the number of peptide copies greater than one), high arginine-content, 
close proximity between each CPP copy, and presence of hydrophobic moieties contribute 
to it’s high endosomolytic activity. While I have shown in this thesis that in fact 
multivalency and high arginine content play a role, other parameters remain to be 
identified. To test this hypothesis, a focused library of peptides based on the dfTAT 
prototype will need to be synthesized in which each parameter is varied. The  peptides will 
then be characterized based on their cellular penetration properties. This will ultimately 
lead to a deeper understanding of the molecular features that are important to achieve 
efficient escape from endosomes. This knowledge is critical because it will lay a solid 
foundation for the rationale design of delivery agents with improved therapeutic value.  
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Future work is necessary to test 1) the effect of the fluorophore on dfTAT’s activity 2) the 
effect of the disulfide bond linker between the two TAT copies 3) the effect of the position 
of the fluorophore and linker with respect to one another.   
1) The effect of the TMR fluorophore 
Fluorophore substitution 
dfTAT contains two tetramethylrodamine fluorophores each conjugated to the side 
chain of a lysine amino acid (see table below). The TMR fluorophore was initially 
conjugated to the TAT peptide as a means to visualize the peptide inside cells using 
fluorescence microscopy. One hypothesis is that TMR plays an important role in the 
endosomolytic activity of dfTAT. To test this hypothesis, replacing the TMR fluorophore 
and conjugating other known fluorophores (Eg. Fluorescein (FL) and 7-
Diethylaminocoumarin-3-carboxylic acid (DEAC)) in place of it could allow one to 
determine the importance of the fluorophore. In addition to giving insight into the role of 
TMR in dfTAT’s activity, this study will be extremely valuable as it could provide a 
variety of fluorescently labeled, highly endosomolytic CPPs with different fluorescence 
emission wavelengths. This is important for delivery of probes that could be labeled with 
fluorophores that emit at a wavelength similar to TMR. Establishing whether TMR could 
be replaced with other fluorophore could increase the applications of this delivery 
methodology. 
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Replace the fluorophore for hydrophobic amino acids 
TMR is composed of multiple aromatic rings in its structure, it is possible that the 
hydrophobicity of this molecule could play a role in dfTAT’s endosomolytic activity. To 
test this hypothesis, the TMR fluorophore in dfTAT could be replaced with aromatic 
amino acids (Phe, Tyr, Trp). These residues are ideal because of the presence of the 
aromatic ring and their hydrophobic nature. Furthermore, these are naturally occurring 
amino acid which make them non-traceable and more attractive as therapeutic tools.  
2) The effect of the linker 
It has been postulated that multimerization of CPPs might increase membrane 
activity by an avidity effect. Attaching several copies of TAT in close proximity could 
indeed create a high local concentration of peptide at the sites where it interacts with the 
membrane. However, how proximity between peptides affects activity is not understood. 
To address this issue, Bis-maleimide (BM) linkers (Pierce) of various length can be used 
to connect two CK(TMR)TAT (BMOE, BMDB, BMB, BMH contain 2,4,5,6 methylenes, 
respectively; BM(PEG)2 and BM(PEG)3 contain 2- and 3-unit polyethylene glycol 
spacers). One possible issue that might arise when introducing linkers of different lengths 
is that other factors, such as hydrophobicity, will also be altered. To address this issue, 
linkers of similar length but of different chemical structures will be compared (e.g. BMH 
vs BM(PEG)2). Furthermore, since these linkers are non-cleavable a control construct will 
be generated similar to dfTAT however not linked via disulfide bonds (eg. CK(TMR)TAT 
can be conjugated to I-CH2-CO-K(TMR)TAT. This construct will not contain a cleavable 
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disulfide bond but will have approximately the same linker length between the two 
monomer TAT copies). Currently, the BMOE-linked CK(TMR)TAT has been generated 
and shows efficient cellular penetration activity (Chapter 2), however further quantitative 
studies are required to compare it’s efficiency to dfTAT. 
3) The effect of linker and fluorophore position  
dfTAT was synthesized with the CysLys(TMR) groups at the N-terminus. A 
working hypothesis is that the disulfide bond formed brings two Lys(TMR) moieties in 
close proximity, creating a hydrophobic “warhead” attached to two hydrophilic peptides. 
Whether this configuration is important for cell penetration is unknown. Test will be 
required to test the working hypothesis by shuffling the position of the Cys and Lys(TMR) 
residues.  
As part of my thesis work, I have generated many of the reagents shown in Figure 
5-2 below. Future work will be required to test the working hypothesis mentioned above 
and compare the efficiency of these modified peptides in comparision to the dfTAT 
prototype.    
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Figure 5-2 Design of future dfTAT analogues. 
 
 
 
 
 
 
 
 
243 
 
REFERENCES 
1. Pan, C., Lu, B., Chen, H. & Bishop, C.E. Reprogramming human fibroblasts using 
HIV-1 TAT recombinant proteins OCT4, SOX2, KLF4 and c-MYC. Molecular 
Biology Reports 37, 2117-2124 (2010). 
2. Kim, T.K. & Eberwine, J.H. Mammalian cell transfection: the present and the 
future. Analytical and Bioanalytical Chemistry 397, 3173-3178 (2010). 
3. McNeil, P.L., Murphy, R.F., Lanni, F. & Taylor, D.L. A method for incorporating 
macromolecules into adherent cells. J Cell Biol 98, 1556-1564 (1984). 
4. Ortiz, D., Baldwin, M.M. & Lucas, J.J. Transient correction of genetic defects in 
cultured animal cells by introduction of functional proteins. Mol Cell Biol 7, 3012-
3017 (1987). 
5. Chakrabarti, R., Wylie, D.E. & Schuster, S.M. Transfer of monoclonal antibodies 
into mammalian cells by electroporation. J Biol Chem 264, 15494-15500 (1989). 
6. Prior, T.I., FitzGerald, D.J. & Pastan, I. Barnase toxin: a new chimeric toxin 
composed of pseudomonas exotoxin A and barnase. Cell 64, 1017-1023 (1991). 
7. Prior, T.I., FitzGerald, D.J. & Pastan, I. Translocation mediated by domain II of 
Pseudomonas exotoxin A: transport of barnase into the cytosol. Biochemistry 31, 
3555-3559 (1992). 
8. Renneisen, K., Leserman, L., Matthes, E., Schroder, H.C. & Muller, W.E. 
Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-
targeted liposomes containing antisense RNA to the env region. J Biol Chem 265, 
16337-16342 (1990). 
9. van den Boorn, J.G., Schlee, M., Coch, C. & Hartmann, G. SiRNA delivery with 
exosome nanoparticles. Nat Biotechnol 29, 325-326 (2011). 
10. Kaczmarczyk, S.J., Sitaraman, K., Young, H.A., Hughes, S.H. & Chatterjee, D.K. 
Protein delivery using engineered virus-like particles. Proc Natl Acad Sci U S A 
108, 16998-17003 (2011). 
11. Fawell, S. et al. Tat-mediated delivery of heterologous proteins into cells. Proc 
Natl Acad Sci U S A 91, 664-668 (1994). 
12. Patel, L.N., Zaro, J.L. & Shen, W.C. Cell penetrating peptides: intracellular 
pathways and pharmaceutical perspectives. Pharm Res 24, 1977-1992 (2007). 
244 
 
13. Frankel, A.D. & Pabo, C.O. Cellular uptake of the tat protein from human 
immunodeficiency virus. Cell 55, 1189-1193 (1988). 
14. Green, M. & Loewenstein, P.M. Autonomous functional domains of chemically 
synthesized human immunodeficiency virus tat trans-activator protein. Cell 55, 
1179-1188 (1988). 
15. Mann, D.A. & Frankel, A.D. Endocytosis and targeting of exogenous HIV-1 Tat 
protein. EMBO J 10, 1733-1739 (1991). 
16. Vivès, E., Brodin, P. & Lebleu, B. A Truncated HIV-1 Tat Protein Basic Domain 
Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell 
Nucleus. Journal of Biological Chemistry 272, 16010-16017 (1997). 
17. Bechara, C. & Sagan, S. Cell-penetrating peptides: 20 years later, where do we 
stand? FEBS Letters 587, 1693-1702 (2013). 
18. Milletti, F. Cell-penetrating peptides: classes, origin, and current landscape. Drug 
Discovery Today 17, 850-860 (2012). 
19. Nishikawa, M. et al. Induction of Tumor-specific Immune Response by Gene 
Transfer of Hsp70-cell-penetrating Peptide Fusion Protein to Tumors in Mice. Mol 
Ther 18, 421-428 (2009). 
20. Deshayes, S., Morris, M.C., Divita, G. & Heitz, F. Interactions of amphipathic 
CPPs with model membranes. Biochimica et Biophysica Acta (BBA) - 
Biomembranes 1758, 328-335 (2006). 
21. Derossi, D., Joliot, A.H., Chassaing, G. & Prochiantz, A. The third helix of the 
Antennapedia homeodomain translocates through biological membranes. Journal 
of Biological Chemistry 269, 10444-10450 (1994). 
22. Pooga, M., Hällbrink, M., Zorko, M., Langel, U. & lo Cell penetration by 
transportan. The FASEB Journal 12, 67-77 (1998). 
23. Morris, M.C., Depollier, J., Mery, J., Heitz, F. & Divita, G. A peptide carrier for 
the delivery of biologically active proteins into mammalian cells. Nat Biotech 19, 
1173-1176 (2001). 
24. Montrose, K., Yang, Y., Sun, X., Wiles, S. & Krissansen, G.W. Xentry, a new 
class of cell-penetrating peptide uniquely equipped for delivery of drugs. Sci. Rep. 
3 (2013). 
25. Crombez, L. et al. A New Potent Secondary Amphipathic Cell-penetrating Peptide 
for siRNA Delivery Into Mammalian Cells. Mol Ther 17, 95-103 (2008). 
245 
 
26. Lorents, A. et al. Cell-penetrating Peptides Split into Two Groups Based on 
Modulation of Intracellular Calcium Concentration. Journal of Biological 
Chemistry 287, 16880-16889 (2012). 
27. Munyendo, W.L., Lv, H., Benza-Ingoula, H., Baraza, L.D. & Zhou, J. Cell 
Penetrating Peptides in the Delivery of Biopharmaceuticals. Biomolecules 2, 187-
202 (2012). 
28. Li, W., Nicol, F. & Szoka Jr, F.C. GALA: a designed synthetic pH-responsive 
amphipathic peptide with applications in drug and gene delivery. Advanced Drug 
Delivery Reviews 56, 967-985 (2004). 
29. Oehlke, J. et al. Cellular uptake of an α-helical amphipathic model peptide with 
the potential to deliver polar compounds into the cell interior non-endocytically. 
Biochimica et Biophysica Acta (BBA) - Biomembranes 1414, 127-139 (1998). 
30. Taylor, B.N. et al. Noncationic Peptides Obtained From Azurin Preferentially 
Enter Cancer Cells. Cancer Research 69, 537 (2009). 
31. Schafmeister, C.E., Po, J. & Verdine, G.L. An All-Hydrocarbon Cross-Linking 
System for Enhancing the Helicity and Metabolic Stability of Peptides. Journal of 
the American Chemical Society 122, 5891-5892 (2000). 
32. Wender, P.A. et al. The design, synthesis, and evaluation of molecules that enable 
or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U 
S A 97, 13003-13008 (2000). 
33. Mitchell, D.J., Kim, D.T., Steinman, L., Fathman, C.G. & Rothbard, J.B. 
Polyarginine enters cells more efficiently than other polycationic homopolymers. 
J Pept Res 56, 318-325 (2000). 
34. Futaki, S. et al. Arginine-rich peptides. An abundant source of membrane-
permeable peptides having potential as carriers for intracellular protein delivery. J 
Biol Chem 276, 5836-5840 (2001). 
35. Richard, J.P. et al. Cell-penetrating peptides. A reevaluation of the mechanism of 
cellular uptake. J Biol Chem 278, 585-590 (2003). 
36. Vives, E., Richard, J.P., Rispal, C. & Lebleu, B. TAT peptide internalization: 
seeking the mechanism of entry. Curr Protein Pept Sci 4, 125-132 (2003). 
37. Thoren, P.E. et al. Uptake of analogs of penetratin, Tat(48-60) and oligoarginine 
in live cells. Biochem Biophys Res Commun 307, 100-107 (2003). 
246 
 
38. Luedtke, N.W., Carmichael, P. & Tor, Y. Cellular uptake of aminoglycosides, 
guanidinoglycosides, and poly-arginine. J Am Chem Soc 125, 12374-12375 
(2003). 
39. Shin, M.C. et al. Cell-penetrating peptides: achievements and challenges in 
application for cancer treatment. Journal of biomedical materials research. Part A 
102, 575-587 (2014). 
40. Lee, Y.-J., Erazo-Oliveras, A. & Pellois, J.-P. Delivery of macromolecules into 
live cells by simple co-incubation with a peptide. Chembiochem : a European 
journal of chemical biology 11, 325-330 (2010). 
41. Kim, D.T. et al. Introduction of soluble proteins into the MHC class I pathway by 
conjugation to an HIV tat peptide. J Immunol 159, 1666-1668 (1997). 
42. Nagy, A. Cre recombinase: the universal reagent for genome tailoring. Genesis 26, 
99-109 (2000). 
43. Kim, D. et al. Generation of Human Induced Pluripotent Stem Cells by Direct 
Delivery of Reprogramming Proteins. Cell Stem Cell 4, 472-476 (2009). 
44. Takahashi, K. & Yamanaka, S. Induction of Pluripotent Stem Cells from Mouse 
Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell 126, 663-676 
(2006). 
45. Ramakrishna, S. et al. Gene disruption by cell-penetrating peptide-mediated 
delivery of Cas9 protein and guide RNA. Genome Res 24, 1020-1027 (2014). 
46. Horvath, P. & Barrangou, R. CRISPR/Cas, the Immune System of Bacteria and 
Archaea. Science 327, 167 (2010). 
47. Wiedenheft, B., Sternberg, S.H. & Doudna, J.A. RNA-guided genetic silencing 
systems in bacteria and archaea. Nature 482, 331-338 (2012). 
48. Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-
745 (2000). 
49. Wagner, H. Toll meets bacterial CpG-DNA. Immunity 14, 499-502 (2001). 
50. Gaj, T., Guo, J., Kato, Y., Sirk, S.J. & Barbas, C.F. Targeted gene knockout by 
direct delivery of zinc-finger nuclease proteins. Nat Meth 9, 805-807 (2012). 
51. Liu, J., Gaj, T., Patterson, J.T., Sirk, S.J. & Barbas, C.F., 3rd Cell-penetrating 
peptide-mediated delivery of TALEN proteins via bioconjugation for genome 
engineering. PLoS One 9, e85755 (2014). 
247 
 
52. Whitehead, K.A., Langer, R. & Anderson, D.G. Knocking down barriers: advances 
in siRNA delivery. Nat Rev Drug Discov 8, 129-138 (2009). 
53. Glover, D.J., Lipps, H.J. & Jans, D.A. Towards safe, non-viral therapeutic gene 
expression in humans. Nat Rev Genet 6, 299-310 (2005). 
54. Eguchi, A. et al. Efficient siRNA delivery into primary cells by a peptide 
transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 27, 
567-571 (2009). 
55. Lebleu, B. et al. Cell penetrating peptide conjugates of steric block 
oligonucleotides. Advanced Drug Delivery Reviews 60, 517-529 (2008). 
56. Kole, R., Vacek, M. & Williams, T. Modification of alternative splicing by 
antisense therapeutics. Oligonucleotides 14, 65-74 (2004). 
57. Krutzfeldt, J. et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 
685-689 (2005). 
58. Kilk, K. et al. Targeting of antisense PNA oligomers to human galanin receptor 
type 1 mRNA. Neuropeptides 38, 316-324 (2004). 
59. Wolf, Y. et al. Structural Requirements for Cellular Uptake and Antisense Activity 
of Peptide Nucleic Acids Conjugated with Various Peptides. Biochemistry 45, 
14944-14954 (2006). 
60. Shiraishi, T., Pankratova, S. & Nielsen, P.E. Calcium Ions Effectively Enhance the 
Effect of Antisense Peptide Nucleic Acids Conjugated to Cationic Tat and 
Oligoarginine Peptides. Chemistry & Biology 12, 923-929 (2005). 
61. Schwarze, S.R., Ho, A., Vocero-Akbani, A. & Dowdy, S.F. In vivo protein 
transduction: delivery of a biologically active protein into the mouse. Science 285, 
1569-1572 (1999). 
62. McCormick, F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 1, 
130-141 (2001). 
63. Hupp, T.R., Sparks, A. & Lane, D.P. Small peptides activate the latent sequence-
specific DNA binding function of p53. Cell 83, 237-245 (1995). 
64. Snyder, E.L., Meade, B.R., Saenz, C.C. & Dowdy, S.F. Treatment of terminal 
peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2, 
E36 (2004). 
65. Michl, J. et al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, 
blocks pancreatic cancer cell growth in vivo. Int J Cancer 119, 1577-1585 (2006). 
248 
 
66. Hosotani, R. et al. Trojan p16 peptide suppresses pancreatic cancer growth and 
prolongs survival in mice. Clin Cancer Res 8, 1271-1276 (2002). 
67. Araki, D. et al. Cell-penetrating D-isomer peptides of p53 C-terminus: long-term 
inhibitory effect on the growth of bladder cancer. Urology 75, 813-819 (2010). 
68. Perea, S.E. et al. Antitumor Effect of a Novel Proapoptotic Peptide that Impairs 
the Phosphorylation by the Protein Kinase 2 (Casein Kinase 2). Cancer Research 
64, 7127 (2004). 
69. Jo, D., Liu, D., Yao, S., Collins, R.D. & Hawiger, J. Intracellular protein therapy 
with SOCS3 inhibits inflammation and apoptosis. Nat Med 11, 892-898 (2005). 
70. Graham, S.H., Chen, J. & Clark, R.S. Bcl-2 family gene products in cerebral 
ischemia and traumatic brain injury. J Neurotrauma 17, 831-841 (2000). 
71. Rizzuti, M., Nizzardo, M., Zanetta, C., Ramirez, A. & Corti, S. Therapeutic 
applications of the cell-penetrating HIV-1 Tat peptide. Drug Discov Today 20, 76-
85 (2015). 
72. Puri, V. et al. Cholesterol modulates membrane traffic along the endocytic 
pathway in sphingolipid-storage diseases. Nat Cell Biol 1, 386-388 (1999). 
73. Hirose, H. et al. Transient Focal Membrane Deformation Induced by Arginine-rich 
Peptides Leads to Their Direct Penetration into Cells. Molecular Therapy 20, 984-
993 (2012). 
74. Jiang, T. et al. Tumor imaging by means of proteolytic activation of cell-
penetrating peptides. Proceedings of the National Academy of Sciences of the 
United States of America 101, 17867-17872 (2004). 
75. Derossi, D. et al. Cell internalization of the third helix of the Antennapedia 
homeodomain is receptor-independent. J Biol Chem 271, 18188-18193 (1996). 
76. Lundin, P. et al. Distinct uptake routes of cell-penetrating peptide conjugates. 
Bioconjug Chem 19, 2535-2542 (2008). 
77. Jones, A.T. & Sayers, E.J. Cell entry of cell penetrating peptides: tales of tails 
wagging dogs. J Control Release 161, 582-591 (2012). 
78. Trehin, R., Krauss, U., Beck-Sickinger, A.G., Merkle, H.P. & Nielsen, H.M. 
Cellular uptake but low permeation of human calcitonin-derived cell penetrating 
peptides and Tat(47-57) through well-differentiated epithelial models. Pharm Res 
21, 1248-1256 (2004). 
249 
 
79. Foerg, C., Ziegler, U., Fernandez-Carneado, J., Giralt, E. & Merkle, H.P. 
Differentiation restricted endocytosis of cell penetrating peptides in MDCK cells 
corresponds with activities of Rho-GTPases. Pharm Res 24, 628-642 (2007). 
80. Barany-Wallje, E., Gaur, J., Lundberg, P., Langel, U. & Graslund, A. Differential 
membrane perturbation caused by the cell penetrating peptide Tp10 depending on 
attached cargo. FEBS Lett 581, 2389-2393 (2007). 
81. Tunnemann, G. et al. Cargo-dependent mode of uptake and bioavailability of TAT-
containing proteins and peptides in living cells. FASEB J 20, 1775-1784 (2006). 
82. Fischer, R., Waizenegger, T., Köhler, K. & Brock, R. A quantitative validation of 
fluorophore-labelled cell-permeable peptide conjugates: fluorophore and cargo 
dependence of import. Biochimica et Biophysica Acta (BBA) - Biomembranes 
1564, 365-374 (2002). 
83. Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R. & Brock, R. A 
comprehensive model for the cellular uptake of cationic cell-penetrating peptides. 
Traffic 8, 848-866 (2007). 
84. Ter-Avetisyan, G. et al. Cell Entry of Arginine-rich Peptides Is Independent of 
Endocytosis. Journal of Biological Chemistry 284, 3370-3378 (2009). 
85. Magzoub, M., Gr, auml & slund, A. Cell-penetrating peptides: small from 
inception to application. Quarterly Reviews of Biophysics 37, 147-195 (2004). 
86. Berlose, J.P., Convert, O., Derossi, D., Brunissen, A. & Chassaing, G. 
Conformational and associative behaviours of the third helix of antennapedia 
homeodomain in membrane-mimetic environments. Eur J Biochem 242, 372-386 
(1996). 
87. Pouny, Y., Rapaport, D., Mor, A., Nicolas, P. & Shai, Y. Interaction of 
antimicrobial dermaseptin and its fluorescently labeled analogues with 
phospholipid membranes. Biochemistry 31, 12416-12423 (1992). 
88. Lee, M.T., Hung, W.C., Chen, F.Y. & Huang, H.W. Many-body effect of 
antimicrobial peptides: On the correlation between lipid's spontaneous curvature 
and pore formation. Biophysical Journal 89, 4006-4016 (2005). 
89. Sun, D., Forsman, J., Lund, M. & Woodward, C.E. Effect of arginine-rich cell 
penetrating peptides on membrane pore formation and life-times: a molecular 
simulation study. Physical Chemistry Chemical Physics 16, 20785-20795 (2014). 
90. Conner, S.D. & Schmid, S.L. Regulated portals of entry into the cell. Nature 422, 
37-44 (2003). 
250 
 
91. Mayor, S. & Pagano, R.E. Pathways of clathrin-independent endocytosis. Nat Rev 
Mol Cell Biol 8, 603-612 (2007). 
92. Fischer, R., Fotin-Mleczek, M., Hufnagel, H. & Brock, R. Break on through to the 
other side-biophysics and cell biology shed light on cell-penetrating peptides. 
Chembiochem 6, 2126-2142 (2005). 
93. Doherty, G.J. & McMahon, H.T. Mechanisms of endocytosis. Annu Rev Biochem 
78, 857-902 (2009). 
94. Plapied, L., Duhem, N., des Rieux, A. & Preat, V. Fate of polymeric nanocarriers 
for oral drug delivery. Curr Opin Colloid In 16, 228-237 (2011). 
95. Sakai, N. & Matile, S. Anion-mediated transfer of polyarginine across liquid and 
bilayer membranes. J Am Chem Soc 125, 14348-14356 (2003). 
96. Nakase, I., Takeuchi, T., Tanaka, G. & Futaki, S. Methodological and cellular 
aspects that govern the internalization mechanisms of arginine-rich cell-
penetrating peptides. Adv Drug Deliv Rev 60, 598-607 (2008). 
97. Favretto, M.E., Wallbrecher, R., Schmidt, S., van de Putte, R. & Brock, R. 
Glycosaminoglycans in the cellular uptake of drug delivery vectors - bystanders or 
active players? J Control Release 180, 81-90 (2014). 
98. Tumova, S., Woods, A. & Couchman, J.R. Heparan Sulfate Chains from Glypican 
and Syndecans Bind the Hep II Domain of Fibronectin Similarly Despite Minor 
Structural Differences. Journal of Biological Chemistry 275, 9410-9417 (2000). 
99. Richard, J.P. et al. Cellular uptake of unconjugated TAT peptide involves clathrin-
dependent endocytosis and heparan sulfate receptors. J Biol Chem 280, 15300-
15306 (2005). 
100. Futaki, S., Nakase, I., Tadokoro, A., Takeuchi, T. & Jones, A.T. Arginine-rich 
peptides and their internalization mechanisms. Biochem Soc Trans 35, 784-787 
(2007). 
101. Suzuki, T. et al. Possible existence of common internalization mechanisms among 
arginine-rich peptides. J Biol Chem 277, 2437-2443 (2002). 
102. Ziegler, A. & Seelig, J. Binding and clustering of glycosaminoglycans: a common 
property of mono- and multivalent cell-penetrating compounds. Biophys J 94, 
2142-2149 (2008). 
103. Fuchs, S.M. & Raines, R.T. Pathway for polyarginine entry into mammalian cells. 
Biochemistry 43, 2438-2444 (2004). 
251 
 
104. Nakase, I. et al. Interaction of Arginine-Rich Peptides with Membrane-Associated 
Proteoglycans Is Crucial for Induction of Actin Organization and 
Macropinocytosis†. Biochemistry 46, 492-501 (2006). 
105. Kawaguchi, Y. et al. Syndecan-4 Is a Receptor for Clathrin-Mediated Endocytosis 
of Arginine-Rich Cell-Penetrating Peptides. Bioconjugate Chemistry 27, 1119-
1130 (2016). 
106. Fuki, I.V., Iozzo, R.V. & Williams, K.J. Perlecan Heparan Sulfate Proteoglycan: 
A NOVEL RECEPTOR THAT MEDIATES A DISTINCT PATHWAY FOR 
LIGAND CATABOLISM. Journal of Biological Chemistry 275, 25742-25750 
(2000). 
107. Argyris, E.G. et al. The perlecan heparan sulfate proteoglycan mediates cellular 
uptake of HIV-1 Tat through a pathway responsible for biological activity. 
Virology 330, 481-486 (2004). 
108. Lambaerts, K., Wilcox-Adelman, S.A. & Zimmermann, P. The signaling 
mechanisms of syndecan heparan sulfate proteoglycans. Current Opinion in Cell 
Biology 21, 662-669 (2009). 
109. Beckett, K., Franch-Marro, X. & Vincent, J.-P. Glypican-mediated endocytosis of 
Hedgehog has opposite effects in flies and mice. Trends in Cell Biology 18, 360-
363 (2008). 
110. Madani, F. et al. Mechanisms of Cellular Uptake of Cell-Penetrating Peptides. 
Journal of Biophysics 2011 (2011). 
111. Kaplan, I.M., Wadia, J.S. & Dowdy, S.F. Cationic TAT peptide transduction 
domain enters cells by macropinocytosis. J Control Release 102, 247-253 (2005). 
112. Nakase, I. et al. Cellular uptake of arginine-rich peptides: roles for 
macropinocytosis and actin rearrangement. Mol Ther 10, 1011-1022 (2004). 
113. Fotin-Mleczek, M. et al. Cationic cell-penetrating peptides interfere with TNF 
signalling by induction of TNF receptor internalization. J Cell Sci 118, 3339-3351 
(2005). 
114. Erazo-Oliveras, A., Muthukrishnan, N., Baker, R., Wang, T.Y. & Pellois, J.P. 
Improving the endosomal escape of cell-penetrating peptides and their cargos: 
strategies and challenges. Pharmaceuticals (Basel) 5, 1177-1209 (2012). 
115. Wadia, J.S., Stan, R.V. & Dowdy, S.F. Transducible TAT-HA fusogenic peptide 
enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 
10, 310-315 (2004). 
252 
 
116. Fittipaldi, A. et al. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-
1 Tat fusion proteins. J Biol Chem 278, 34141-34149 (2003). 
117. Gump, J.M., June, R.K. & Dowdy, S.F. Revised Role of Glycosaminoglycans in 
TAT Protein Transduction Domain-mediated Cellular Transduction. Journal of 
Biological Chemistry 285, 1500-1507 (2010). 
118. Swanson, J.A. & Watts, C. Macropinocytosis. Trends in Cell Biology 5, 424-428 
(1995). 
119. Meier, O. et al. Adenovirus triggers macropinocytosis and endosomal leakage 
together with its clathrin-mediated uptake. The Journal of Cell Biology 158, 1119 
(2002). 
120. Mishra, A. et al. Translocation of HIV TAT peptide and analogues induced by 
multiplexed membrane and cytoskeletal interactions. Proceedings of the National 
Academy of Sciences 108, 16883-16888 (2011). 
121. Swanson, J.A. Shaping cups into phagosomes and macropinosomes. Nat Rev Mol 
Cell Biol 9, 639-649 (2008). 
122. Stoorvogel, W., Oorschot, V. & Geuze, H.J. A novel class of clathrin-coated 
vesicles budding from endosomes. The Journal of Cell Biology 132, 21-33 (1996). 
123. Fridolfsson, H.N., Roth, D.M., Insel, P.A. & Patel, H.H. Regulation of intracellular 
signaling and function by caveolin. The FASEB Journal 28, 3823-3831 (2014). 
124. Gruenberg, J., Griffiths, G. & Howell, K.E. Characterization of the early endosome 
and putative endocytic carrier vesicles in vivo and with an assay of vesicle fusion 
in vitro. J Cell Biol 108, 1301-1316 (1989). 
125. Gruenberg, J. The endocytic pathway: a mosaic of domains. Nat Rev Mol Cell Biol 
2, 721-730 (2001). 
126. Stenmark, H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell 
Biol 10, 513-525 (2009). 
127. Griffiths, G., Hoflack, B., Simons, K., Mellman, I. & Kornfeld, S. The mannose 
6-phosphate receptor and the biogenesis of lysosomes. Cell 52, 329-341 (1988). 
128. Kobayashi, T. et al. A lipid associated with the antiphospholipid syndrome 
regulates endosome structure and function. Nature 392, 193-197 (1998). 
129. Matsuo, H. et al. Role of LBPA and Alix in multivesicular liposome formation and 
endosome organization. Science 303, 531-534 (2004). 
253 
 
130. Roth, S.L. & Whittaker, G.R. Promotion of vesicular stomatitis virus fusion by the 
endosome-specific phospholipid bis(monoacylglycero)phosphate (BMP). FEBS 
Letters 585, 865-869 (2011). 
131. Le Blanc, I. et al. Endosome-to-cytosol transport of viral nucleocapsids. Nat Cell 
Biol 7, 653-664 (2005). 
132. Yang, S.-T., Zaitseva, E., Chernomordik, L.V. & Melikov, K. Cell-Penetrating 
Peptide Induces Leaky Fusion of Liposomes Containing Late Endosome-Specific 
Anionic Lipid. Biophysical Journal 99, 2525-2533 (2010). 
133. Xu, H. & Ren, D. Lysosomal Physiology. Annual review of physiology 77, 57-80 
(2015). 
134. Lee, Y.J., Datta, S. & Pellois, J.P. Real-time fluorescence detection of protein 
transduction into live cells. J Am Chem Soc 130, 2398-2399 (2008). 
135. Gillmeister, M.P., Betenbaugh, M.J. & Fishman, P.S. Cellular Trafficking and 
Photochemical Internalization of Cell Penetrating Peptide Linked Cargo Proteins: 
A Dual Fluorescent Labeling Study. Bioconjug Chem 22, 556-566 (2011). 
136. Appelbaum, Jacob S. et al. Arginine Topology Controls Escape of Minimally 
Cationic Proteins from Early Endosomes to the Cytoplasm. Chemistry & Biology 
19, 819-830 (2012). 
137. Burlina, F., Sagan, S., Bolbach, G. & Chassaing, G. A direct approach to 
quantification of the cellular uptake of cell-penetrating peptides using MALDI-
TOF mass spectrometry. Nat. Protocols 1, 200-205 (2006). 
138. Paramelle, D. et al. A Straightforward Approach for Cellular-Uptake 
Quantification. Angewandte Chemie International Edition 49, 8240-8243 (2010). 
139. Loison, F. et al. A ubiquitin-based assay for the cytosolic uptake of protein 
transduction domains. Mol Ther 11, 205-214 (2005). 
140. Falnes, P.Ø., Wesche, J. & Olsnes, S. Ability of the Tat Basic Domain and VP22 
To Mediate Cell Binding, but Not Membrane Translocation of the Diphtheria 
Toxin A-Fragment. Biochemistry 40, 4349-4358 (2001). 
141. Thorén, P.E.G. et al. Membrane Binding and Translocation of Cell-Penetrating 
Peptides†. Biochemistry 43, 3471-3489 (2004). 
142. Tiriveedhi, V. & Butko, P. A Fluorescence Spectroscopy Study on the Interactions 
of the TAT-PTD Peptide with Model Lipid Membranes. Biochemistry 46, 3888-
3895 (2007). 
254 
 
143. Ruzza, P., Biondi, B., Marchiani, A., Antolini, N. & Calderan, A. Cell-Penetrating 
Peptides: A Comparative Study on Lipid Affinity and Cargo Delivery Properties. 
Pharmaceuticals 3, 1045-1062 (2010). 
144. Lee, Y.-J., Johnson, G. & Pellois, J.-P. Modeling of the Endosomolytic Activity of 
HA2-TAT Peptides with Red Blood Cells and Ghosts. Biochemistry 49, 7854-
7866 (2010). 
145. Leventis, P.A. & Grinstein, S. The Distribution and Function of 
Phosphatidylserine in Cellular Membranes. Annual Review of Biophysics 39, 407-
427 (2010). 
146. Cahill, K.E. Molecular Electroporation and the Transduction of Oligoarginines. 
Biophysical Journal 98, 83a. 
147. Tünnemann, G. et al. Live-cell analysis of cell penetration ability and toxicity of 
oligo-arginines. Journal of Peptide Science 14, 469-476 (2008). 
148. El-Sayed, A., Futaki, S. & Harashima, H. Delivery of Macromolecules Using 
Arginine-Rich Cell-Penetrating Peptides: Ways to Overcome Endosomal 
Entrapment. The AAPS Journal 11, 13-22 (2009). 
149. Lönn, P. et al. Enhancing Endosomal Escape for Intracellular Delivery of 
Macromolecular Biologic Therapeutics. Scientific Reports 6, 32301 (2016). 
150. Erbacher, P., Roche, A.C., Monsigny, M. & Midoux, P. Putative Role of 
Chloroquine in Gene Transfer into a Human Hepatoma Cell Line by 
DNA/Lactosylated Polylysine Complexes. Experimental Cell Research 225, 186-
194 (1996). 
151. Ciftci, K. & Levy, R.J. Enhanced plasmid DNA transfection with lysosomotropic 
agents in cultured fibroblasts. Int J Pharm 218, 81-92 (2001). 
152. Caron, N.J., Quenneville, S.P. & Tremblay, J.P. Endosome disruption enhances 
the functional nuclear delivery of Tat-fusion proteins. Biochem Biophys Res 
Commun 319, 12-20 (2004). 
153. Shiraishi, T. & Nielsen, P.E. Enhanced delivery of cell-penetrating peptide-peptide 
nucleic acid conjugates by endosomal disruption. Nat Protoc 1, 633-636 (2006). 
154. Forgac, M. Vacuolar ATPases: rotary proton pumps in physiology and 
pathophysiology. Nat Rev Mol Cell Biol 8, 917-929 (2007). 
255 
 
155. Wharton, S.A., Martin, S.R., Ruigrok, R.W., Skehel, J.J. & Wiley, D.C. Membrane 
fusion by peptide analogues of influenza virus haemagglutinin. J Gen Virol 69 ( 
Pt 8), 1847-1857 (1988). 
156. Michiue, H. et al. The NH2 terminus of influenza virus hemagglutinin-2 subunit 
peptides enhances the antitumor potency of polyarginine-mediated p53 protein 
transduction. J Biol Chem 280, 8285-8289 (2005). 
157. Erazo-Oliveras, A. et al. Protein delivery into live cells by incubation with an 
endosomolytic agent. Nat Meth 11, 861-867 (2014). 
158. Cabantous, S., Terwilliger, T.C. & Waldo, G.S. Protein tagging and detection with 
engineered self-assembling fragments of green fluorescent protein. Nat Biotechnol 
23, 102-107 (2005). 
159. Cabantous, S. & Waldo, G.S. In vivo and in vitro protein solubility assays using 
split GFP. Nat Methods 3, 845-854 (2006). 
160. Maiolo, J.R., Ottinger, E.A. & Ferrer, M. Specific Redistribution of Cell-
Penetrating Peptides from Endosomes to the Cytoplasm and Nucleus upon Laser 
Illumination. Journal of the American Chemical Society 126, 15376-15377 (2004). 
161. Matsushita, M. et al. Photo-acceleration of protein release from endosome in the 
protein transduction system. FEBS Letters 572, 221-226 (2004). 
162. Srinivasan, D. et al. Conjugation to the cell-penetrating peptide TAT potentiates 
the photodynamic effect of carboxytetramethylrhodamine. PLoS One 6, e17732 
(2011). 
163. Muthukrishnan, N., Johnson, G.A., Erazo-Oliveras, A. & Pellois, J.P. Synergy 
Between Cell-Penetrating Peptides and Singlet Oxygen Generators Leads to 
Efficient Photolysis of Membranes. Photochemistry and photobiology (2012). 
164. Choi, Y., McCarthy, J.R., Weissleder, R. & Tung, C.-H. Conjugation of a 
Photosensitizer to an Oligoarginine-Based Cell-Penetrating Peptide Increases the 
Efficacy of Photodynamic Therapy. ChemMedChem 1, 458-463 (2006). 
165. Endoh, T., Sisido, M. & Ohtsuki, T. Spatial regulation of specific gene expression 
through photoactivation of RNAi. Journal of Controlled Release 137, 241-245 
(2009). 
166. Lee, Y.C. et al. Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc 
lectin. Dependence on fine structural features. Journal of Biological Chemistry 
258, 199-202 (1983). 
256 
 
167. Mammen, M., Choi, S.-K. & Whitesides, G.M. Polyvalent Interactions in 
Biological Systems: Implications for Design and Use of Multivalent Ligands and 
Inhibitors. Angewandte Chemie International Edition 37, 2754-2794 (1998). 
168. Kiessling, L.L., Gestwicki, J.E. & Strong, L.E. Synthetic multivalent ligands in the 
exploration of cell-surface interactions. Current Opinion in Chemical Biology 4, 
696-703 (2000). 
169. Sung, M., Poon, G.M. & Gariepy, J. The importance of valency in enhancing the 
import and cell routing potential of protein transduction domain-containing 
molecules. Biochim Biophys Acta 1758, 355-363 (2006). 
170. Torchilin, V.P., Rammohan, R., Weissig, V. & Levchenko, T.S. TAT peptide on 
the surface of liposomes affords their efficient intracellular delivery even at low 
temperature and in the presence of metabolic inhibitors. Proceedings of the 
National Academy of Sciences 98, 8786-8791 (2001). 
171. Torchilin, V.P. TAT peptide-modified liposomes for intracellular delivery of drugs 
and DNA. Cell Mol Biol Lett 7, 265-267 (2002). 
172. Torchilin, V.P. et al. Cell transfection in vitro and in vivo with nontoxic TAT 
peptide-liposome-DNA complexes. Proc Natl Acad Sci U S A 100, 1972-1977 
(2003). 
173. Tseng, Y.L., Liu, J.J. & Hong, R.L. Translocation of liposomes into cancer cells 
by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol 
Pharmacol 62, 864-872 (2002). 
174. Zhao, M., Kircher, M.F., Josephson, L. & Weissleder, R. Differential conjugation 
of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. 
Bioconjug Chem 13, 840-844 (2002). 
175. Koch, A.M., Reynolds, F., Merkle, H.P., Weissleder, R. & Josephson, L. Transport 
of surface-modified nanoparticles through cell monolayers. Chembiochem 6, 337-
345 (2005). 
176. Lewin, M. et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo 
tracking and recovery of progenitor cells. Nat Biotechnol 18, 410-414 (2000). 
177. Kircher, M.F. et al. In vivo high resolution three-dimensional imaging of antigen-
specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 63, 6838-6846 
(2003). 
178. Phelan, A., Elliott, G. & O'Hare, P. Intercellular delivery of functional p53 by the 
herpesvirus protein VP22. Nat Biotechnol 16, 440-443 (1998). 
257 
 
179. Johnson, C.R., Morin, P.E., Arrowsmith, C.H. & Freire, E. Thermodynamic 
analysis of the structural stability of the tetrameric oligomerization domain of p53 
tumor suppressor. Biochemistry 34, 5309-5316 (1995). 
180. Lee, W. et al. Solution structure of the tetrameric minimum transforming domain 
of p53. Nat Struct Biol 1, 877-890 (1994). 
181. Kawamura, K.S., Sung, M., Bolewska-Pedyczak, E. & Gariepy, J. Probing the 
impact of valency on the routing of arginine-rich peptides into eukaryotic cells. 
Biochemistry 45, 1116-1127 (2006). 
182. Wang, J. et al. Grb10, a positive, stimulatory signaling adapter in platelet-derived 
growth factor BB-, insulin-like growth factor I-, and insulin-mediated mitogenesis. 
Mol Cell Biol 19, 6217-6228 (1999). 
183. Chen, M., Won, D.J., Krajewski, S. & Gottlieb, R.A. Calpain and mitochondria in 
ischemia/reperfusion injury. J Biol Chem 277, 29181-29186 (2002). 
184. Kang, H., DeLong, R., Fisher, M.H. & Juliano, R.L. Tat-Conjugated PAMAM 
Dendrimers as Delivery Agents for Antisense and siRNA Oligonucleotides. 
Pharmaceutical Research 22, 2099-2106 (2005). 
185. Juliano, R.L. Intracellular delivery of oligonucleotide conjugates and dendrimer 
complexes. Ann N Y Acad Sci 1082, 18-26 (2006). 
186. Pantos, A., Tsiourvas, D., Nounesis, G. & Paleos, C.M. Interaction of functional 
dendrimers with multilamellar liposomes: design of a model system for studying 
drug delivery. Langmuir 21, 7483-7490 (2005). 
187. Kim, J.B. et al. Enhanced transfection of primary cortical cultures using arginine-
grafted PAMAM dendrimer, PAMAM-Arg. J Control Release 114, 110-117 
(2006). 
188. Medina, S.H. & El-Sayed, M.E. Dendrimers as carriers for delivery of 
chemotherapeutic agents. Chem Rev 109, 3141-3157 (2009). 
189. Sheldon, K., Liu, D., Ferguson, J. & Gariepy, J. Loligomers: design of de novo 
peptide-based intracellular vehicles. Proc Natl Acad Sci U S A 92, 2056-2060 
(1995). 
190. Singh, D., Kiarash, R., Kawamura, K., LaCasse, E.C. & Gariepy, J. Penetration 
and intracellular routing of nucleus-directed peptide-based shuttles (loligomers) in 
eukaryotic cells. Biochemistry 37, 5798-5809 (1998). 
258 
 
191. Kawamura, K.S. et al. In vivo generation of cytotoxic T cells from epitopes 
displayed on peptide-based delivery vehicles. J Immunol 168, 5709-5715 (2002). 
192. Singh, D., Bisland, S.K., Kawamura, K. & Gariepy, J. Peptide-based intracellular 
shuttle able to facilitate gene transfer in mammalian cells. Bioconjug Chem 10, 
745-754 (1999). 
193. Dawson, P.E., Muir, T.W., Clark-Lewis, I. & Kent, S.B. Synthesis of proteins by 
native chemical ligation. Science 266, 776 (1994). 
194. Angeles-Boza, A.M., Erazo-Oliveras, A., Lee, Y.J. & Pellois, J.P. Generation of 
endosomolytic reagents by branching of cell-penetrating peptides: tools for the 
delivery of bioactive compounds to live cells in cis or trans. Bioconjug Chem 21, 
2164-2167 (2010). 
195. Rudolph, C. et al. Application of novel solid lipid nanoparticle (SLN)-gene vector 
formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm 
Res 21, 1662-1669 (2004). 
196. Lee, S.J., Yoon, S.H. & Doh, K.O. Enhancement of gene delivery using novel 
homodimeric tat peptide formed by disulfide bond. J Microbiol Biotechnol 21, 
802-807 (2011). 
197. Elmquist, A. & Langel, U. In vitro uptake and stability study of pVEC and its all-
D analog. Biol Chem 384, 387-393 (2003). 
198. Purkayastha, N. et al. Enantiomeric and diastereoisomeric (mixed) L/ D-
octaarginine derivatives - a simple way of modulating the properties of cell-
penetrating peptides. Chem Biodivers 10, 1165-1184 (2013). 
199. Verdurmen, W.P. et al. Preferential uptake of L- versus D-amino acid cell-
penetrating peptides in a cell type-dependent manner. Chem Biol 18, 1000-1010 
(2011). 
200. Khafagy, E.-S. et al. Efficiency of cell-penetrating peptides on the nasal and 
intestinal absorption of therapeutic peptides and proteins. International Journal of 
Pharmaceutics 381, 49-55 (2009). 
201. Rennert, R., Wespe, C., Beck-Sickinger, A.G. & Neundorf, I. Developing novel 
hCT derived cell-penetrating peptides with improved metabolic stability. 
Biochimica et Biophysica Acta (BBA) - Biomembranes 1758, 347-354 (2006). 
202. Chorev, M. & Goodman, M. Recent developments in retro peptides and proteins-
-an ongoing topochemical exploration. Trends Biotechnol 13, 438-445 (1995). 
259 
 
203. Chorev, M. The partial retro-inverso modification: a road traveled together. 
Biopolymers 80, 67-84 (2005). 
204. Fischer, P.M. The design, synthesis and application of stereochemical and 
directional peptide isomers: a critical review. Curr Protein Pept Sci 4, 339-356 
(2003). 
205. Li, C. et al. Limitations of peptide retro-inverso isomerization in molecular 
mimicry. J Biol Chem 285, 19572-19581 (2010). 
206. Brugidou, J., Legrand, C., Mery, J. & Rabie, A. The retro-inverso form of a 
homeobox-derived short peptide is rapidly internalised by cultured neurones: a 
new basis for an efficient intracellular delivery system. Biochem Biophys Res 
Commun 214, 685-693 (1995). 
207. Lyu, P.C., Sherman, J.C., Chen, A. & Kallenbach, N.R. Alpha-helix stabilization 
by natural and unnatural amino acids with alkyl side chains. Proc Natl Acad Sci U 
S A 88, 5317-5320 (1991). 
208. Jones, S. & Howl, J. Charge delocalisation and the design of novel mastoparan 
analogues: enhanced cytotoxicity and secretory efficacy of [Lys5, Lys8, 
Aib10]MP. Regul Pept 121, 121-128 (2004). 
209. Chen, F., Ma, B., Yang, Z.C., Lin, G. & Yang, D. Extraordinary metabolic stability 
of peptides containing alpha-aminoxy acids. Amino Acids 43, 499-503 (2012). 
210. Ma, Y., Yang, D., Ma, Y. & Zhang, Y.H. Novel cell-penetrating peptides based on 
alpha-aminoxy acids. Chembiochem 13, 73-79 (2012). 
211. Potocky, T.B., Menon, A.K. & Gellman, S.H. Effects of conformational stability 
and geometry of guanidinium display on cell entry by beta-peptides. J Am Chem 
Soc 127, 3686-3687 (2005). 
212. Youngblood, D.S., Hatlevig, S.A., Hassinger, J.N., Iversen, P.L. & Moulton, H.M. 
Stability of cell-penetrating peptide-morpholino oligomer conjugates in human 
serum and in cells. Bioconjug Chem 18, 50-60 (2007). 
213. Foged, C. et al. Cellular uptake and membrane-destabilising properties of alpha-
peptide/beta-peptoid chimeras: lessons for the design of new cell-penetrating 
peptides. Biochim Biophys Acta 1778, 2487-2495 (2008). 
214. Jing, X. et al. Membrane adsorption and binding, cellular uptake and cytotoxicity 
of cell-penetrating peptidomimetics with alpha-peptide/beta-peptoid backbone: 
effects of hydrogen bonding and alpha-chirality in the beta-peptoid residues. 
Biochim Biophys Acta 1818, 2660-2668 (2012). 
260 
 
215. Farrera-Sinfreu, J., Giralt, E., Castel, S., Albericio, F. & Royo, M. Cell-penetrating 
cis-gamma-amino-l-proline-derived peptides. J Am Chem Soc 127, 9459-9468 
(2005). 
216. Lattig-Tunnemann, G. et al. Backbone rigidity and static presentation of 
guanidinium groups increases cellular uptake of arginine-rich cell-penetrating 
peptides. Nat Commun 2, 453 (2011). 
217. Rothbard, J.B. et al. Arginine-rich molecular transporters for drug delivery: role of 
backbone spacing in cellular uptake. J Med Chem 45, 3612-3618 (2002). 
218. Qian, Z. et al. Early endosomal escape of a cyclic cell-penetrating peptide allows 
effective cytosolic cargo delivery. Biochemistry 53, 4034-4046 (2014). 
219. Lian, W., Jiang, B., Qian, Z. & Pei, D. Cell-permeable bicyclic peptide inhibitors 
against intracellular proteins. J Am Chem Soc 136, 9830-9833 (2014). 
220. Craik, D.J., Swedberg, J.E., Mylne, J.S. & Cemazar, M. Cyclotides as a basis for 
drug design. Expert Opin Drug Discov 7, 179-194 (2012). 
221. Gould, A., Ji, Y., Aboye, T.L. & Camarero, J.A. Cyclotides, a novel ultrastable 
polypeptide scaffold for drug discovery. Current Pharmaceutical Design 17, 
4294-4307 (2011). 
222. Fominaya, J., Bravo, J. & Rebollo, A. Strategies to stabilize cell penetrating 
peptides for in vivo applications. Ther Deliv 6, 1171-1194 (2015). 
223. Holm, T. et al. Retro-inversion of certain cell-penetrating peptides causes severe 
cellular toxicity. Biochim Biophys Acta 1808, 1544-1551 (2011). 
224. Najjar, K., Erazo-Oliveras, A. & Pellois, J.-P. Delivery of Proteins, Peptides or 
Cell-impermeable Small Molecules into Live Cells by Incubation with the 
Endosomolytic Reagent dfTAT. e53175 (2015). 
225. Hussain, A.F. et al. Targeted Delivery of Dendritic Polyglycerol–Doxorubicin 
Conjugates by scFv-SNAP Fusion Protein Suppresses EGFR+ Cancer Cell 
Growth. Biomacromolecules 14, 2510-2520 (2013). 
226. Takeuchi, T. et al. Direct and Rapid Cytosolic Delivery Using Cell-Penetrating 
Peptides Mediated by Pyrenebutyrate. ACS Chemical Biology 1, 299-303 (2006). 
227. Sakakibara, D. et al. Protein structure determination in living cells by in-cell NMR 
spectroscopy. Nature 458, 102-105 (2009). 
228. Schwarze, S.R., Hruska, K.A. & Dowdy, S.F. Protein transduction: unrestricted 
delivery into all cells? Trends in Cell Biology 10, 290-295 (2000). 
261 
 
229. Dietz, G.P.H. & Bδhr, M. Delivery of bioactive molecules into the cell: the Trojan 
horse approach. Molecular and Cellular Neuroscience 27, 85-131 (2004). 
230. Pan, C., Lu, B., Chen, H. & Bishop, C. Reprogramming human fibroblasts using 
HIV-1 TAT recombinant proteins OCT4, SOX2, KLF4 and c-MYC. Molecular 
Biology Reports 37, 2117-2124 (2010). 
231. Gratton, J. et al. Cell-permeable peptides improve cellular uptake and therapeutic 
gene delivery of replication-deficient viruses in cells and in vivo. Nat Med 9, 357 
- 362 (2003). 
232. Massignani, M. et al. Enhanced Fluorescence Imaging of Live Cells by Effective 
Cytosolic Delivery of Probes. PLoS One 5, e10459 (2010). 
233. Erazo-Oliveras, A., Muthukrishnan, N., Baker, R., Wang, T.Y. & Pellois, J.P. 
Improving the Endosomal Escape of Cell-Penetrating Peptides and Their Cargos: 
Strategies and Challenges. Pharmaceuticals 5, 1177-1209 (2012). 
234. Hoyer, J., Schatzschneider, U., Schulz-Siegmund, M. & Neundorf, I. Dimerization 
of a cell-penetrating peptide leads to enhanced cellular uptake and drug delivery. 
Beilstein Journal of Organic Chemistry 8, 1788-1797 (2012). 
235. Eguchi, A. et al. Efficient siRNA delivery into primary cells by a peptide 
transduction domain-dsRNA binding domain fusion protein. Nat Biotech 27, 567-
571 (2009). 
236. Austin, C.D. et al. Oxidizing potential of endosomes and lysosomes limits 
intracellular cleavage of disulfide-based antibody–drug conjugates. Proceedings 
of the National Academy of Sciences of the United States of America 102, 17987-
17992 (2005). 
237. Dominska, M. & Dykxhoorn, D.M. Breaking down the barriers: siRNA delivery 
and endosome escape. Journal of Cell Science 123, 1183-1189 (2010). 
238. Koivusalo, M. et al. Amiloride inhibits macropinocytosis by lowering 
submembranous pH and preventing Rac1 and Cdc42 signaling. The Journal of Cell 
Biology 188, 547-563 (2010). 
239. Johnson, L.S., Dunn, K.W., Pytowski, B. & McGraw, T.E. Endosome acidification 
and receptor trafficking: bafilomycin A1 slows receptor externalization by a 
mechanism involving the receptor's internalization motif. Molecular Biology of the 
Cell 4, 1251-1266 (1993). 
240. Vercauteren, D. et al. The Use of Inhibitors to Study Endocytic Pathways of Gene 
Carriers: Optimization and Pitfalls. Mol Ther 18, 561-569 (2010). 
262 
 
241. Rejman, J., Bragonzi, A. & Conese, M. Role of Clathrin- and Caveolae-Mediated 
Endocytosis in Gene Transfer Mediated by Lipo- and Polyplexes. Mol Ther 12, 
468-474 (2005). 
242. Sun, X. et al. Development of SNAP-Tag Fluorogenic Probes for Wash-Free 
Fluorescence Imaging. Chembiochem 12, 2217-2226 (2011). 
243. Johnson, J.R., Kocher, B., Barnett, E.M., Marasa, J. & Piwnica-Worms, D. 
Caspase-Activated Cell-Penetrating Peptides Reveal Temporal Coupling Between 
Endosomal Release and Apoptosis in an RGC-5 Cell Model. Bioconjug Chem 23, 
1783-1793 (2012). 
244. Wadia, J.S., Stan, R.V. & Dowdy, S.F. Transducible TAT-HA fusogenic peptide 
enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 
10, 310-315 (2004). 
245. Csaszar, E. et al. An automated system for delivery of an unstable transcription 
factor to hematopoietic stem cell cultures. Biotechnol Bioeng 103, 402-412 (2009). 
246. Amsellem, S. et al. Ex vivo expansion of human hematopoietic stem cells by direct 
delivery of the HOXB4 homeoprotein. Nat Med 9, 1423-1427 (2003). 
247. Krosl, J. et al. In vitro expansion of hematopoietic stem cells by recombinant TAT-
HOXB4 protein. Nat Med 9, 1428-1432 (2003). 
248. Will, E. et al. HOXB4 Inhibits Cell Growth in a Dose-Dependent Manner and 
Sensitizes Cells Towards Extrinsic Cues. Cell cycle 5, 14-22 (2006). 
249. Muthukrishnan, N., Johnson, G.A., Lim, J., Simanek, E.E. & Pellois, J.P. TAT-
mediated photochemical internalization results in cell killing by causing the release 
of calcium into the cytosol of cells. Biochim Biophys Acta 1820, 1734-1743 
(2012). 
250. Marino, J. et al. Lysosomal and mitochondrial permeabilization mediates zinc(II) 
cationic phthalocyanine phototoxicity. The International Journal of Biochemistry 
& Cell Biology 45, 2553-2562 (2013). 
251. Pourahmad, J., Hosseini, M.-J., Eskandari, M.R., Shekarabi, S.M. & Daraei, B. 
Mitochondrial/lysosomal toxic cross-talk plays a key role in cisplatin 
nephrotoxicity. Xenobiotica 40, 763-771 (2010). 
252. Yang, M. et al. Lysosomal membrane permeabilization: Carbon nanohorn-induced 
reactive oxygen species generation and toxicity by this neglected mechanism. 
Toxicology and Applied Pharmacology 280, 117-126 (2014). 
263 
 
253. Bird, P.I., Trapani, J.A. & Villadangos, J.A. Endolysosomal proteases and their 
inhibitors in immunity. Nat Rev Immunol 9, 871-882 (2009). 
254. Scharf, B. et al. Annexin A2 binds to endosomes following organelle 
destabilization by particulate wear debris. Nat Commun 3, 755 (2012). 
255. Tung, C.-H., Mueller, S. & Weissleder, R. Novel Branching Membrane 
Translocational Peptide as Gene Delivery Vector. Bioorganic & Medicinal 
Chemistry 10, 3609-3614 (2002). 
256. Peitz, M., Pfannkuche, K., Rajewsky, K. & Edenhofer, F. Ability of the 
hydrophobic FGF and basic TAT peptides to promote cellular uptake of 
recombinant Cre recombinase: A tool for efficient genetic engineering of 
mammalian genomes. Proceedings of the National Academy of Sciences 99, 4489-
4494 (2002). 
257. Pellois, J.P. & Muir, T.W. A ligation and photorelease strategy for the temporal 
and spatial control of protein function in living cells. Angewandte Chemie 44, 
5713-5717 (2005). 
258. Boukamp, P. et al. Normal keratinization in a spontaneously immortalized 
aneuploid human keratinocyte cell line. The Journal of Cell Biology 106, 761-771 
(1988). 
259. Woods, L.K. et al. Comparison of Four New Cell Lines from Patients with 
Adenocarcinoma of the Ovary. Cancer Research 39, 4449-4459 (1979). 
260. Jiang, N., Bénard, C.Y., Kébir, H., Shoubridge, E.A. & Hekimi, S. Human CLK2 
Links Cell Cycle Progression, Apoptosis, and Telomere Length Regulation. 
Journal of Biological Chemistry 278, 21678-21684 (2003). 
261. Gonzalez-Vallina, R. et al. Lipoprotein and apolipoprotein secretion by a newborn 
piglet intestinal cell line (IPEC-1), Vol. 271. (1996). 
262. Hunt, M.E., Scherrer, M.P., Ferrari, F.D. & Matz, M.V. Very Bright Green 
Fluorescent Proteins from the Pontellid Copepod <italic>Pontella 
mimocerami</italic>. PLoS One 5, e11517 (2010). 
263. Wessel, D. & Flügge, U.I. A method for the quantitative recovery of protein in 
dilute solution in the presence of detergents and lipids. Analytical Biochemistry 
138, 141-143 (1984). 
264. Najjar, K., Erazo-Oliveras, A., Brock, D.J., Wang, T.-Y. & Pellois, J.-P. An l- to 
d-Amino Acid Conversion in an Endosomolytic Analog of the Cell-penetrating 
264 
 
Peptide TAT Influences Proteolytic Stability, Endocytic Uptake, and Endosomal 
Escape. Journal of Biological Chemistry 292, 847-861 (2017). 
265. Zorko, M. & Langel, Ü. Cell-penetrating peptides: mechanism and kinetics of 
cargo delivery. Advanced Drug Delivery Reviews 57, 529-545 (2005). 
266. Gupta, B., Levchenko, T.S. & Torchilin, V.P. Intracellular delivery of large 
molecules and small particles by cell-penetrating proteins and peptides. Advanced 
Drug Delivery Reviews 57, 637-651 (2005). 
267. Stewart, M.P. et al. In vitro and ex vivo strategies for intracellular delivery. Nature 
538, 183-192 (2016). 
268. Munyendo, W.L.L., Lv, H., Benza-Ingoula, H., Baraza, L.D. & Zhou, J. Cell 
Penetrating Peptides in the Delivery of Biopharmaceuticals. Biomolecules 2, 187-
202 (2012). 
269. Palm, C., Jayamanne, M., Kjellander, M. & Hällbrink, M. Peptide degradation is 
a critical determinant for cell-penetrating peptide uptake. Biochimica et 
Biophysica Acta (BBA) - Biomembranes 1768, 1769-1776 (2007). 
270. Elmquist, A. & Langel, Ü. in Biological Chemistry, Vol. 384 387 (2003). 
271. Lindgren, M.E., HÄLlbrink, M.M., Elmquist, A.M. & Langel, Ü. Passage of cell-
penetrating peptides across a human epithelial cell layer in vitro. Biochemical 
Journal 377, 69-76 (2004). 
272. Pujals, S., Sabidó, E., Tarragó, T. & Giralt, E. all-D proline-rich cell-penetrating 
peptides: a preliminary in vivo internalization study. Biochemical Society 
Transactions 35, 794-796 (2007). 
273. Youngblood, D.S., Hatlevig, S.A., Hassinger, J.N., Iversen, P.L. & Moulton, H.M. 
Stability of Cell-Penetrating Peptide−Morpholino Oligomer Conjugates in Human 
Serum and in Cells. Bioconjug Chem 18, 50-60 (2007). 
274. Wender, P.A. et al. The design, synthesis, and evaluation of molecules that enable 
or enhance cellular uptake: Peptoid molecular transporters. Proceedings of the 
National Academy of Sciences of the United States of America 97, 13003-13008 
(2000). 
275. Mitchell, D.J., Steinman, L., Kim, D.T., Fathman, C.G. & Rothbard, J.B. 
Polyarginine enters cells more efficiently than other polycationic homopolymers. 
The Journal of Peptide Research 56, 318-325 (2000). 
265 
 
276. Derossi, D. et al. Cell Internalization of the Third Helix of the Antennapedia 
Homeodomain Is Receptor-independent. Journal of Biological Chemistry 271, 
18188-18193 (1996). 
277. Pujals, S., Fernández-Carneado, J., Ludevid, M.D. & Giralt, E. D-SAP: A New, 
Noncytotoxic, and Fully Protease Resistant Cell-Penetrating Peptide. 
ChemMedChem 3, 296-301 (2008). 
278. Olson, E.S. et al. In vivo characterization of activatable cell penetrating peptides 
for targeting protease activity in cancer. Integrative biology : quantitative 
biosciences from nano to macro 1, 382-393 (2009). 
279. Brugidou, J., Legrand, C., Mery, J. & Rabie, A. The Retro-inverso Form of a 
Homeobox-Derived Short Peptide Is Rapidly Internalized by Cultured Neurons: A 
New Basis for an Efficient Intracellular Delivery System. Biochemical and 
Biophysical Research Communications 214, 685-693 (1995). 
280. Mueller, J., Kretzschmar, I., Volkmer, R. & Boisguerin, P. Comparison of Cellular 
Uptake Using 22 CPPs in 4 Different Cell Lines. Bioconjug Chem 19, 2363-2374 
(2008). 
281. Verdurmen, Wouter P.R. et al. Preferential Uptake of L- versus D-Amino Acid 
Cell-Penetrating Peptides in a Cell Type-Dependent Manner. Chemistry & Biology 
18, 1000-1010 (2011). 
282. Tunnemann, G. et al. Live-cell analysis of cell penetration ability and toxicity of 
oligo-arginines. Journal of peptide science : an official publication of the 
European Peptide Society 14, 469-476 (2008). 
283. Erazo-Oliveras, A. et al. The Late Endosome and Its Lipid BMP Act as Gateways 
for Efficient Cytosolic Access of the Delivery Agent dfTAT and Its 
Macromolecular Cargos. Cell chemical biology 23, 598-607 (2016). 
284. Fretz, Marjan M. et al. Temperature-, concentration- and cholesterol-dependent 
translocation of L- and D-octa-arginine across the plasma and nuclear membrane 
of CD34+ leukaemia cells. Biochemical Journal 403, 335-342 (2007). 
285. Peitz, M., Pfannkuche, K., Rajewsky, K. & Edenhofer, F. Ability of the 
hydrophobic FGF and basic TAT peptides to promote cellular uptake of 
recombinant Cre recombinase: a tool for efficient genetic engineering of 
mammalian genomes. Proc Natl Acad Sci U S A 99, 4489-4494 (2002). 
286. Colpitts, T.M., Moore, A.C., Kolokoltsov, A.A. & Davey, R.A. Venezuelan equine 
encephalitis virus infection of mosquito cells requires acidification as well as 
266 
 
mosquito homologs of the endocytic proteins Rab5 and Rab7. Virology 369, 78-
91 (2007). 
287. Bucci, C., Thomsen, P., Nicoziani, P., McCarthy, J. & van Deurs, B. Rab7: A Key 
to Lysosome Biogenesis. Molecular Biology of the Cell 11, 467-480 (2000). 
288. Kobayashi, T. et al. Late endosomal membranes rich in lysobisphosphatidic acid 
regulate cholesterol transport. Nat Cell Biol 1, 113-118 (1999). 
289. Kobayashi, T., Startchev, K., Whitney Andrew, J. & Gruenberg, J. Localization of 
Lysobisphosphatidic Acid-Rich Membrane Domains in Late Endosomes. 
Biological Chemistry 382, 483-485 (2001). 
290. Piper, R.C. & Katzmann, D.J. Biogenesis and Function of Multivesicular Bodies. 
Annual Review of Cell and Developmental Biology 23, 519-547 (2007). 
291. Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R. & Brock, R. A 
Comprehensive Model for the Cellular Uptake of Cationic Cell-penetrating 
Peptides. Traffic 8, 848-866 (2007). 
292. Tamai, M. et al. IN VITRO AND IN VIVO INHIBITION OF CYSTEINE 
PROTEINASES BY EST, A NEW ANALOG OF E-64. Journal of Pharmacobio-
Dynamics 9, 672-677 (1986). 
293. Vidard, L., Rock, K.L. & Benacerraf, B. The generation of immunogenic peptides 
can be selectively increased or decreased by proteolytic enzyme inhibitors. The 
Journal of Immunology 147, 1786-1791 (1991). 
294. Poon, G.M. & Gariepy, J. Cell-surface proteoglycans as molecular portals for 
cationic peptide and polymer entry into cells. Biochemical Society Transactions 
35, 788-793 (2007). 
295. Al-Taei, S. et al. Intracellular traffic and fate of protein transduction domains HIV-
1 TAT peptide and octaarginine. Implications for their utilization as drug delivery 
vectors. Bioconjug Chem 17, 90-100 (2006). 
296. Nishi, K. & Saigo, K. Cellular Internalization of Green Fluorescent Protein Fused 
with Herpes Simplex Virus Protein VP22 via a Lipid Raft-mediated Endocytic 
Pathway Independent of Caveolae and Rho Family GTPases but Dependent on 
Dynamin and Arf6. Journal of Biological Chemistry 282, 27503-27517 (2007). 
297. Wang, T.-Y. et al. Membrane oxidation enables the cytosolic entry of polyarginine 
cell-penetrating peptides. Journal of Biological Chemistry (2016). 
267 
 
298. Kosuge, M., Takeuchi, T., Nakase, I., Jones, A.T. & Futaki, S. Cellular 
internalization and distribution of arginine-rich peptides as a function of 
extracellular peptide concentration, serum, and plasma membrane associated 
proteoglycans. Bioconjug Chem 19, 656-664 (2008). 
299. Thompson, D.B., Cronican, J.J. & Liu, D.R. Engineering and identifying 
supercharged proteins for macromolecule delivery into mammalian cells. Methods 
Enzymol 503, 293-319 (2012). 
300. Freire, J.M., Santos, N.C., Veiga, A.S., Da Poian, A.T. & Castanho, M.A. 
Rethinking the capsid proteins of enveloped viruses: multifunctionality from 
genome packaging to genome transfection. FEBS J 282, 2267-2278 (2015). 
301. Tanaka, G. et al. CXCR4 Stimulates Macropinocytosis: Implications for Cellular 
Uptake of Arginine-Rich Cell-Penetrating Peptides and HIV. Chemistry & Biology 
19, 1437-1446 (2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
268 
 
APPENDIX A  
 
 
 
 
 
 
 
 
 
 
Figure A-1 D-dfTAT similar to dfTAT can efficiently delivery the DEAC-k5 peptide 
into the cytosolic space of MCH58 cells. MCH58 cell were co-incubated with dfTAT or 
D-dfTAT (5 M) in presence of DEAC-k5 (10 M). Cells were washed and then imaged 
using a 20X objective. Scale bars, 100 m.  
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Figure A-2 Comparison of the affinity of dfTAT and D-dfTAT to LE MLVs. L.E 
MLVs at various concentrations were incubated with either peptide at 3 M. The samples 
were spun down at 87,000 RPM and the fluorescence signal in the supernatant 
corresponding to the unbound peptide was quantified.  
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Figure A-3 BMP-mediated partitioning of dfTAT and D-dfTAT into hexanes. dfTAT 
or D-dfTAT (3 M)  was incubated in a phosphate buffer (pH 5.5) and the lipids PC or 
PG dissolved in hexanes at various concentrations were added. The fraction of peptide 
that remain in the aqueous phase upon mixing was measured by fluorescence 
spectroscopy.  
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Figure A-4 D-dfTAT does not impact cellular proliferation of HeLa cells after 
cytosolic delivery. Proliferation assays. HeLa cells were incubated with 5 µM dfTAT or 
D-dfTAT for 1h. Cells were then incubated in growth media (DMEM/10%FBS) and 
cellular proliferation was monitored over a period of 36 h using a MTT assay.  
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Figure A-5 Images for the RNA-seq analysis of HDF and MCH58 cells treated with 
D-dfTAT or dfTAT (5µM) in L-15 for 1 h. HDF and MCH58 cell were incubated with 
dfTAT or D-dfTAT (5 M). Cells were washed and then either immediately imaged or 
returned to the incubator and images 24 h post-delivery. Scale bars, 100 m.  
